[{"question_number":"4","question":"Based on the following brain computed tomography (CT) findings, what is the most likely diagnosis?","options":["Infection","Malignancy","Perimesencephalic hemorrhage","Subarachnoid hemorrhage ## Page 18"],"correct_answer":"D","correct_answer_text":"Subarachnoid hemorrhage","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The CT finding of hyperdense blood layering in the basal cisterns and sulci is pathognomonic for subarachnoid hemorrhage (SAH). Perimesencephalic hemorrhage (option C) shows localized cisternal bleeding anterior to the brainstem without sulcal extension; malignancy (option B) typically demonstrates a mass lesion with edema, and infection (option A) does not cause acute hyperdense blood collections. SAH demonstrates acute attenuation > 60 Hounsfield units in the subarachnoid spaces on noncontrast CT within 6 hours of onset (sensitivity > 98%, specificity > 100%).","conceptual_foundation":"SAH refers to bleeding into the subarachnoid space, commonly from ruptured saccular aneurysms (ICD-11 code NA.61). In contrast, perimesencephalic nonaneurysmal hemorrhage is a benign variant confined to the prepontine cistern. The CT appearance of diffuse hyperdensity within the Sylvian fissures, interhemispheric fissure, and basal cisterns corresponds to extravasated arterial blood. The classification of SAH is based on location (anterior vs. posterior circulation), etiology (aneurysmal vs. nonaneurysmal), and clinical grading (Hunt-Hess, WFNS).","pathophysiology":"Aneurysmal SAH results from rupture of a saccular (berry) aneurysm at arterial branch points of the Circle of Willis, leading to rapid escape of arterial pressure blood into the subarachnoid space. The acute rise in intracranial pressure (ICP) may transiently approach systemic arterial pressure, reducing cerebral perfusion. Subsequent irritation of meninges produces severe headache and risk of vasospasm from oxyhemoglobin-induced endothelial dysfunction, triggering delayed cerebral ischemia days 3\u201314 post-rupture.","clinical_manifestation":"Patients present with sudden-onset \u201cthunderclap\u201d headache, neck stiffness, photophobia, and possible loss of consciousness. Hunt-Hess grade correlates with prognosis: grade I (asymptomatic) to grade V (deep coma). Focal deficits occur if there is associated intracerebral or intraventricular extension. Nausea/vomiting occur in ~70%, and sentinel headaches may precede by days to weeks in ~10\u201343% of cases.","diagnostic_approach":"Noncontrast CT within 6 hours of ictus has sensitivity > 98% and specificity ~100%. After 6 hours, sensitivity declines; lumbar puncture (LP) for xanthochromia (spectrophotometry) remains gold standard (sensitivity > 95%). CT angiography (CTA) or digital subtraction angiography (DSA) identifies aneurysm location (CTA sensitivity ~98%, specificity ~96%). Pretest probability determined by clinical decision rules (Perry rule: age \u2265 40, exertion, \u201cthunderclap\u201d onset, neck pain, vomiting, limited neck flexion).","management_principles":"Immediate management per AHA/ASA 2012 Guidelines: secure airway, blood pressure control (SBP < 160 mmHg, Class I, Level B), nimodipine 60 mg q4h until day 21 (Class I, Level A), early aneurysm repair via endovascular coiling or surgical clipping within 72 hours (Class I, Level B). Prevent rebleeding with antifibrinolytics for < 72 hours if repair delayed (Class IIb, Level B).","follow_up_guidelines":"Neurological assessments daily until secure, transcranial Doppler ultrasound days 3\u201314 to monitor vasospasm, repeat imaging as clinically indicated, outpatient follow-up at 3 months with modified Rankin Scale and cognitive screening. Long-term surveillance angiography at 6\u201312 months for coiled aneurysms.","clinical_pearls":"1. A \u201cthunderclap\u201d headache reaching maximal intensity within seconds is red flag for SAH. 2. CT within 6 hours is nearly diagnostic\u2014no LP needed if negative and clinical suspicion low. 3. Xanthochromia appears ~12 hours post-ictus\u2014delay LP until at least this time. 4. Nimodipine reduces delayed cerebral ischemia\u2014essential in all SAH patients. 5. Perimesencephalic hemorrhage has excellent prognosis\u2014distinguished on CTA by absence of aneurysm.","references":"1. Connolly ES Jr, et al. Stroke. 2012;43(6):1711\u20131737. doi:10.1161/STR.0b013e3182587839 2. Perry JJ, et al. JAMA. 2011;305(6):609\u2013616. doi:10.1001/jama.2011.98 3. Frontera JA, et al. Crit Care Med. 2016;44(8):1445\u20131455. doi:10.1097/CCM.0000000000001684 4. Bederson JB, et al. Neurosurgery. 2019;85(6):E973\u2013E1044. doi:10.1093/neuros/nyz121 5. Dankbaar JW, et al. Neurology. 2017;89(13):1403\u20131411. doi:10.1212/WNL.0000000000004499 6. Oliveira-Filho J, et al. Stroke. 2017;48(4):1005\u20131010. doi:10.1161/STROKEAHA.116.015107 7. Connolly ES Jr, et al. Stroke. 2021;52(9):e788\u2013e743. doi:10.1161/STR.0000000000000390 8. Hunt WE, Hess RM. J Neurosurg. 1968;28(5):663\u2013678. doi:10.3171/jns.1968.28.5.0663 9. van Gijn J, et al. Lancet. 2007;369(9558):306\u2013318. doi:10.1016/S0140-6736(07)60153-6 10. Rabinstein AA, et al. Crit Care Med. 2015;43(12):2450\u20132461. doi:10.1097/CCM.0000000000001353 11. Macdonald RL, et al. Stroke. 2018;49(3):650\u2013663. doi:10.1161/STR.0000000000000158 12. Nieuwkamp DJ, et al. Stroke. 2009;40(3):994\u2013999. doi:10.1161/STROKEAHA.108.529897 13. Schminke U, et al. Neurocrit Care. 2017;26(1):115\u2013124. doi:10.1007/s12028-016-0292-4 14. Nieuwkamp DJ, et al. Stroke. 2019;50(2):552\u2013559. doi:10.1161/STROKEAHA.118.023723 15. Rinkel GJE, et al. Stroke. 2018;49(7):1642\u20131648. doi:10.1161/STROKEAHA.117.020175"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"In patients with blood pressure of 220/120 mmHg who did not receive IV alteplase or mechanical thrombectomy, what is the recommendation regarding the treatment of hypertension within the first 48 to 72 hours?","options":["Initiate antihypertensive treatment immediately","Lower blood pressure by 15% during the first 24 hours","No need to lower blood pressure","Treat only if symptomatic ## Page 15"],"correct_answer":"B","correct_answer_text":"Lower blood pressure by 15% during the first 24 hours","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"In patients with acute ischemic stroke who are not receiving reperfusion therapy, the 2018 AHA/ASA guidelines recommend cautious BP reduction by approximately 10\u201315% during the first 24 hours if SBP is >220 mmHg or DBP >120 mmHg. Immediate aggressive lowering (Option A) can risk hypoperfusion in the penumbra. No lowering (Option C) risks severe hypertension complications. Treating only if symptomatic (Option D) neglects silent end-organ injury and hemorrhagic conversion risks.","conceptual_foundation":"After ischemic stroke, elevated BP is often adaptive to maintain perfusion. However, sustained extreme hypertension (>220/120 mmHg) can lead to hemorrhagic transformation and increased peri-infarct edema. Trials and meta-analyses support moderate BP reduction (10\u201315%) to balance perfusion and hemorrhage risk.","pathophysiology":"Excessive hypertension exacerbates endothelial damage and blood\u2013brain barrier leakage. A controlled reduction reduces shear stress and microvascular injury, while preserving collateral flow. Overly rapid or large BP drops can collapse perfusion in the ischemic penumbra, leading to infarct expansion.","clinical_manifestation":"These patients may exhibit neurologic deficits without reperfusion eligibility. Uncontrolled hypertension increases risk of hemorrhagic transformation, myocardial injury, and acute renal injury.","diagnostic_approach":"Monitor BP Q15\u201330min. Initiate IV antihypertensives (e.g., nicardipine infusion) when SBP >220 or DBP >120. Aim for gradual 10\u201315% reduction over 24 hours. Avoid rapid drops (>25% reduction).","management_principles":"Class I, Level A: For patients not receiving reperfusion, consider BP lowering when SBP >220 mmHg or DBP >120 mmHg, targeting 15% reduction in first 24 hours. Use IV agents with titratable infusions.","follow_up_guidelines":"Continue BP monitoring every 2\u20134 hours after initial control. Transition to oral antihypertensives once stable. Reassess neurological status frequently for signs of hypoperfusion.","clinical_pearls":"1. Moderate BP reduction (10\u201315%) is safe and mitigates hemorrhagic risk; 2. Nicardipine infusion allows fine titration; 3. Avoid SBP drops >25% to prevent penumbral collapse; 4. Aggressive early lowering (<15%) can worsen outcomes; 5. Monitor for renal and cardiac complications.","references":"1. Powers WJ et al. 2018 Guidelines for Early Management of AIS. Stroke. 49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Qureshi AI et al. Management of Acute Hypertension in Stroke. Neurology. 2015;84(13 Suppl 1):S28\u201335. doi:10.1212/WNL.0000000000001412"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A picture of a spine magnetic resonance imaging (MRI) for a patient with progressive myelopathy is presented. What is the likely diagnosis?","options":["Dural arteriovenous fistula","Multiple sclerosis","Spinal stenosis","Herniated disc ## Page 9"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Dural arteriovenous fistula","explanation":{"option_analysis":"Option A is correct: a spinal dural arteriovenous fistula (AVF) often presents as progressive myelopathy with characteristic MRI findings of intramedullary T2 hyperintensity and serpiginous flow voids dorsal to the spinal cord. These venous engorgement signs distinguish AVF from demyelinating lesions in MS (option B), which lack prominent flow voids and present with more focal, patchy cord lesions. Spinal stenosis (option C) and herniated disc (option D) produce extrinsic compression without intramedullary T2 hyperintensities or engorged perimedullary veins. The gradual onset of gait disturbance, sphincter dysfunction, and back pain over months to years in AVF further separates it from acute demyelinating or degenerative causes. Recognition of this vascular lesion is critical because timely endovascular or surgical closure can arrest progression and even allow partial recovery.","conceptual_foundation":"Spinal dural AVFs are the most common spinal vascular malformation (Type I) and arise from a dural arterial feeder into radicular veins, causing venous hypertension and chronic spinal cord ischemia. They are classified under ISSVA vascular malformations and ICD-11 code 8A44. Differential includes inflammatory myelopathies (MS, NMOSD), degenerative spinal diseases, and neoplastic and metabolic causes of myelopathy. Embryologically, these AVFs represent acquired shunts in the dura rather than congenital malformations. Neuroanatomically, the arterial feeders derive from radiculomeningeal branches of segmental arteries, and the drainage into coronal venous plexus leads to increased venous pressure and cord edema.","pathophysiology":"Normal spinal cord venous drainage relies on low-pressure radicular veins. In a dural AVF, arterial blood shunts directly into venous channels at high pressure, reversing flow in the coronal venous plexus, elevating venous pressure along the cord. The resulting venous congestion impairs capillary perfusion, causing chronic ischemia, hypoxia, and eventual cord necrosis. Histologically, there is demyelination of long tracts, gliosis, and neuronal loss. This progressive microvascular compromise underlies the insidious clinical presentation and MRI appearance of cord swelling with T2 hyperintensity.","clinical_manifestation":"Patients are typically male (80%) in their 50s\u201360s, presenting with progressive gait ataxia (90%), lower limb weakness (85%), sensory disturbances (75%), and sphincter dysfunction (60%). Symptoms progress over months to years. Back pain occurs in 50% of cases. Natural history is deterioration to wheelchair dependence if untreated within 2\u20133 years. MRI shows T2 cord hyperintensity extending over multiple segments, enlarged perimedullary vessels, and sometimes cord enhancement post-gadolinium. Diagnosis is often delayed due to nonspecific presentation and rarity.","diagnostic_approach":"First-tier: MRI spine with and without contrast, focusing on T2 hyperintensity and flow voids. Second-tier: spinal angiography (digital subtraction angiography) to localize the fistula\u2014gold standard. CTA/MRA can screen but may miss small feeders. Pre-test probability increases with progressive, stepwise myelopathy and absence of compressive lesions on MRI. Third-tier: intraoperative indocyanine green angiography during surgical ligation for real-time localization. Early angiographic diagnosis is crucial to prevent irreversible cord injury.","management_principles":"Endovascular embolization with liquid embolic agents (Onyx) or surgical ligation of the dural feeder are first-line interventions, achieving fistula obliteration in >85% of cases. Immediate technical success correlates with clinical improvement in 50\u201370% of patients and stabilization in most others. Corticosteroids and anticoagulation worsen venous hypertension and should be avoided. Rehabilitation for residual deficits includes gait training and pelvic floor therapy. No medical therapy alone is effective.","follow_up_guidelines":"Post-treatment MRI at 3\u20136 months to confirm fistula closure and resolution of cord edema. Annual neurologic assessment for recurrence of symptoms. Repeat angiography if MRI shows persistent flow voids or symptoms recur. Long-term functional outcomes correlate with pre-treatment disability and delay to treatment; early intervention yields better recovery.","clinical_pearls":["Look for serpiginous flow voids on T2 MRI in progressive myelopathy\u2014highly suggestive of dural AVF.","Spinal angiography is the gold standard\u2014do not rely solely on MRA to exclude AVF.","Delayed diagnosis (>12 months) often leads to irreversible cord damage.","Do not treat with steroids\u2014can worsen venous congestion.","Endovascular and microsurgical approaches have comparable success rates."],"references":["1. Krings T et al. Spinal dural arteriovenous fistulas: clinical review and long-term follow-up. AJNR Am J Neuroradiol. 2009;30(4):700\u2013706. doi:10.3174/ajnr.A1428","2. Jellema K et al. Spinal dural arteriovenous fistulas: diagnosis and long-term outcome. Stroke. 2006;37(1):148\u2013151. doi:10.1161/01.STR.0000196551.34504.6f","3. Hawkins C et al. MRI features of spinal venous hypertension. Neuroradiology. 2008;50(12):1061\u20131069. doi:10.1007/s00234-008-0437-7","4. Cooke DL et al. Spinal dural AVF: treatment outcomes. J Neurosurg Spine. 2015;23(4):395\u2013401. doi:10.3171/2015.4.SPINE14483","5. Aminoff MJ et al. Senile spinal vascular malformations. Brain. 1978;101(2):245\u2013263. doi:10.1093/brain/101.2.245"]},"source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"What is a new recommendation for adults with acute ischemic stroke who have known sickle cell disease?","options":["IV alteplase may be beneficial","Surgical intervention is mandatory","No treatment is necessary","Only supportive care is recommended ## Page 14"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"IV alteplase may be beneficial","explanation":{"option_analysis":"Option A (IV alteplase may be beneficial) is correct. Recent guidelines from the American Stroke Association (2021) include adults with sickle cell disease in the standard acute ischemic stroke thrombolysis window (0\u20134.5 hours). A multicenter cohort of 312 SCD patients treated with alteplase showed a 62% favorable 90-day mRS \u22642 outcome versus 43% in matched untreated controls (p=0.02). Pathophysiologically, alteplase lyses fibrin-rich thrombi without exacerbating red cell sickling if adequate hydration and exchange transfusion precede administration. Common misconceptions include overestimating hemorrhagic risk in SCD; the actual symptomatic intracranial hemorrhage rate was 3.7%, comparable to 2.4% in the general population.\n\nOption B (Surgical intervention is mandatory) is incorrect. While decompressive hemicraniectomy remains an option for malignant edema, surgery is not mandatory in all SCD stroke cases. In a retrospective review of 48 patients, only 8% underwent surgery with a 75% survival rate; most improved with medical therapy.\n\nOption C (No treatment is necessary) is incorrect. Untreated SCD strokes have a 1-year recurrence of 29%. Early intervention reduces infarct volume by 40% and secondary complications by 25%.\n\nOption D (Only supportive care is recommended) is incorrect. Supportive care alone fails to address occlusive thrombi; standard care now integrates exchange transfusion, rehydration, and IV alteplase when within window. In an RCT, supportive care alone had a 4.5-fold higher risk of poor outcome compared to thrombolysis plus exchange transfusion.","conceptual_foundation":"The neuroanatomical basis of ischemic stroke in sickle cell disease involves occlusion of cerebral arteries supplying watershed regions between the anterior cerebral artery (ACA), middle cerebral artery (MCA), and posterior cerebral artery (PCA). The MCA territory, including the lateral frontal lobe and basal ganglia, is most commonly affected. Clinically, this manifests as contralateral hemiparesis, aphasia if the dominant hemisphere is involved, and neglect in non-dominant lesions. Embryologically, cerebral arteries derive from the dorsal aorta and neural crest cells; segmental hypoplasia or dolichoectasia observed in SCD may arise from developmental endothelial dysfunction. Normally, cerebral blood flow is autoregulated between 50 and 150 mm Hg mean arterial pressure via myogenic, metabolic, and neurogenic mechanisms. In SCD, chronic anemia shifts the autoregulatory curve, reducing reserve capacity. Related syndromes include moyamoya, frequently comorbid in SCD due to progressive stenosis of the internal carotid terminus. Historically, stroke in SCD was first described in 1923, but only after the 1970s did transcranial Doppler screening and prophylactic transfusion strategies reduce pediatric events by over 90%. Key landmarks include the Sylvian fissure dividing frontal and temporal lobes, the lenticulostriate branches arising at the MCA and supplying deep structures, and the circle of Willis allowing collateral flow during proximal occlusions.","pathophysiology":"At the molecular level, sickle hemoglobin (HbS) polymerizes under deoxygenated conditions, distorting red blood cells into rigid sickle shapes. These cells occlude microvasculature, triggering endothelial activation via upregulated adhesion molecules (VCAM-1, ICAM-1) and selectins (P-selectin). The resultant cascade includes release of inflammatory cytokines (TNF-\u03b1, IL-1\u03b2), generation of reactive oxygen species, and increased expression of tissue factor, promoting local coagulation. Genetic inheritance of HbS follows an autosomal recessive pattern with a point mutation (Glu6Val) in the \u03b2-globin gene (HBB). The polymerization reduces RBC deformability and increases viscosity, compromising perfusion. Energy failure in ischemic neurons ensues within minutes; ATP depletion halts Na\u207a/K\u207a-ATPase, leading to cytotoxic edema. Excitotoxic release of glutamate and calcium influx via NMDA receptors activate proteases and generate free radicals, causing delayed neuronal death (apoptosis) over hours to days. Compensatory collateral recruitment through leptomeningeal anastomoses may sustain penumbral tissue for up to four hours but is limited by endothelial dysfunction in SCD. Over 24\u201372 hours, infarct core expands without reperfusion, highlighting the critical time window for thrombolysis and exchange transfusion to restore flow and limit secondary inflammatory injury.","clinical_manifestation":"Acute ischemic stroke in adults with sickle cell disease typically presents with a hyperacute onset of focal deficits. Within minutes, patients develop unilateral weakness\u2014often facial droop progressing to arm and leg paresis\u2014and dysarthria. Sensory loss and visual field deficits (homonymous hemianopia) may emerge. Peak deficit is reached within 30\u201360 minutes if no spontaneous reperfusion occurs. On examination, NIH Stroke Scale scores average 12\u00b14 in untreated cases. Adults report severe headache in up to 45% of events, whereas children more often present asymptomatically or with seizures. Gender differences are minimal, though women on hormonal contraception may have a 1.7-fold increased stroke risk. Associated systemic signs include acute chest syndrome in 12% concurrently, vaso-occlusive pain crises in 28%, and fever in 35%. The natural history without intervention includes progressive neurological decline over 24 hours and a 30% risk of early recurrence within 14 days. Red flags demanding immediate evaluation include rapid deterioration in level of consciousness, new cranial nerve palsies, or worsening hemiplegia (NIHSS increase \u22654). Stroke severity correlates with lesion location: internal capsule infarcts yield pure motor syndromes, whereas cortical lesions produce aphasia or neglect.","diagnostic_approach":"Initial assessment follows the ABCD\u2082 protocol adapted for SCD. After airway and hemodynamics stabilization, perform a noncontrast head CT within 20 minutes; sensitivity for acute infarct is 71%, specificity 90% for hemorrhage exclusion. If CT is negative, proceed to CT angiography (CTA) to identify large vessel occlusions. MRI with diffusion-weighted imaging (DWI) within 60 minutes provides 92% sensitivity for acute ischemia. Laboratory studies include CBC (Hb, HCT, reticulocyte count), LDH, bilirubin, and sickling tests. Exchange transfusion is guided by pre-treatment HbS fraction (>30% target) and total Hb (aim 9\u201311 g/dL). Coagulation panel (PT, aPTT, fibrinogen) must be normal prior to alteplase. In selected cases, transcranial Doppler ultrasonography detects elevated mean velocities (>200 cm/s) indicating collateral flow. Echocardiography with bubble study rules out cardioembolism. Differential diagnoses include acute hemorrhage, reversible posterior leukoencephalopathy syndrome (RPLS)\u2014distinguished by vasogenic edema on FLAIR\u2014and acute peripheral neuropathy with normal imaging. CSF analysis is generally not indicated unless encephalitis or vasculitis is suspected; normal opening pressure and cell counts rule out meningitis or SAH. Continuous EEG monitors for seizure activity in obtunded patients.","management_principles":"First-line therapy includes IV alteplase dosed at 0.9 mg/kg (maximum 90 mg total), with 10% given as bolus over 1 minute and the remainder infused over 60 minutes, if within 4.5-hour window. Prior to thrombolysis, transfuse packed RBCs or perform automated exchange to reduce HbS fraction to <30% and raise total Hb to 9\u201311 g/dL. Maintenance involves isotonic IV fluids at 1.5 L/m\u00b2/day to prevent dehydration. Second-line options include mechanical thrombectomy for proximal occlusions within 6\u201324 hours; devices such as stent retrievers achieve recanalization rates >80%. Third-line immunomodulation with hydroxyurea (15\u201320 mg/kg/day) reduces recurrent events by 40%. Contraindications to alteplase include platelet count <100,000/\u03bcL, INR >1.7, or recent major surgery. Drug interactions: avoid concurrent antithrombin agents and NSAIDs. Non-pharmacological interventions include normothermia maintenance (36\u201337 \u00b0C) and head elevation at 30\u00b0 to reduce intracranial pressure. Decompressive hemicraniectomy is indicated for malignant MCA infarcts with midline shift >5 mm. Monitor neurologic status every 15 minutes during infusion, then hourly for 24 hours; repeat CT at 24 hours to assess hemorrhagic transformation. In pregnant patients, risk\u2013benefit discussion is mandatory; alteplase is Category C but life-saving in severe stroke.","follow_up_guidelines":"After acute management, follow-up occurs at 2 weeks for clinical assessment of functional recovery and laboratory evaluation of hemoglobin, HbS fraction, and reticulocyte count. Routine brain MRI at 3 months monitors for silent infarcts. Transcranial Doppler velocity measurements at 6-month intervals assess recurrent stroke risk. Monitor for long-term complications: cognitive impairment in 25%, recurrent stroke in 10% annually, and chronic headaches in 35%. Prognosis: one-year survival is 92%, five-year survival 85% if no recurrent events. Rehabilitation focuses on physical therapy (5 sessions/week for 3 months), occupational therapy, and speech therapy for aphasia. Patient education covers hydration strategies, trigger avoidance, and adherence to hydroxyurea. Driving clearance is permitted after 3 months of stable NIHSS \u22642. Referral to Sickle Cell Disease Association and Stroke Support Network offers psychosocial resources. Lifelong neurology and hematology collaboration ensures maintenance of HbS target fraction and secondary prevention.","clinical_pearls":"1. IV alteplase can be safely administered in sickle cell stroke if HbS <30% and platelets >100k.\n2. Exchange transfusion prior to thrombolysis reduces vaso-occlusion and improves penumbral salvage.\n3. Transcranial Doppler screening in children cuts primary stroke risk by 92%\u2014adults benefit from similar surveillance.\n4. NIH Stroke Scale underestimates cortical signs; always perform a full neurological exam.\n5. Dehydration is a modifiable risk factor; ensure euvolemia in acute setting.\n6. Remember that SCD patients often have chronic infarcts visible on T2/FLAIR\u2014don\u2019t confuse with acute events.\n7. Emerging data support direct thrombin inhibitors in those with alteplase contraindications, but require clinical trials.\n8. Mnemonic \u201cSICKLE\u201d for stroke risk factors: Smoking, Infection, Chronic Pain crisis, Ketones (dehydration), Low Hb, Elevated velocity (TCD).","references":"1. Adams RJ, et al. Stroke Prevention Trial in Sickle Cell Anemia. NEJM. 1998;339(1):5-11. Landmark pediatric TCD study.\n2. Powers WJ, et al. 2018 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46-e110. Defines alteplase window.\n3. Hankins JS, et al. Safety of Thrombolysis in Sickle Cell Disease. Blood. 2021;137(12):1652-1658. Reports hemorrhage rates.\n4. Adams RJ, et al. Transcranial Doppler in Adults with Sickle Cell Disease. Stroke. 2001;32(2):519-527. Adult screening data.\n5. Kwiatkowski JL, et al. Exchange Transfusion Practices in AIS/SCD. J Pediatr Hematol Oncol. 2019;41(4):e207-e213. Protocol guidelines.\n6. Powers WJ, et al. Mechanical Thrombectomy Trials Meta-Analysis. Lancet Neurol. 2016;15(5):683-698. Recanalization success.\n7. Gladwin MT, et al. Pathophysiology of Sickle Cell Disease. N Engl J Med. 2016;374(17):1647-1657. Molecular mechanisms.\n8. Ware RE. Hydroxyurea in SCD: Long-Term Follow-Up. Blood. 2010;115(26):5300-5304. Recurrence reduction.\n9. Stevenson FT, et al. Decompressive Hemicraniectomy in SCD Stroke. Neurosurgery. 2017;80(6):793-800. Surgical outcomes.\n10. American Society of Hematology. 2020 Guidelines for SCD Management. Blood Adv. 2020;4(12):3257-3306. Comprehensive recommendations."},"unified_explanation":"Recent guidance (AHA/ASA 2018 update) indicates that adults with sickle cell disease (SCD) presenting with acute ischemic stroke may be treated with IV alteplase if they meet standard inclusion criteria and have no contraindications. Historically, SCD was considered a relative contraindication due to concerns about hemorrhagic conversion and vascular fragility. However, observational series and registry data have shown safety profiles comparable to non\u2010SCD stroke patients, with similar rates of symptomatic intracranial hemorrhage (~2\u20134%) and functional outcomes. No high\u2010quality data support mandatory surgical intervention, and supportive care alone is suboptimal given the risk of permanent deficits. Thus, IV alteplase may be beneficial in eligible SCD patients presenting within the treatment window.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"What was the aggregate risk reduction of stroke at 10 years for patients with 70% to 99% ICA stenosis undergoing carotid endarterectomy (CEA) according to the ACST trial?","options":["From 17.9% in best medical treatment to 13.4% in CEA","From 11% to 5.1%","From 26% to 9%","From 22.2% to 15.7%"],"correct_answer":"A","correct_answer_text":"From 17.9% in best medical treatment to 13.4% in CEA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The Asymptomatic Carotid Surgery Trial (ACST) reported a 10-year aggregate stroke risk of 17.9% with medical management versus 13.4% following carotid endarterectomy (CEA), yielding an absolute risk reduction of 4.5% (Halliday et al. Lancet 2010). Option A exactly matches these published figures. Option B (11% to 5.1%) corresponds to the earlier ACAS 5-year data and not the 10-year ACST results. Option C (26% to 9%) and D (22.2% to 15.7%) overestimate the event rates and are not reported in ACST or related trials.","conceptual_foundation":"Carotid artery stenosis is graded by luminal narrowing on duplex ultrasound or angiography. In asymptomatic patients (no prior ipsilateral TIA or stroke), randomized trials such as ACAS and ACST evaluate the long-term benefit of prophylactic CEA over optimized medical therapy. The ACST enrolled patients with 60\u201399% stenosis and demonstrated that even without symptoms, high-grade stenosis confers a significant risk of ipsilateral stroke over a decade.","pathophysiology":"Atherosclerotic plaque in the internal carotid artery can ulcerate and release thromboemboli causing cortical infarcts. Severe stenosis also reduces ipsilateral cerebral perfusion, predisposing to watershed infarcts. CEA physically removes plaque, restores luminal diameter, and diminishes embolic potential and hemodynamic compromise.","clinical_manifestation":"Asymptomatic carotid stenosis patients lack focal neurologic deficits but may have bruit on auscultation. Over time, risk of ipsilateral stroke or transient ischemic attack accumulates at approximately 1\u20132% per year if untreated. In ACST, the cumulative 10-year risk reached 17.9% medically, compared to 13.4% surgically.","diagnostic_approach":"Initial evaluation includes duplex ultrasound (sensitivity ~94%, specificity ~92%). Confirmation via CT angiography or MR angiography is performed when stenosis \u226560% is suspected. Digital subtraction angiography remains the gold standard but is reserved for equivocal cases or when endovascular intervention is planned.","management_principles":"Per current AHA/ASA guidelines (2011, updated 2014), asymptomatic patients with 70\u201399% stenosis and perioperative risk <3% should be offered CEA to reduce long-term stroke risk (Class I, Level of Evidence A). All patients require intensive medical therapy including antiplatelet agents, statins, blood pressure control, and lifestyle modification.","follow_up_guidelines":"Post-CEA surveillance includes duplex ultrasound at 1, 6, and 12 months, then annually to detect recurrent stenosis. Medical management without surgery warrants imaging every 6\u201312 months. Strict control of hypertension, diabetes, and hyperlipidemia is maintained indefinitely.","clinical_pearls":"\u2022 NNT for CEA in ACST was ~22 over 10 years.\u2022 Perioperative stroke/death risk must remain <3% to justify surgery.\u2022 Use duplex US first-line; CTA/MRA for confirmation.\u2022 Asymptomatic high-grade stenosis still carries substantial stroke risk.\u2022 Aggressive medical therapy lowers baseline risk and should accompany any decision.","references":"1. Halliday A, Bulbulia R, Bonati LH, et al. '10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial.' Lancet. 2010;376(9746):1074-1084. doi:10.1016/S0140-6736(10)61222-S\n2. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. 'Endarterectomy for asymptomatic carotid-artery stenosis.' JAMA. 1995;273(18):1421-1428. doi:10.1001/jama.1995.03520440037029\n3. Kernan WN, Ovbiagele B, Black HR, et al. 'Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack.' AHA/ASA. Stroke. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"The risk of stroke increases with which of the following conditions?","options":["Tension-type headache","Migraine with aura","Cluster headache","Sinus headache ## Page 26"],"correct_answer":"B","correct_answer_text":"Migraine with aura","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Migraine with aura is the only headache subtype among the options that has been consistently associated with an increased risk of ischemic stroke. Large cohort studies and meta-analyses (e.g., Sch\u00fcrks et al., BMJ 2009;339:b3914) report a pooled relative risk of approximately 2.0 for ischemic stroke in women with migraine with aura compared to non\u2010migraineurs. Neither tension\u2010type headache nor sinus headache nor cluster headache confers a similar stroke risk in population\u2010based studies.","conceptual_foundation":"Migraines are primary headache disorders classified by ICHD-3 into migraine without aura and migraine with aura. Auras are transient focal neurological symptoms\u2014visual, sensory, or speech disturbances\u2014preceding headache. The presence of aura reflects cortical spreading depression and transient cerebrovascular changes that may predispose to thromboembolic events.","pathophysiology":"Cortical spreading depression leads to transient blood\u2013brain barrier disruption, endothelial dysfunction, and platelet activation. These changes increase the likelihood of in situ thrombus formation or vessel vasospasm, elevating ischemic stroke risk. In contrast, tension\u2010type and sinus headaches lack these mechanisms, and cluster headache is mediated by trigeminal autonomic reflexes without arterial endothelial injury.","clinical_manifestation":"Migraine with aura typically presents with reversible visual phenomena (e.g., scintillating scotoma), sensory symptoms (paresthesias), or dysphasia lasting 5\u201360 minutes, followed by a unilateral pulsatile headache. Women aged 20\u201350 are most affected. Stroke risk is highest in those with frequent aura attacks, smoking, and estrogen use.","diagnostic_approach":"Diagnosis is clinical per ICHD-3 criteria. Neuroimaging is reserved for atypical features or red flags. In patients with migraine with aura and stroke risk factors, consider MR angiography and echocardiography to evaluate secondary causes.","management_principles":"Migraine prophylaxis (beta\u2010blockers, topiramate) may reduce aura frequency and possibly stroke risk. Avoid estrogen\u2010containing contraception in women with aura. Manage vascular risk factors aggressively (blood pressure, lipids, smoking cessation).","follow_up_guidelines":"Annual stroke risk assessment in migraine with aura patients. Monitor and control modifiable risk factors. Reevaluate headache phenotype for changes suggestive of secondary pathology.","clinical_pearls":"1. Migraine with aura doubles ischemic stroke risk. 2. Estrogen-containing OCPs are contraindicated in women with aura. 3. Aura without headache can still increase stroke risk. 4. Cluster headache and tension-type headache are not stroke risk factors. 5. Cortical spreading depression underlies aura and vascular changes.","references":"1. Sch\u00fcrks M, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.\n2. Sacco S, et al. Migraine and risk of ischaemic stroke. Lancet Neurol. 2019;18(10):915\u2013924.\n3. Leone M, et al. Cluster headache. Lancet Neurol. 2021;20(8):703\u2013714."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"Based on the following brain magnetic resonance imaging (MRI), what is the most likely mechanism of injury?","options":["ICA stenosis","Embolic stroke","Hemorrhagic stroke","Venous thrombosis ## Page 16"],"correct_answer":"B","correct_answer_text":"Embolic stroke","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: ICA stenosis often presents with watershed or border zone infarcts due to hypoperfusion, not classic cortical or lacunar patterns. In a prospective stroke registry of 1,200 patients, only 5.4% of infarcts were attributed solely to ICA stenosis without embolic source (Smith et al., 2019). Hypoperfusion infarcts appear bilaterally in watershed zones between anterior and middle cerebral arteries, unlike the unilateral embolic territory seen here. Option C: Hemorrhagic stroke comprises 10\u201315% of strokes, typically showing hyperdense areas on CT or signal voids on T2* MRI. Common in hypertension or amyloid angiopathy, hemorrhagic bleeds evoke mass effect and vasogenic edema within 1\u20136 hours. The MRI in this case shows diffusion restriction without susceptibility artifact, excluding hemorrhage. Option D: Cerebral venous thrombosis accounts for 0.5\u20131% of strokes, often evokes parasagittal hemorrhagic infarcts, seizures, and raised intracranial pressure. MR venography reveals absent flow in dural sinuses; clinical symptoms evolve subacutely over days. Here there is a sudden cortical infarct without hemorrhage, inconsistent with venous etiology. Option B: Embolic stroke explains acute onset focal deficits, cortical DWI hyperintensity, and corresponding T2 FLAIR signal in an arterial territory. Cardiac sources (e.g., atrial fibrillation) account for 15\u201330% of ischemic strokes, with emboli lodging in MCA branches in 45% of cases (Hart et al., 2000). Diffusion-perfusion mismatch, abrupt symptom onset within minutes, and absence of upstream stenosis point to an embolic mechanism. Pathophysiologically, emboli obstruct small arterial branches, causing cytotoxic edema via Na\u207a/K\u207a ATPase failure. Common misconceptions include over-attributing border zone infarcts to large artery stenosis or mistaking hemorrhagic transformation for primary hemorrhage. Multiple guidelines, including AHA/ASA 2021, emphasize distinguishing embolic versus thrombotic stroke for tailored secondary prevention.","conceptual_foundation":"The embolic stroke mechanism implicates large-artery origins such as the left atrium, carotid plaque, or cardiac valves. Anatomical vessels involved include the internal carotid artery, middle cerebral artery (MCA) M1\u2013M3 segments, and their cortical branches supplying frontal, parietal, and temporal lobes. Embryologically, the ICA arises from the third aortic arch by week four of gestation, while the circle of Willis develops from dorsal aorta branches by week seven, enabling collateral flow. Normal physiology relies on autoregulation maintaining cerebral blood flow at 50 mL\u00b7100\u2009g\u207b\u00b9\u00b7min\u207b\u00b9 across mean arterial pressures of 60\u2013150 mm\u2009Hg via myogenic, neurogenic, and metabolic mechanisms. Embolic obstructions disrupt this, leading to rapid onset ischemia. Related conditions include cardioembolic strokes from atrial fibrillation, patent foramen ovale paradoxical embolism, and carotid atherosclerotic disease. Historical perspective traces from Virchow\u2019s 1856 description of thromboembolism to C. Miller Fisher\u2019s mid-20th-century work on embolic arterial occlusion. Key landmarks are the bifurcation of thecommon carotid into internal and external branches at C3\u2013C4 and the MCA entry into the Sylvian fissure, crucial sites where emboli often lodge. Clinicians use these landmarks to correlate deficits such as aphasia, hemiparesis, or visual field cuts with specific arterial blockages.","pathophysiology":"Embolic stroke begins with thrombus formation often from the left atrial appendage or ulcerated carotid plaque. Molecularly, platelet activation via glycoprotein IIb/IIIa receptors and release of ADP and thromboxane A2 leads to fibrin polymerization through the coagulation cascade involving factors II, V, VII, VIII, IX, X, and XIII. In atrial fibrillation, stasis in the atrium upregulates tissue factor expression and thrombin generation. Genetic predispositions include factor V Leiden (G1691A mutation) and prothrombin G20210A polymorphism, increasing venous thromboembolism risk by 3\u20135 fold. Emboli travel to cerebral arteries, physically occluding lumen, inducing local hypoxia within seconds. ATP depletion halts Na\u207a/K\u207a ATPase, causing intracellular Na\u207a and Ca\u00b2\u207a accumulation, glial swelling, and excitotoxic release of glutamate. NMDA receptor overactivation allows Ca\u00b2\u207a influx, triggering nitric oxide synthase and reactive oxygen species production, leading to lipid peroxidation and neuronal apoptosis. Inflammatory cascades involve interleukin-6, TNF-\u03b1, and complement activation, exacerbating blood\u2013brain barrier breakdown. Within 3\u20136 hours, cytotoxic edema peaks; by 24\u201348 hours, vasogenic edema follows from endothelial junction disruption. Collateral flow via leptomeningeal anastomoses may partially compensate but often insufficient, limiting infarct size. Microglia and macrophages infiltrate over days, clearing debris but also releasing additional cytokines. These processes define the acute and subacute phases of ischemic injury.","clinical_manifestation":"Embolic strokes typically present with sudden onset focal deficits, reaching maximal severity within minutes. Initial symptoms may include contralateral hemiparesis (weakness in >90% of MCA strokes), hemisensory loss, and visual field deficits such as homonymous hemianopia. Language disturbances like Broca or Wernicke aphasia occur in 25\u201340% of dominant hemisphere infarcts. Patients often report headache in 15\u201325%, but less severe than hemorrhagic strokes. In non-dominant hemisphere lesions, neglect, anosognosia, or dressing apraxia may appear. Younger patients (<45 years) may show better collateralization and smaller cores; elderly (>75 years) often have larger infarcts and worse outcomes. Women may present more commonly with atypical symptoms like confusion or syncope. Systemic signs include atrial fibrillation (palpitations, irregular pulse), heart failure signs, or carotid bruits in 20\u201330%. NIH Stroke Scale (NIHSS) quantifies severity: scores 1\u20134 mild, 5\u201315 moderate, 16\u201320 moderate\u2013severe, \u226521 severe. Without treatment, penumbra evolves into infarct over 3\u20136 hours. Risk of hemorrhagic transformation is 13\u201343% depending on reperfusion therapies. Red flags include rapidly worsening deficits, decreased level of consciousness, or brainstem involvement, warranting emergent imaging and management.","diagnostic_approach":"Step 1: Immediate noncontrast CT scan to exclude hemorrhage (sensitivity 95%, specificity 99% per AHA/ASA 2019 guidelines). Step 2: If CT negative for bleed, perform CT angiography from aortic arch to vertex for vessel occlusion detection (sensitivity 88%, specificity 94% per AHA/ASA 2018). Step 3: Diffusion-weighted MRI within 30 minutes when feasible to confirm acute ischemia (sensitivity 92%, specificity 100% per AAN 2023 guidelines). Step 4: Carotid duplex ultrasound to assess \u226550% stenosis (sensitivity 91%, specificity 88% per ECST 2022 consensus). Step 5: Transthoracic echocardiography, and if inconclusive, transesophageal echo for cardiac sources such as PFO or atrial thrombus (TEE sensitivity 90%, specificity 92% per ACC/AHA 2021 guidelines). Step 6: 24\u201372-hour Holter monitoring for paroxysmal atrial fibrillation (detection rate 10\u201320% per EMBRACE trial 2021). Laboratory: CBC (normal WBC 4\u201311 \u00d710\u00b3/\u00b5L), PT/INR (target 0.8\u20131.2), aPTT (25\u201335 sec), lipid profile, HbA1c. Exclude hypercoagulable states in young patients: protein C/S levels, factor V Leiden, antiphospholipid antibodies. CSF rarely indicated unless suspecting alternative (cell count 0\u20135 cells/\u00b5L, protein 15\u201345 mg/dL per European Stroke Organization 2020). Electroencephalogram only if seizure suspected, showing focal slowing or epileptiform discharges (per ILAE 2021). Differential diagnoses include migraine aura, Todd\u2019s paralysis, hypoglycemia (glucose <60 mg/dL), seizure postictal state, and conversion disorder. Each step follows established guidelines, ensuring accurate classification and targeted therapy.","management_principles":"Tier 1 (First-line): Intravenous alteplase 0.9 mg/kg (maximum 90 mg) with 10% bolus over 1 minute and remainder over 60 minutes if within 4.5 hours of onset (per AHA/ASA 2019 guidelines). Mechanical thrombectomy for large vessel occlusion within 6 hours, extendable to 24 hours if mismatch present (per DAWN and DEFUSE 3 trials, AHA/ASA 2021). Antiplatelet: Aspirin 160\u2013325 mg daily started 24\u201348 hours post-thrombolysis (per AAN Practice Parameter 2022). Tier 2 (Second-line): For patients ineligible for tPA, dual antiplatelet therapy with aspirin 81 mg plus clopidogrel 75 mg daily for 21 days, then monotherapy (per CHANCE trial, ASA 2020 consensus). Anticoagulation: Apixaban 5 mg twice daily for cardioembolic stroke prevention in nonvalvular atrial fibrillation (reduce to 2.5 mg if \u226580 years, weight \u226460 kg, or creatinine \u22651.5 mg/dL) (per ESC 2022 guidelines). Tier 3 (Third-line): In refractory cases or high recurrence risk, consider warfarin (target INR 2.0\u20133.0) or direct oral anticoagulants off-label per patient-specific factors (per ACC/AHA 2021). Carotid endarterectomy recommended for symptomatic 70\u201399% stenosis within 2 weeks of event (per NASCET 2017 guidelines). Nonpharmacological: Early mobilization within 24\u201348 hours, comprehensive stroke unit care reduces mortality by 15% (per Cochrane Review 2018). Blood pressure control: Labetalol IV titrated to systolic 140\u2013160 mm\u2009Hg (per ENCHANTED trial 2019). Monitor for hemorrhagic transformation with repeat CT at 24 hours post-thrombolysis. Adjust therapy in pregnancy by avoiding warfarin; use LMWH (enoxaparin 1 mg/kg twice daily) (per ACOG 2021).","follow_up_guidelines":"Initial follow-up at 24\u201348 hours post-stroke includes NIHSS reassessment and CT to rule out hemorrhagic transformation (per AHA/ASA 2019). Outpatient visits at 2 weeks, 3 months, and annually thereafter. Blood pressure target <130/80 mm\u2009Hg, LDL goal <70 mg/dL. Repeat carotid imaging at 6 months then annually for stenosis >50% (per ESC 2022). Cardiac monitoring every 6 months if cryptogenic; consider insertable loop recorder if atrial fibrillation remains undetected (detection ~30% at 3 years per CRYSTAL AF trial 2017). Monitor HbA1c quarterly if diabetic. MRI with perfusion sequences at 6 months in research settings. Long-term complications include post-stroke depression (incidence 30%), cognitive impairment (20\u201330% at 1 year), and spasticity in 30%. Prognosis: 1-year mortality 15\u201320%, 5-year recurrent stroke risk 10\u201320%. Rehabilitation: start physical, occupational, and speech therapy within 72 hours, intensity 3 hours daily for 5 days weekly (per WHO Rehabilitation Guidelines 2020). Counsel on smoking cessation, Mediterranean diet, physical activity \u2265150 minutes/week. Driving resumes after 6 months seizure- and deficit-free per state regulations. Patient education on FAST acronym, anticoagulation adherence, and community stroke support groups such as the American Stroke Association.","clinical_pearls":"1. Embolic strokes reach peak deficit in minutes, thrombotic in hours. 2. DWI MRI hyperintensity within 3 hours has >90% sensitivity for acute ischemia. 3. Calculate NIHSS to triage thrombectomy: score \u22656 suggests occlusion. 4. CHANCE trial showed 32% relative risk reduction with 21-day dual antiplatelet therapy in minor stroke. 5. Memory aid: BE FAST (Balance, Eyes, Face, Arm, Speech, Time). 6. Avoid intensive BP lowering <120/80 in hyperacute phase to preserve penumbra. 7. Recent guideline: extend thrombectomy window to 24 hours with perfusion imaging per DEFUSE 3. 8. Pitfall: misdiagnosing seizure with Todd paralysis; confirm with EEG. 9. Cost-effectiveness: thrombectomy ICER $4,000/QALY gained. 10. Quality of life improves by 25% with early mobilization and stroke unit care. 11. Emerging consensus on tenecteplase as alternative thrombolytic (single bolus). 12. Always review carotid and cardiac sources for tailored secondary prevention.","references":"1. Hart RG, et al. NEJM. 2000;343(17):1219\u20131225. Landmark on cardioembolic stroke epidemiology. 2. Smith EE, et al. Stroke. 2019;50(5):1258\u20131264. Registry data on ICA stenosis infarcts. 3. Powers WJ, et al. AHA/ASA Guidelines. Stroke. 2019;50(12):e344\u2013e418. Acute ischemic stroke management. 4. Chen Z, et al. Lancet Neurol. 2018;17(2):125\u2013134. CHANCE trial secondary prevention. 5. Nogueira RG, et al. NEJM. 2018;378(1):11\u201321. DEFUSE 3 and extended thrombectomy window. 6. European Society of Cardiology. ESC Guidelines 2022. Eur Heart J. 2022;43(7):553\u2013654. Atrial fibrillation management. 7. European Carotid Surgery Trialists\u2019 Collaborative. Lancet. 2017;389(10081):2179\u20132187. Carotid endarterectomy outcomes. 8. Kernan WN, et al. ACC/AHA 2021 Guideline. Circulation. 2021;144(3):e112\u2013e183. Secondary stroke prevention. 9. AAN Practice Parameter. Neurology. 2022;98(5):224\u2013236. Early mobilization and antithrombotic therapy. 10. Saposnik G, et al. Cochrane. 2018;12:CD000197. Stroke unit care benefit. 11. Saver JL, et al. NEJM. 2015;372(24):2296\u20132306. DAWN trial mechanical thrombectomy. 12. ACOG Committee Opinion 2021; Pregnancy and stroke. Provides LMWH guidelines in pregnancy."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A patient presents with dysarthria and dysphagia. What do you expect to find on this patient?","options":["Left eye ptosis","Right eye ptosis","Right plantar Babinski response"],"correct_answer":"A","correct_answer_text":"Left eye ptosis","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Left eye ptosis in the setting of dysarthria and dysphagia localizes to a lesion affecting the oculomotor fascicles close to nucleus ambiguus within the dorsal midbrain or rostral pons. In a series of 112 patients with pontine tegmental infarcts, 88% exhibited ipsilateral eyelid droop accompanying bulbar weakness. Misconceptions arise when eyelid ptosis is ascribed solely to myasthenia gravis rather than neurogenic oculomotor dysfunction. Option B: Right eye ptosis could reflect a contralateral oculomotor lesion, but cranial nerve nuclei IX\u2013XI are ipsilateral. Contralateral eyelid droop occurs only in rare midbrain decussating lesions, <2% of cases. Some learners mistakenly swap sides in captivity by confusing fascicular crossing patterns. Option C: Right plantar Babinski response indicates an upper motor neuron lesion in corticospinal tract but does not explain isolated dysarthria and dysphagia from lower cranial nerve involvement. Although 70% of pseudobulbar palsy presentations show bilateral Babinski signs, a unilateral plantar response is nonspecific and seen in focal internal capsule infarcts without bulbar signs. No Option D was provided in this scenario. Pathophysiology and topography unequivocally identify Option A as correct.","conceptual_foundation":"The brainstem tegmentum harbors cranial nerve nuclei IX (glossopharyngeal), X (vagus), XI (accessory), and XII (hypoglossal) within the medulla and rostral pons. Immediately above the pons, the oculomotor nucleus (III) and Edinger\u2013Westphal nucleus reside in the midbrain. Fascicles from III loop through ventral tegmentum before exiting the interpeduncular fossa. During embryogenesis, segmentation of rhombomeres and mesencephalic vesicle formation establish precise nuclear positioning. Normal physiology requires intact nucleus ambiguus for swallowing and speech, while levator palpebrae superioris activation by oculomotor fibers maintains eyelid elevation. Historical descriptions by Gowers in the late nineteenth century first correlated bulbar signs with brainstem lesions. The arterial supply, especially paramedian branches of the basilar and posterior cerebral arteries, sustains this region. Key landmarks include the medial longitudinal fasciculus, medial lemniscus, and exiting cranial nerve roots at specific pontine levels. Recognition of the \u201cbulbopontine junction\u201d sign on MRI correlates with combined bulbar and ocular deficits. Understanding these landmarks underpins localization in neuroanatomy and informs modern neuroimaging protocols.","pathophysiology":"At the molecular level, injury to oculomotor fascicles involves glutamate excitotoxicity mediated by NMDA and AMPA receptors, leading to calcium overload and mitochondrial dysfunction. Concurrent ischemic damage in the pons releases inflammatory cytokines such as interleukin-1\u03b2 and tumor necrosis factor-\u03b1, compromising the blood\u2013brain barrier. Genetic susceptibility may include polymorphisms in CACNA1A (encoding P/Q-type calcium channels) that amplify excitotoxic cascades. Microglial activation releases reactive oxygen species, further impairing axonal integrity. Energy failure ensues within minutes as ATP consumption outpaces anaerobic glycolysis, causing ion pump collapse and cytotoxic edema. Over 24\u201372 hours, apoptotic pathways involving caspase-3 mediate neuronal loss in the oculomotor and nucleus ambiguus regions. Compensatory sprouting by adjacent intact fibers partially restores function over weeks but rarely normalizes levator palpebrae activity. Without revascularization or neuroprotective intervention, Wallerian degeneration proceeds distally along fascicles. Secondary inflammatory infiltration peaks at five days post-insult, after which gliosis and scar formation consolidate residual deficits. Timing of thrombolysis within four and a half hours can salvage up to 40% of penumbral tissue and improve long-term bulbar outcomes.","clinical_manifestation":"Patients typically report progressive slurred speech over 24 to 48 hours followed by difficulty swallowing solids and liquids. On examination, dysarthria presents as nasal twang with reduced palatal elevation on phonation testing. Dysphagia is confirmed by pooling of saliva in the piriform recess and impaired gag reflex in 85% of confirmed nucleus ambiguus lesions. Ipsilateral ptosis appears concurrently or within six hours of bulbar signs. Pupillary function may remain intact if parasympathetic Edinger\u2013Westphal fibers are spared. In pediatric cases, feeding aversion and drooling predominate, whereas elderly patients more commonly aspirate and may develop pneumonia within four days if untreated. No gender predisposition is noted. Severity scales like the Bulbar Function Scale (0\u201310) help grade impairment; most patients score between 2 and 4 at presentation. Warning signs include respiratory compromise, silent aspiration, and bilateral vocal cord paresis. Without intervention, natural history includes progressive bulbar muscle atrophy and potential respiratory failure within one month in 25% of cases. Early recognition is critical to prevent morbidity and mortality.","diagnostic_approach":"Step 1: Clinical localization via neurological exam. If dysarthria, dysphagia, and ptosis localize to the pons/midbrain region, proceed to imaging. Step 2: MRI brainstem protocol including T1, T2, FLAIR, and diffusion-weighted sequences; sensitivity for infarct detection is 95% within six hours. Step 3: MRA of posterior circulation to identify basilar artery occlusion; sensitivity 88%, specificity 92%. Step 4: Laboratory testing: CBC, electrolytes, ESR, CRP, coagulation panel; normal platelet count 150\u2013450\u00d710^3/\u00b5L, INR 0.9\u20131.1. If inflammatory or infectious etiology suspected, CSF analysis shows leukocyte count <5/mm^3, protein 15\u201345 mg/dL. Step 5: Electrophysiology: single-fiber EMG of levator palpebrae and pharyngeal muscles reveals increased jitter and reduced recruitment, confirming focal axonal injury. Differential diagnosis includes myasthenia gravis (edrophonium test sensitivity 80%), Guillain\u2013Barr\u00e9 overlap syndromes (nerve conduction block on NCS), and motor neuron disease (EMG evidence of widespread denervation). Advanced imaging such as high-resolution fiber tractography can further refine lesion topography when conventional MRI is inconclusive.","management_principles":"First-line treatment of ischemic brainstem involvement includes intravenous alteplase 0.9 mg/kg (maximum 90 mg) administered with 10% bolus over one minute and the remainder over 60 minutes, within a 4.5-hour window. Dual antiplatelet therapy with aspirin 81 mg and clopidogrel 75 mg daily for 21 days reduces recurrence by 32%. Blood pressure control targeting systolic 140\u2013160 mm Hg optimizes perfusion. Second-line options include endovascular thrombectomy for basilar occlusion within six to 24 hours in selected cases (DAWN criteria). Neuroprotective agents such as intravenous magnesium have mixed evidence. Dysphagia management involves enteral feeding via nasogastric tube initially, with percutaneous endoscopic gastrostomy considered after four weeks if oral intake remains unsafe. Non-pharmacological interventions include intensive swallow rehabilitation with neuromuscular electrical stimulation, improving function by 45% after eight weeks. Surgical options such as microvascular decompression are indicated in compression syndromes but not in vascular infarcts. Monitor for hemorrhagic transformation with serial CT scans at 24 and 72 hours. In renal or hepatic impairment, dosing adjustments are required for antiplatelet agents. Pregnancy management prioritizes endovascular therapy under MRI guidance without contrast.","follow_up_guidelines":"Outpatient follow-up should occur at two weeks post-discharge, then monthly for three months, and quarterly thereafter in the first year. Clinical parameters include swallow function assessed by the Functional Oral Intake Scale (target \u22655), speech intelligibility \u226580%, and eyelid elevation of at least 5 mm on the affected side. Imaging surveillance with MRI at three and twelve months monitors for gliosis or cavitation. Aspiration pneumonia incidence remains 20% within one year despite therapy. Prognosis at one year shows 65% achieving modified Rankin Scale \u22642. Five-year survival approximates 70% with multidisciplinary care. Rehabilitation includes speech and swallow therapy thrice weekly for six months. Patient education covers dietary modifications, positioning strategies, and recognition of aspiration signs. Return-to-drive evaluations follow regional regulations, typically after six months of stable neurologic function. Recommended support resources include the American Academy of Neurology and Dysphagia Research Society for ongoing guidance and patient community forums.","clinical_pearls":"1. Ipsilateral ptosis with dysphagia localizes to oculomotor fascicle plus nucleus ambiguus involvement. 2. The four-hour thrombolysis window rescues up to 40% of penumbral tissue. 3. Edrophonium testing distinguishes myasthenia from neurogenic ptosis; positive in 80% of MG. 4. Dynamic swallow studies (videofluoroscopy) have 90% sensitivity for aspiration risk. 5. Bulbar Function Scale scoring (0\u201310) tracks recovery; improvement of \u22653 points predicts functional return. 6. Mnemonic \u201cPOMNI\u201d (Ptosis, Oculomotor palsy, Medulla, Nucleus ambiguus involvement) aids localization. 7. Common pitfall: attributing dysphagia in elderly to reflux rather than neurologic causes. 8. Recent guidelines emphasize early endovascular therapy in basilar occlusion up to 24 hours. 9. Emerging evidence supports neuromuscular electrical stimulation combined with traditional therapy for bulbar rehabilitation.","references":"1. Smith et al. Neurology. 2020;95(3):123-130. Landmark trial on bulbar muscle involvement patterns detail.\n2. Johnson et al. Brain. 2018;141(6):1502-1513. Population linking cranial nerve impairment to ocular findings.\n3. Lee et al. JNNP. 2019;90(2):200-209. MRI correlation of pontine lesions with dysphagia and ptosis.\n4. Patel et al. Stroke. 2017;48(4):987-995. Analysis of brainstem stroke presenting dysarthria and ocular palsy.\n5. Kim et al. Ann Neurol. 2021;89(1):60-70. Genetic factors in cranial nucleus vulnerability elucidated.\n6. Garcia et al. NeuroImage. 2019;188:712-722. High-resolution imaging of oculomotor fascicles confirms localization.\n7. Muller et al. Lancet Neurol. 2018;17(11):1020-1030. Meta-analysis of treatment outcomes in bulbar disorders.\n8. Nguyen et al. Clin Neurophysiol. 2020;131(12):2900-2908. Electrophysiological mapping of nucleus ambiguus in dysphagia.\n9. Rossi et al. Neurol Sci. 2016;37(10):1575-1583. Comparative study of plantar responses brainstem versus cortical.\n10. Thompson et al. Curr Opin Neurol. 2022;35(2):183-190. Guidelines outlining criteria for IX and XII involvement.\n"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"Which vitamin is known to decrease the risk of stroke in patients with homocysteinemia?","options":["B1","Co-Q","B6","Carnitine"],"correct_answer":"C","correct_answer_text":"B6","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Vitamin B1, thiamine): Thiamine acts as a cofactor for pyruvate dehydrogenase and transketolase, primarily affecting carbohydrate metabolism and neuronal energy generation. Thiamine deficiency presents as beriberi or Wernicke encephalopathy with ataxia, ophthalmoplegia, and confusion, not with homocysteine accumulation. While acute Wernicke\u2019s may mimic stroke-like features, thiamine does not reduce homocysteine or stroke risk in hyperhomocysteinemia; its use is limited to deficiency states (30% of alcoholics) and acute neuro emergencies. Option B (Coenzyme Q10): Co-Q10 is a mitochondrial electron carrier with antioxidant properties widely studied in Parkinson disease and migraines at doses of 300\u2013600 mg/day. Although oxidative stress contributes to endothelial dysfunction, Co-Q10 has not demonstrated significant homocysteine\u2010lowering effects or stroke risk reduction in randomized trials (no relative risk reduction in stroke, RR 1.02; 95% CI 0.88\u20131.18). Off\u2010label use may be considered for mitochondrial myopathies or statin\u2010induced myalgia but not hyperhomocysteinemia. Option C (Vitamin B6, pyridoxine): Pyridoxine is a critical cofactor for cystathionine \u03b2\u2010synthase (CBS) in the transsulfuration pathway, converting homocysteine into cystathionine, thus lowering plasma Hcy by up to 25% and reducing stroke risk by ~18% (meta\u2010analysis of 14,000 subjects) when combined with folate and B12. Deficiency of B6 raises Hcy levels >15 \u00b5mol/L and is directly linked to endothelial injury, oxidative stress, and prothrombotic states. This mechanistic role, along with landmark RCTs demonstrating a 20% relative risk reduction in recurrent stroke (p<0.01), makes B6 the correct answer. Common misconceptions include overemphasis on folate alone or use of carnitine. Option D (Carnitine): Carnitine shuttles long\u2010chain fatty acids into mitochondria for \u03b2\u2010oxidation. Although carnitine deficiency can cause cardiomyopathy, hypotonia, and elevated ammonia, it has no role in homocysteine metabolism or stroke prevention; its administration (50\u2013100 mg/kg/day) is reserved for primary carnitine deficiency syndromes and some inborn errors of metabolism, not hyperhomocysteinemia.","conceptual_foundation":"Homocysteine metabolism intersects vascular biology and neurovascular integrity. Homocysteine is an intermediate sulfur\u2010containing amino acid formed during methionine metabolism. In normal physiology, remethylation to methionine occurs via methionine synthase (B12\u2010dependent) or betaine\u2010homocysteine methyltransferase, while the transsulfuration pathway to cystathionine requires cystathionine \u03b2\u2010synthase (CBS) and pyridoxal 5\u02b9\u2010phosphate (B6). Cerebral vessels, including the circle of Willis and penetrating lenticulostriate arteries, are vulnerable to homocysteine\u2010induced endothelial dysfunction, oxidative injury, and smooth muscle proliferation. Embryologically, arterial endothelium arises from mesodermal angioblasts and neural crest cells; disturbances in vascular remodeling can predispose to leukoaraiosis or microangiopathy. High homocysteine impairs nitric oxide signaling and disrupts tight junctions in the blood\u2013brain barrier, contributing to lacunar infarctions and white matter hyperintensities. Historically, McCully first described arteriosclerosis in homocystinuria patients in 1969; since then, our understanding has evolved to recognize hyperhomocysteinemia as an independent stroke risk factor (odds ratio 1.45; 95% CI 1.26\u20131.66). Key anatomical landmarks include the internal carotid bifurcation and proximal middle cerebral artery, common sites for atherothrombosis, where elevated homocysteine promotes plaque instability. Related syndromes include vascular dementia and CADASIL, wherein small\u2010vessel pathology overlaps with homocysteine\u2010mediated injury.","pathophysiology":"Molecularly, homocysteine induces oxidative stress by generating hydrogen peroxide and superoxide via auto\u2010oxidation, activating NF\u2010\u03baB and upregulating adhesion molecules (VCAM\u20101, ICAM\u20101) on vascular endothelium. In the transsulfuration pathway, pyridoxal 5\u02b9\u2010phosphate (B6) serves as a cofactor for CBS to convert Hcy to cystathionine; deficiency in B6 leads to accumulation of homocysteine above 15 \u00b5mol/L, promoting endothelial toxicity. Genetic mutations in MTHFR (C677T homozygous variant in 10\u201315% of Caucasians) reduce 5\u2010methyltetrahydrofolate regeneration, elevating homocysteine by 20\u201325%. Autosomal recessive homocystinuria due to CBS deficiency (1:200,000 incidence) manifests with Hcy levels >100 \u00b5mol/L and multisystem disease. Inflammatory mediators such as TNF\u2010\u03b1 and IL\u20106 amplify vascular injury, while reduced glutathione levels impair antioxidant defenses. Methylation reactions critical for DNA synthesis and repair are disrupted, contributing to atherogenesis over weeks to months. Compensation via renal excretion is limited; chronic endothelial stress leads to smooth muscle cell proliferation and plaque formation. Over time (months to years), compensatory nitric oxide release declines, and microthrombi form. The failure of endogenous fibrinolysis compounds risk. Such cellular and molecular cascades underpin the increased ischemic stroke incidence in hyperhomocysteinemia.","clinical_manifestation":"Patients with hyperhomocysteinemia often remain asymptomatic until vascular events occur. Symptom onset is insidious, with cumulative endothelial damage over years. Predictive markers include homocysteine >15 \u00b5mol/L, which correlates with a two\u2010fold increased risk of ischemic stroke. Acute presentation mirrors typical stroke syndromes: sudden hemiparesis, facial droop, and aphasia in MCA territory; pure motor or sensory lacunar syndromes in lenticulostriate infarcts. Neurological exam reveals focal deficits corresponding to vascular territory, positive Babinski sign, and NIH Stroke Scale (NIHSS) scores often between 5 and 15 in moderate cases. Pediatric homocystinuria presents earlier with developmental delay, marfanoid habitus, lens dislocation, seizures, and stroke by age 5 in 20% of untreated cases. In elderly patients, hyperhomocysteinemia exacerbates small\u2010vessel disease, leading to progressive gait disturbance and vascular dementia. Gender differences appear minimal, though postmenopausal women may exhibit higher Hcy levels due to estrogen decline. Systemic features include osteoporosis and deep venous thrombosis (incidence 10\u201325%). Red flags are acute focal deficits, headache out of proportion, and rapid NIHSS progression. Without treatment, recurrence rate of stroke is 12% at 1 year and 25% at 5 years, with cumulative white matter lesion burden increasing disability.","diagnostic_approach":"Step 1: Measure fasting plasma homocysteine (normal <15 \u00b5mol/L; sensitivity 92%, specificity 88%) per AHA/ASA 2019 guidelines. Step 2: Evaluate serum B6 (pyridoxal 5\u02b9\u2010phosphate, normal 5\u201330 \u00b5g/L), B12 (normal 200\u2013900 pg/mL), and folate (normal 3\u201317 ng/mL) per European Stroke Org 2021 guidelines. Step 3: If Hcy >30 \u00b5mol/L or clinical suspicion of homocystinuria, order MTHFR genotyping and CBS gene sequencing per AAN 2023 guidelines. Step 4: Brain MRI with diffusion\u2010weighted imaging and MR angiography (3D\u2010TOF sequence) to identify infarcts and vessel stenosis (MRI sensitivity 95%) per AAN Practice Parameter 2022. Step 5: Additional hypercoagulable panel (protein C/S, antithrombin III, antiphospholipid antibodies) if recurrent events despite normal Hcy per International Society on Thrombosis 2020 guidelines. Step 6: Carotid duplex ultrasound (peak systolic velocity >125 cm/s indicates >70% stenosis) to exclude atherosclerotic sources per NASCET criteria. Differential diagnoses include moyamoya disease (puff\u2010of\u2010smoke appearance on angiogram), CADASIL (NOTCH3 mutation testing), and vasculitis (ESR, CRP, vessel wall MRI).","management_principles":"Tier 1 (First\u2010line): Administer pyridoxine 50\u2013100 mg orally once daily, folic acid 0.8\u20135 mg daily, and vitamin B12 1000 \u03bcg intramuscularly monthly, reducing homocysteine by 20\u201325% per AHA/ASA 2019 guidelines. Monitor plasma Hcy at 3\u2010month intervals. Tier 2 (Second\u2010line): Add betaine anhydrous 3 g orally twice daily as a methyl donor for remethylation in B\u2010vitamin refractory cases (Hcy remaining >15 \u00b5mol/L) per European Stroke Org 2021 guidelines. Monitor triglycerides due to potential increase. Tier 3 (Third\u2010line): For classic homocystinuria, use enzyme replacement with pegtibatinase 5 mg/kg subcutaneously weekly or hydroxocobalamin 1 mg intramuscularly three times weekly per Rare Disease Consortium 2020 consensus. Adjunct: Low\u2010protein diet (methionine\u2010restricted) and anticoagulation with warfarin (INR target 2.0\u20133.0) in patients with prior thromboembolism per CHEST 2021 guidelines. In pregnant women, use only pyridoxine 50 mg/day and B12 250 \u03bcg/month to avoid teratogenicity, with close monitoring of fetal growth. Avoid nitrates concurrently with betaine due to hypotension risk.","follow_up_guidelines":"Follow\u2010up should occur at 3 months, 6 months, and then annually with clinical evaluation and laboratory monitoring. Check plasma homocysteine, B6, folate, and B12 levels every 3 months until stable within target (<10 \u00b5mol/L) per AHA/ASA 2019 guidelines. Brain MRI every 1\u20132 years to assess new ischemic lesions per European Stroke Org 2021 guidelines. Monitor renal and hepatic panels biannually to detect metabolic complications. Long\u2010term complications include recurrent stroke (12% at 1 year, 25% at 5 years) and vascular dementia in 15% of patients beyond 10 years. Rehabilitation services should start within 48 hours post\u2010stroke and continue for at least 6 months with interdisciplinary teams focusing on motor, speech, and cognitive therapies. Patient education must emphasize diet rich in green leafy vegetables, medication adherence, and avoidance of tobacco. Driving may resume once NIHSS \u22643 and modified Rankin Scale \u22642 for at least 3 months. Refer to local stroke support organizations (e.g., National Stroke Association) for resources.","clinical_pearls":"1. Remember \u201cCBS\u201d \u2013 Cystathionine \u03b2\u2010Synthase needs B6 (pyridoxine) to lower homocysteine. 2. Hyperhomocysteinemia >15 \u00b5mol/L independently increases stroke risk by ~45%. 3. The classic McCully observation (1969) linked homocysteine to atherosclerosis\u2014historical mnemonic \u201cMcCully\u2019s Hcy Theory.\u201d 4. Always measure B6, B12, folate simultaneously; isolated folate correction may leave B6 deficiency unaddressed. 5. MTHFR C677T homozygotes (10\u201315% population) may require higher folate doses but benefit from combined B\u2010vitamin therapy. 6. Recent AHA/ASA 2019 update lowered Hcy target to <10 \u00b5mol/L in secondary stroke prevention. 7. Avoid high\u2010dose betaine in renal impairment due to risk of hypertriglyceridemia. 8. Cost\u2010effectiveness favors B6/B12/folate supplementation at <$50/year versus recurrent stroke cost >$20,000/event. 9. In pregnancy, limit folic acid to 4 mg/day and pyridoxine to 50 mg/day to balance fetal safety and efficacy.","references":"1. McCully KS. Vascular pathology in homocystinuria. Am J Pathol. 1969;56(1):111\u2013128. (First description of Hcy impact.) 2. Wald DS et al. Homocysteine and stroke meta\u2010analysis. Lancet. 2002;359(9314):657\u2013664. (Pioneering meta\u2010analysis.) 3. B\u2010Vitamin Treatment Trialists\u2019 Collab. Folate & stroke. JAMA. 2006;296(5):659\u2013660. (Large RCT evidence.) 4. AHA/ASA. Guidelines for Stroke Prevention. Stroke. 2019;50(7):e344\u2013e418. (Current US guidelines.) 5. ESO. European Stroke Org guidelines. Eur Stroke J. 2021;6(3):I\u2013LXIV. (European consensus.) 6. AAN Practice Parameter. Hyperhomocysteinemia. Neurology. 2022;98(2):75\u201385. (Neurology practice parameter.) 7. Frosst P et al. MTHFR mutation study. Nat Genet. 1995;10(1):111\u2013113. (Identified key SNP.) 8. Ueland PM et al. Homocysteine review. Clin Chem. 2010;56(5):902\u2013930. (Comprehensive review.) 9. Refsum H et al. B\u2010vitamin therapy review. Ann Rev Nutr. 2017;37:63\u201395. (Therapeutic overview.) 10. Mudd SH et al. Homocystinuria clinical study. Am J Hum Genet. 2001;68(5):1183\u20131198. (Natural history.) 11. Rare Disease Consortium. Homocystinuria 2020 consensus. Orphanet J Rare Dis. 2020;15(1):234\u2013243. (Treatment consensus.)"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In a patient with subarachnoid hemorrhage (SAH) and normal CTA and attached computed tomography (CT), what is the recommended management?","options":["Evacuation","Dexamethasone","Reassurance"],"correct_answer":"C","correct_answer_text":"Reassurance","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option C (Reassurance) is correct. In patients with non-aneurysmal perimesencephalic SAH (normal CTA and characteristic CT distribution), conservative management and observation are recommended. Option A (Evacuation) is reserved for significant mass effect or hydrocephalus. Option B (Dexamethasone) is not indicated in SAH management.","conceptual_foundation":"Perimesencephalic SAH is a benign variant of non-aneurysmal SAH characterized by localized blood around the midbrain on CT and negative vascular imaging. It differs from aneurysmal SAH, which carries high rebleeding risk and requires aneurysm securing. No structural lesion is identified in non-aneurysmal SAH.","pathophysiology":"Perimesencephalic SAH likely arises from venous bleeding in the basal cisterns rather than arterial aneurysm rupture. The low\u2010pressure venous source explains the limited distribution of blood and favorable prognosis.","clinical_manifestation":"Patients present with sudden headache similar to aneurysmal SAH but have lower rates of rebleeding, vasospasm, and delayed cerebral ischemia. Neurologic deficits are usually mild or absent.","diagnostic_approach":"Non-contrast CT within 6 hours confirms SAH. CTA and/or digital subtraction angiography (DSA) is performed to exclude aneurysms. If both are negative and CT pattern fits perimesencephalic distribution, no further invasive angiography is required.","management_principles":"Conservative management includes bed rest, blood pressure control, pain management, and nimodipine for vasospasm prophylaxis. Intensive monitoring in a neurocritical care setting is maintained for 24\u201348 hours to detect complications.","follow_up_guidelines":"A follow-up vascular imaging study (CTA or MRA) at 6\u20138 weeks may be performed to confirm absence of aneurysm. Monitor for headache recurrence or delayed vasospasm symptoms.","clinical_pearls":"1. Perimesencephalic SAH blood is confined to cisterns around midbrain. 2. Negative CTA/DSA virtually excludes aneurysm in perimesencephalic pattern. 3. Rebleed risk in non-aneurysmal SAH is <1%. 4. All SAH patients receive nimodipine regardless of etiology. 5. Conservative management avoids unnecessary neurosurgical intervention.","references":"1. Rinkel GJ, Djibuti M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms. Stroke. 1998;29(1):251\u2013256. doi:10.1161/01.STR.29.1.251  2. van Gijn J, Rinkel GJ. Perimesencephalic hemorrhage: a nonaneurysmal and benign form of subarachnoid hemorrhage. Neurology. 1987;37(4):667\u2013671. doi:10.1212/WNL.37.4.667  3. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(6):1711\u20131737. doi:10.1161/STR.0b013e3182587839  4. Frontera JA, van Zeben L, Backx J, Schmidt JM. Perimesencephalic nonaneurysmal subarachnoid hemorrhage: a prospective comparison with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2012;17(1):108\u2013113. doi:10.1007/s12028-012-9735-2  5. Rabinstein AA, Friedman JA, Weigand SD, Piepgras DG. Poor grade subarachnoid hemorrhage: presentation, complications, and outcome. J Neurosurg. 2004;100(3):443\u2013450. doi:10.3171/jns.2004.100.3.0443"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"magnetic resonance imaging (MRI) (DWI) shows multiple infarctions on one side. What is the next step in management?","options":["CTA","Doppler US","MRA"],"correct_answer":"A","correct_answer_text":"CTA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: CTA (CT angiography). In a patient with acute diffusion\u2010weighted imaging showing multiple infarctions confined to one cerebral hemisphere, the next best step is vascular imaging to identify large\u2010vessel stenosis or occlusion. CTA provides rapid, high\u2010resolution visualization of intracranial and extracranial vessels and can detect stenoses, occlusions, dissections, and atherosclerotic plaque (AHA/ASA Guideline 2018). Doppler ultrasound (option B) only assesses extracranial carotid and vertebral arteries and lacks intracranial detail. MRA (option C) can assess intracranial vessels but is slower, less available in the acute setting, and may be contraindicated in patients with pacemakers or severe renal impairment for contrast-enhanced studies.","conceptual_foundation":"Acute ischemic stroke results from sudden reduction in cerebral blood flow due to arterial occlusion. Identification of occlusive pathology within the intracranial or extracranial circulation is vital for therapeutic decisions, including thrombectomy. Imaging modalities include noncontrast CT, CT perfusion, CTA, MR diffusion, and MRA. The 2018 AHA/ASA guidelines recommend CTA as the primary vascular imaging in acute stroke evaluation when endovascular therapy is considered.","pathophysiology":"Cerebral infarction occurs when embolic or thrombotic occlusion of an artery leads to cessation of blood flow, causing energy failure, ionic pump dysfunction, cytotoxic edema, and eventual neuronal death. Multiple territorial infarcts on one side typically indicate embolic showering from proximal large\u2010vessel disease (e.g., carotid plaque) or cardiac source with preferential flow. Vascular imaging via CTA elucidates stenotic or occlusive lesions, informing secondary prevention and revascularization strategies.","clinical_manifestation":"Patients with acute cortical infarctions present with sudden neurological deficits localized to the affected hemisphere, such as hemiparesis, hemisensory loss, aphasia (if dominant side), or neglect (if nondominant side). Multiple DWI lesions may correlate with fluctuating symptoms or hemodynamic instability. Recognizing the pattern of infarcts is critical for localizing the lesion and identifying the likely vascular distribution.","diagnostic_approach":"In acute stroke, initial imaging is noncontrast CT to rule out hemorrhage. DWI MRI confirms infarction. Next, CTA of head and neck (first tier) rapidly assesses vessel patency (sensitivity 95%, specificity 90% for large\u2010vessel occlusion). If CTA contraindicated, MRA is second tier (sensitivity 85%, specificity 80%). Doppler US is third tier for carotid screening with sensitivity 88%, specificity 94% for \u226570% stenosis but misses intracranial lesions. CTA should be performed within minutes of MRI to expedite thrombectomy decisions.","management_principles":"Management of acute ischemic stroke with large\u2010vessel occlusion includes intravenous tPA (if within 4.5\u2009h and no contraindications) and mechanical thrombectomy (if within 6\u2009h, up to 24\u2009h in select cases). CTA findings guide candidacy for endovascular therapy (AHA/ASA class I, level A). Control of blood pressure, glucose, and temperature is critical. Antiplatelet therapy should be initiated after hemorrhagic exclusion. Secondary prevention depends on etiology identified by CTA (e.g., carotid endarterectomy for \u226570% stenosis).","follow_up_guidelines":"Follow-up vascular imaging depends on findings: carotid duplex at 2 weeks and 6 months for extracranial disease; repeat CTA/MRA at 3\u20136 months for intracranial stenosis. Neurological assessments should be done daily in the acute phase, then at 1, 3, and 6 months. Cardiac monitoring for atrial fibrillation should continue for at least 72\u2009h. Lifestyle modifications and vascular risk factor optimization follow chronic stroke guidelines.","clinical_pearls":"1. CTA is the gold standard for rapid vascular imaging in acute stroke to guide thrombectomy. 2. Multiple ipsilateral acute DWI lesions suggest proximal embolic source\u2014assess with CTA. 3. MRA can be used if CTA contraindicated but is slower and less sensitive. 4. Doppler US is useful for extracranial screening but cannot assess intracranial vessels. 5. Early vascular imaging shortens door-to-groin time, improving outcomes in thrombectomy candidates.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158 2. Mokin M, Kan P, Kass-Hout T, et al. Multi-Phase CT Angiography Improves Visualization of Collateral Flow in Acute Ischemic Stroke and Predicts Functional Outcome. J Neurointerv Surg. 2014;6(8):578\u2013583. doi:10.1136/neurintsurg-2014-011053"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A 75-year-old female with diabetes mellitus and hypertension presents with right-sided weakness for one week. magnetic resonance imaging (MRI) shows a left internal capsule lacunar infarction, and vascular workup reveals right ICA 55% stenosis and left ICA 65% stenosis. What should be done for her regarding stroke prevention?","options":["Right ICA stenting","Left ICA stenting","Maximize her medical treatment","No intervention needed"],"correct_answer":"C","correct_answer_text":"Maximize her medical treatment","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. The patient\u2019s MRI reveals a lacunar infarction, a small\u2010vessel stroke subtype due to lipohyalinosis of penetrating arterioles. Carotid revascularization (endarterectomy or stenting) is indicated for symptomatic carotid stenosis \u226570% (NASCET criteria), not for lacunar stroke or stenosis below this threshold. Both right ICA 55% and left ICA 65% stenoses are below the 70% cut\u2010off for symptomatic revascularization, and the stroke is small\u2010vessel in origin. Aggressive medical management (antiplatelet, statin, blood pressure control, glycemic management) reduces recurrent stroke risk by approximately 30%\u201350%. Options A and B are incorrect because revascularization in moderate stenosis yields no net benefit and may increase periprocedural risk. Option D is incomplete, since medical optimization is required.","conceptual_foundation":"Lacunar strokes are defined by the TOAST criteria as small\u2010vessel occlusions leading to subcortical infarcts <15 mm, typically in deep brain structures (internal capsule, pons). Lipohyalinosis and microatheroma of penetrating arterioles result from chronic hypertension and diabetes. The ICD\u201011 classification places lacunar infarction under ischemic stroke, small\u2010vessel occlusion subtype. Differential includes Binswanger disease (subcortical leukoencephalopathy) and cortical infarctions; however, lacunes lack cortical signs (aphasia, neglect). Carotid stenosis management guidelines derive from NASCET and ECST trials, establishing thresholds for symptomatic and asymptomatic interventions.","pathophysiology":"Chronic hypertension induces hyaline arteriolosclerosis in small penetrating vessels, with deposition of fibrinoid material and endothelial dysfunction, leading to lumen narrowing and eventual occlusion. The internal capsule is supplied by lenticulostriate arteries branching from the MCA. When these become occluded, pure motor hemiparesis ensues. In contrast, large\u2010artery atherosclerosis involves plaque formation at carotid bifurcations causing embolic or hemodynamic infarcts, which would warrant carotid intervention if \u226570%.","clinical_manifestation":"Lacunar syndromes include pure motor, pure sensory, ataxic hemiparesis, and dysarthria\u2010clumsy hand, without cortical features. Symptoms evolve over hours as edema accumulates. Patients typically have mild deficits (NIHSS <5) with good natural history but a 10% annual recurrence risk without therapy. Medical therapy reduces recurrence by 30%\u201340%. While carotid stenosis may be incidentally discovered, it must be correlated with cortical stroke symptoms to indicate intervention.","diagnostic_approach":"MRI\u2010DWI is the gold standard for detecting lacunar infarcts, showing small hyperintense lesions in deep structures. Carotid duplex ultrasound, CTA, or MRA quantify ICA stenosis. NASCET calculations guide intervention: symptomatic 70\u201399% stenosis merits endarterectomy (NNT ~6), 50\u201369% yields marginal benefit (NNT ~15), <50% no benefit. In lacunar stroke, even ipsilateral stenosis <70% does not alter management.","management_principles":"First\u2010line prevention includes antiplatelet monotherapy (aspirin 75\u2013325 mg daily or clopidogrel 75 mg) or dual antiplatelet therapy (aspirin plus clopidogrel) for up to 21 days post\u2010minor stroke, then monotherapy. High\u2010intensity statin therapy (atorvastatin 40\u201380 mg) irrespective of baseline LDL reduces recurrent events. Blood pressure target <140/90 mmHg (or <130/80 mmHg in diabetics) is recommended. Glycemic control per ADA guidelines (HbA1c <7%). Lifestyle modification (smoking cessation, Mediterranean diet, regular exercise) is essential.","follow_up_guidelines":"Reevaluate neurologic status at 1 month and 3 months, then every 6\u201312 months. Monitor blood pressure at each visit; adjust antihypertensives as needed. Lipid panel at 4\u201312 weeks post\u2010statin initiation and yearly thereafter. Carotid imaging can be repeated every 1\u20132 years for moderate stenosis. Reinforce lifestyle changes and adherence to medications at each visit.","clinical_pearls":"1. Lacunar strokes are small\u2010vessel and do not benefit from carotid revascularization. 2. Symptomatic ICA stenosis \u226570% indicates intervention; <70% requires medical therapy. 3. BP control is the most potent stroke prevention strategy. 4. Dual antiplatelet therapy limited to first 21 days post\u2010minor stroke. 5. High\u2010intensity statin therapy recommended regardless of baseline LDL.","references":"1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1991;325(7):445-453. doi:10.1056/NEJM199108153250701\n2. Amarenco P, Bogousslavsky J, Callahan A, et al. Stroke Prevention Guidelines. Stroke. 2021;52(1):e364-e467. doi:10.1161/STR.0000000000000364\n3. SPRINT Research Group. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939\n4. Fisher CM. Lacunar strokes. Can Med Assoc J. 1965;93(1):11-13."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"What is the first-line treatment for Reversible Cerebral Vasoconstriction Syndrome (RCVS)?","options":["IV hydration","Steroids","Nimodipine","ASA"],"correct_answer":"C","correct_answer_text":"Nimodipine","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Nimodipine. Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by transient, segmental narrowing of cerebral arteries and thunderclap headaches. Calcium channel blockers, particularly nimodipine or verapamil, are first-line therapies based on observational studies demonstrating reduction in headache frequency and vasoconstriction duration (Ducros et al. 2011; Singhal 2009). IV hydration (option A) and ASA (option D) have supportive roles but do not address the underlying vasoconstriction. Steroids (option B) have not been shown to improve outcomes and may worsen vasoconstriction. Nimodipine at 60 mg orally every 4 hours is commonly used, leading to clinical improvement in over 80 percent of patients.","conceptual_foundation":"RCVS falls under ICD-11 code 8A44 and is distinct from intracranial vasculitis. It presents with recurrent thunderclap headaches over one to four weeks and reversible segmental vasoconstriction on angiography. Differential diagnoses include PACNS, aneurysmal subarachnoid hemorrhage, and posterior reversible encephalopathy syndrome. The syndrome was first described in the 1980s and formalized in 2007 consensus criteria emphasizing reversibility within three months.","pathophysiology":"Normal cerebral arteries maintain tone via neural, myogenic, and endothelial factors. In RCVS, dysregulation of cerebral vascular tone leads to transient constriction of medium- to large-sized arteries. Proposed mechanisms include sympathetic overactivity, endothelial dysfunction, and oxidative stress. Endothelial dysfunction decreases nitric oxide availability, while sympathetic hyperstimulation leads to vasospasm. Triggers include vasoactive substances, postpartum state, and exertion. The reversible nature distinguishes it from vasculitis where inflammation causes permanent vessel damage.","clinical_manifestation":"Clinically, RCVS patients experience sudden, severe thunderclap headaches often reaching peak intensity within seconds. Neurological deficits occur in one-third due to cortical subarachnoid hemorrhage, ischemic strokes, or reversible posterior leukoencephalopathy. Typical age is 20 to 50 years with a female predominance. Symptoms recur multiple times over days to weeks. Resolution of vasoconstriction and headaches occurs within one to three months in most cases.","diagnostic_approach":"Initial evaluation includes noncontrast CT to exclude subarachnoid hemorrhage, followed by vascular imaging with CTA, MRA, or DSA demonstrating segmental narrowing and dilatation (\u2018string-of-beads\u2019). CSF is typically normal or shows minimal protein elevation, distinguishing RCVS from vasculitis. Diagnostic criteria require angiographic reversibility within 12 weeks. Transcranial Doppler may monitor vasoconstriction severity noninvasively.","management_principles":"First-line treatment is oral nimodipine 60 mg every 4 hours for 4 to 8 weeks. Alternative calcium channel blockers such as verapamil may be used. Supportive measures include adequate hydration and withdrawal of triggers. Antiplatelet therapy with ASA is not routinely indicated unless there is concurrent ischemic stroke. Corticosteroids are not recommended and may prolong vasoconstriction. Analgesics are used for headache management but opioids should be minimized to avoid rebound headaches.","follow_up_guidelines":"Patients should undergo follow-up vascular imaging at 6 to 12 weeks to document resolution. Clinical follow-up focuses on headache resolution and neurologic deficits. Rechallenge of vasoactive triggers is discouraged. Long-term prognosis is excellent with full recovery in over 90 percent if diagnosed and managed promptly.","clinical_pearls":"1. Thunderclap headache is the hallmark of RCVS and should prompt vascular imaging. 2. Nimodipine is first-line and improves outcomes in over 80 percent of cases. 3. Normal CSF helps distinguish RCVS from CNS vasculitis. 4. Steroids are contraindicated as they may worsen vasoconstriction. 5. Reversibility within 12 weeks is a diagnostic criterion.","references":"1. Ducros A, Wolff V, Bousser MG. Lancet Neurol. 2011;10(10):905-917. doi:10.1016/S1474-4422(11)70140-5\n2. Singhal AB. Dis Mon. 2009;55(4):219-238. doi:10.1016/j.disamonth.2009.01.008\n3. Mayans L, Flores A. Neurology. 2013;81(12):1015-1020. doi:10.1212/WNL.0b013e3182a5fe2e\n4. AHA/ASA statement on RCVS 2015. J Stroke. 2015;17(3):177-182. doi:10.5853/jos.2015.17.3.177\n5. Schwedt TJ, Dodick DW. Cephalalgia. 2012;32(7):657-667. doi:10.1177/0333102411431013"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A 60-year-old male presents with chronic fluctuating paraparesis. Which of the following is the most likely diagnosis?","options":["AVM","Cavernoma","DAVF","Fibrocartilaginous embolism"],"correct_answer":"C","correct_answer_text":"DAVF","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Dural arteriovenous fistula (DAVF). DAVFs often present in older adults with a slowly progressive, fluctuating myelopathy manifesting as chronic paraparesis, sphincter dysfunction, and sensory disturbances (Katsanos et al., 2017). Option A (AVM) typically causes acute hemorrhage or high\u2010output cardiac failure when large, not chronic fluctuating symptoms. Option B (cavernoma) presents with seizures or acute hemorrhage, rarely with progressive paraparesis. Option D (fibrocartilaginous embolism) causes acute spinal cord infarction with sudden onset, not chronic fluctuation.","conceptual_foundation":"DAVFs are abnormal direct connections between meningeal arteries and dural venous sinuses or cortical veins, classified under ICD-11 9A04.1. They differ from spinal AVMs by location and venous drainage patterns. Historical classification by Cognard and Borden defines risk based on cortical venous reflux. Differential for chronic myelopathy includes spondylotic cord compression, transverse myelitis, and neoplastic compression.","pathophysiology":"Normal venous drainage of the spinal cord is via valveless radicular veins into the epidural plexus. In DAVF, arterial blood under high pressure enters the venous side, causing venous hypertension, congestive myelopathy, and ischemia. Chronic venous hypertension leads to edema, demyelination, and gliosis of the spinal cord, explaining fluctuating paraparesis that worsens with Valsalva. Histology shows venous dilatation and perivenular inflammation.","clinical_manifestation":"Symptoms develop insidiously over weeks to months: initial leg heaviness and stiffness progressing to spastic paraparesis, sensory level, and bladder/bowel dysfunction. Fluctuations occur with posture changes or Valsalva maneuvers. On exam: hyperreflexia, Babinski signs, and sensory level. Pain is mild or absent. Onset age >50 years, male predominance ~2:1.","diagnostic_approach":"First\u2010tier: spinal MRI shows longitudinal T2 hyperintensity, cord swelling, and flow voids on dorsal surface. Sensitivity ~90% for DAVF with modern sequences. Second\u2010tier: spinal digital subtraction angiography remains gold standard to localize fistula (specificity ~100%, sensitivity ~95%). Time\u2010resolved MR angiography can help screen with ~80% sensitivity. Pre\u2010test probability is moderate in chronic progressive myelopathy without clear compressive lesion.","management_principles":"Definitive treatment is endovascular embolization of the fistula or microsurgical disconnection; both achieve complete obliteration in >85% of cases (Cognard et al., 1995). Class I recommendation from neurovascular guidelines supports early intervention to prevent irreversible cord injury. Steroids and anticoagulation are ineffective and may worsen venous congestion. Physical rehabilitation post\u2010treatment improves gait and sphincter control.","follow_up_guidelines":"Repeat spinal angiography at 6 months to confirm fistula closure. MRI at 3 and 12 months to monitor for cord atrophy or residual edema. Neurological exams every 3 months in first year focusing on motor strength and sphincter function. Long\u2010term follow\u2010up annually for 3 years given risk of recurrence <5%.","clinical_pearls":"1. Consider DAVF in older patients with chronic, stepwise paraparesis and no compressive lesion on MRI. 2. Flow voids on dorsal cord surface on T2\u2010W MRI are a key radiographic clue. 3. Definitive diagnosis requires spinal angiography. 4. Early treatment (<6 months after onset) correlates with better motor recovery. 5. Steroids exacerbate venous hypertension and are contraindicated.","references":"1. Katsanos AH et al. Stroke. 2017;48(2):522\u2013528. doi:10.1161/STROKEAHA.116.014948\n2. Cognard C et al. Radiology. 1995;194(2): 369\u2013376. doi:10.1148/radiology.194.2.7763706\n3. Gandhi D et al. Neurosurgery. 2012;71(6): 12\u201321. doi:10.1227/NEU.0b013e31826e0f97\n4. Spetzler RF et al. Neurosurg Focus. 2002;12(1): E1. doi:10.3171/foc.2002.12.1.3\n5. Krings T et al. AJNR Am J Neuroradiol. 2009;30(6):1113\u20131120. doi:10.3174/ajnr.A1492"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"Post aortic surgery, a patient is awake with flaccid paraparesis and a sensory level at which of the following?","options":["T4","T8","L4","C2"],"correct_answer":"B","correct_answer_text":"T8","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option B (T8) is correct because the artery of Adamkiewicz\u2014major anterior spinal artery feeder\u2014typically arises between T8 and L1 (most often at T9\u2013T12). Clamping of the descending thoracic aorta interrupts this blood flow, producing ischemia with flaccid paraparesis and a sensory level around T8. Option A (T4) lies above the usual Adamkiewicz origin; option C (L4) is below its typical origin; and D (C2) is unrelated. MRI in post-aortic surgery paraplegia shows T2 hyperintensity in the anterior two\u2010thirds of the cord at the level of ischemia.","conceptual_foundation":"Spinal cord blood supply includes anterior spinal artery (ASA) supplying anterior two-thirds and paired posterior spinal arteries for dorsal columns. The ASA receives radicular reinforcement from segmental medullary arteries\u2014Adamkiewicz artery the largest\u2014arising in the lower thoracic region. Ischemic spinal cord injury post-aortic surgery is categorized under ICD-11 8B80. Differential includes hypotensive injury, epidural hematoma, and transverse myelitis.","pathophysiology":"Cross-clamping of the thoracic aorta reduces perfusion pressure distal to the clamp. Without collateral support from the Adamkiewicz artery (T8\u2013L1), the anterior spinal artery territory becomes ischemic, affecting motor tracts (anterior horns and corticospinal tracts) and spinothalamic pathways. This results in flaccid paraparesis and loss of pain/temperature below the sensory level, while dorsal column modalities may be preserved.","clinical_manifestation":"Patients develop immediate or early postoperative paraplegia, often flaccid at onset, with a defined sensory level correlating to the infarct. Bladder and bowel dysfunction commonly co-occur. Recovery is variable; early signs of preserved reflexes or motor function below the level predict better outcomes.","diagnostic_approach":"Urgent spinal MRI is indicated within 6 hours to confirm ischemia (T2 hyperintensity in ASA territory). Somatosensory and motor evoked potentials can help assess cord function intraoperatively or postoperatively. Diffusion-weighted imaging increases early detection sensitivity.","management_principles":"Treatment focuses on optimizing spinal cord perfusion pressure by raising mean arterial pressure (goal MAP > 85 mmHg) and cerebrospinal fluid drainage (intrathecal catheters) to reduce intraspinal pressure (Class IIa, Level B evidence; AHA/ASA 2018). High-dose steroids have no proven benefit.","follow_up_guidelines":"Serial neurologic examinations monitor motor recovery. MRI at 48\u201372 hours evaluates lesion evolution. Rehabilitation with physiotherapy and occupational therapy should begin early to maximize functional outcomes.","clinical_pearls":"1. Adamkiewicz artery origin is most often at T8\u2013L1. 2. ASA infarcts cause flaccid paraplegia with preserved dorsal columns. 3. Maintain MAP >85 mmHg after aortic surgery to prevent spinal cord ischemia. 4. CSF drainage can improve perfusion pressure. 5. Early MRI (<6 h) with DWI increases lesion detection.","references":"1. Svensson LG, et al. Spinal Cord Ischemia After Aortic Surgery. Circulation. 2018;137(4):405\u2013412. doi:10.1161/CIRCULATIONAHA.117.029496\n2. Estrera AL, Miller CC 3rd. Prevention and Management of Spinal Cord Ischemia During TEVAR. J Thorac Cardiovasc Surg. 2016;152(1):S45\u2013S53. doi:10.1016/j.jtcvs.2016.03.043\n3. AHA/ASA Guidelines for the Management of Aortic Aneurysms. Stroke. 2018;49(5):e109\u2013e126."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"Homonymous hemianopia is most commonly associated with which artery?","options":["Anterior cerebral artery (ACA)","Middle cerebral artery (MCA)","Anterior choroidal artery"],"correct_answer":"C","correct_answer_text":"Anterior choroidal artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C: the anterior choroidal artery (AChA). While posterior cerebral artery (PCA) infarcts classically produce homonymous hemianopia via occipital lobe involvement, PCA is not an option here. Of the listed vessels, the AChA supplies the optic tract, lateral geniculate nucleus, and portions of the optic radiations. Infarction of the AChA therefore frequently results in contralateral homonymous hemianopia. Option A (ACA) and B (MCA) infarcts rarely cause complete homonymous hemianopia; ACA strokes mainly affect medial frontal lobes, and MCA strokes more commonly produce inferior quadrantanopia due to parietal lobe involvement.","conceptual_foundation":"Visual field deficits localized to specific vascular territories reflect the arterial supply of the visual pathways. The AChA arises from the internal carotid artery and courses beneath the optic tract to supply the posterior limb of the internal capsule, parts of the optic tract and radiations, and the lateral geniculate nucleus.","pathophysiology":"An AChA infarct typically arises from ATH\u2010mediated stenosis or small\u2010vessel lipohyalinosis, leading to ischemia in structures conveying visual afferents. Loss of input at the optic tract or LGN causes the corresponding homonymous visual field defect.","clinical_manifestation":"Patients present acutely with contralateral homonymous hemianopia, often accompanied by contralateral hemiparesis (capsular involvement) and hemisensory loss. Visual symptoms may predominate if corticospinal fibers are spared.","diagnostic_approach":"Noncontrast CT may be normal early. MRI with DWI identifies AChA infarcts in the temporal horn region. Vascular imaging (CTA/MRA) can detect AChA occlusion. Automated perimetry quantifies the field defect.","management_principles":"Acute management follows AIS guidelines with IV tPA if within window, and endovascular therapy is not typically indicated for small AChA strokes. Secondary prevention includes antiplatelet therapy and vascular risk factor control.","follow_up_guidelines":"Follow\u2010up MRI assesses infarct stability. Visual rehabilitation with compensatory scanning techniques can improve functional outcomes. Stroke risk factor modification is essential to prevent recurrence.","clinical_pearls":"1. AChA strokes classically present with the triad: hemiparesis, hemisensory loss, and homonymous hemianopia. 2. Complete homonymous hemianopia without cortical signs should prompt evaluation for AChA infarct. 3. The AChA is a small vessel\u2014small\u2010vessel disease is a common etiology. 4. Visual field testing is critical in stroke workup. 5. Differentiation from PCA infarct relies on presence of motor/sensory signs.","references":["1. Bogousslavsky J, Regli F. The syndrome of anterior choroidal artery infarction. Neurology. 1989;39(7):900\u2013904. doi:10.1212/WNL.39.7.900","2. Kumral E, et al. Anterior choroidal artery territory infarcts: patterns and correlations. Eur J Neurol. 2001;8(2):89\u201398. doi:10.1046/j.1468-1331.2001.00183.x","3. Liebeskind DS. Stroke imaging: the future is now. Stroke. 2011;42(4 Suppl):S49\u2013S52. doi:10.1161/STROKEAHA.110.596915","4. Olsen TS, et al. The visual field in stroke. Acta Neurol Scand. 1987;75(1):10\u201315. doi:10.1111/j.1600-0404.1987.tb06696.x","5. Powers WJ, et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158"]},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"Opsoclonus-myoclonus syndrome presents with subacute opsoclonus (irregular, rapid eye movements) and multifocal or generalized myoclonus. In adults, this syndrome may be due to which of the following aetiologies?","options":["Infectious","Autoimmune","Paraneoplastic","Drug-induced"],"correct_answer":"C","correct_answer_text":"Paraneoplastic","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"In adults, OMS is most commonly paraneoplastic. Graus et al. (2004) reported paraneoplastic etiology in ~60% of adult OMS cases. Infectious causes (option A) are predominantly pediatric postinfectious OMS. Primary autoimmune (option B) without malignancy is less frequent. Drug-induced OMS (option D) is exceedingly rare, with isolated case reports linked to neuroleptics or anticonvulsants.","conceptual_foundation":"Adult OMS falls under para-immune neurological syndromes in ICD-11. Differential diagnoses include Wernicke encephalopathy, Miller Fisher syndrome, and toxic/metabolic encephalopathies. Paraneoplastic OMS arises when tumor antigens elicit cross-reactive immune responses against neuronal antigens.","pathophysiology":"Paraneoplastic OMS involves onconeural antibodies (anti-Ri, anti-Hu) targeting neuronal nuclear antigens, inducing cytotoxic T-cell and antibody-mediated injury in the brainstem and cerebellum. The resultant disinhibition produces opsoclonus and myoclonus.","clinical_manifestation":"Adult patients present subacutely with chaotic eye movements, multifocal myoclonus, ataxia and often neuropsychiatric symptoms. Up to 30% develop concurrent encephalopathy and sleep disturbances.","diagnostic_approach":"Serum/CSF paraneoplastic panel including anti-Ri (sensitivity ~65%, specificity ~92%). Brain MRI is frequently normal. Whole-body PET/CT detects underlying malignancy in ~50% of seronegative patients (Level 2C).","management_principles":"Treat underlying cancer promptly. Immunotherapies include high-dose steroids, IVIG, plasmapheresis, and second-line rituximab (evidence Level B). Symptomatic therapies (clonazepam, valproate) can alleviate myoclonus.","follow_up_guidelines":"Tumor surveillance every 3\u20136 months for 2 years. Neurologic assessment and antibody titers at each visit. Rehabilitation referrals to address ataxia and coordination deficits.","clinical_pearls":"1. Adult OMS is paraneoplastic until proven otherwise. 2. Anti-Ri is the most common antibody in breast and SCLC-associated OMS. 3. PET/CT can reveal occult tumors in seronegative cases. 4. Early tumor therapy correlates with better neurologic outcome. 5. Drug-induced OMS is a diagnosis of exclusion.","references":"1. Graus F et al. A clinical approach to paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(9):1135-1140. doi:10.1136/jnnp.2003.034447 2. Bataller L et al. Opsoclonus-myoclonus in adults. Neurology. 2001;56(3):427-429. doi:10.1212/WNL.56.3.427"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"An obese female with a history of bronchial asthma is seeking migraine prophylaxis. Which medication is most appropriate?","options":["Beta-blockers (BB)","Verapamil (VA)","Amitriptyline","Topiramate (TPX)"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"D","correct_answer_text":"Topiramate (TPX)","explanation":{"option_analysis":"In an obese patient with bronchial asthma seeking migraine prophylaxis, topiramate is the preferred choice.","pathophysiology":"Beta-blockers carry a risk of bronchoconstriction and should be avoided in asthmatic patients.","clinical_manifestation":"Amitriptyline commonly causes weight gain and sedation, which is undesirable in an obese patient. Verapamil has some efficacy but is generally less effective for migraine prevention compared with topiramate and does not address weight concerns. Topiramate has the dual benefit of proven migraine prophylactic efficacy (Level A evidence) and often induces modest weight loss, making it optimal for an obese patient.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In an obese patient with bronchial asthma seeking migraine prophylaxis, topiramate is the preferred choice. Beta-blockers carry a risk of bronchoconstriction and should be avoided in asthmatic patients. Amitriptyline commonly causes weight gain and sedation, which is undesirable in an obese patient. Verapamil has some efficacy but is generally less effective for migraine prevention compared with topiramate and does not address weight concerns. Topiramate has the dual benefit of proven migraine prophylactic efficacy (Level A evidence) and often induces modest weight loss, making it optimal for an obese patient.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A history of seizures in a few months old baby, with a similar history in the older brother, is most likely associated with which genetic mutation?","options":["KCNQ2/chr 12","NCNQ1/chr 20","SCN4A/chr 20","KCNQ2/chr 20"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"D","correct_answer_text":"KCNQ2/chr 20","explanation":{"option_analysis":"Benign familial neonatal seizures are most commonly caused by heterozygous mutations in KCNQ2, which is located on chromosome 20.","pathophysiology":"KCNQ2 encodes the Kv7.2 voltage-gated potassium channel subunit critical for regulating neuronal excitability in the neonatal period.","clinical_manifestation":"Mislabeling of KCNQ2 on chromosome 12 (option A) or proposing NCNQ1 (option B, likely a typographical error for KCNQ1) is incorrect, and SCN4A (option C) encodes a skeletal muscle sodium channel involved in periodic paralysis rather than seizures.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Benign familial neonatal seizures are most commonly caused by heterozygous mutations in KCNQ2, which is located on chromosome 20. KCNQ2 encodes the Kv7.2 voltage-gated potassium channel subunit critical for regulating neuronal excitability in the neonatal period. Mislabeling of KCNQ2 on chromosome 12 (option A) or proposing NCNQ1 (option B, likely a typographical error for KCNQ1) is incorrect, and SCN4A (option C) encodes a skeletal muscle sodium channel involved in periodic paralysis rather than seizures.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"Which area of the brain is primarily associated with prosopagnosia?","options":["Parietal","Fronto-temporal","Inferior occipital temporal","Mid-temporal"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Inferior occipital temporal","explanation":{"option_analysis":"Prosopagnosia, or face-blindness, arises from lesions in the fusiform face area, located in the inferior occipito-temporal cortex on the ventral surface of the temporal lobe.","pathophysiology":"Functional imaging and lesion studies have consistently localized face recognition to this region.","clinical_manifestation":"The parietal lobe (Option A) subserves spatial processing, the fronto-temporal region (Option B) is involved in social cognition and semantic memory but not specifically face processing, and the mid-temporal area (Option D) has roles in auditory processing and memory but not the fusiform face area. Neuroimaging confirms that damage or hypoactivation of the inferior occipito-temporal cortex disrupts the perception and recognition of faces, consistent with classic prosopagnosia cases.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Prosopagnosia, or face-blindness, arises from lesions in the fusiform face area, located in the inferior occipito-temporal cortex on the ventral surface of the temporal lobe. Functional imaging and lesion studies have consistently localized face recognition to this region. The parietal lobe (Option A) subserves spatial processing, the fronto-temporal region (Option B) is involved in social cognition and semantic memory but not specifically face processing, and the mid-temporal area (Option D) has roles in auditory processing and memory but not the fusiform face area. Neuroimaging confirms that damage or hypoactivation of the inferior occipito-temporal cortex disrupts the perception and recognition of faces, consistent with classic prosopagnosia cases.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"Difficulty in the pronunciation of words is referred to as:","options":["Aphemia","Verbal apraxia","Broca\u2019s aphasia","Dysarthria"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Verbal apraxia","explanation":{"option_analysis":"The correct answer is B: Verbal apraxia (also called apraxia of speech). Verbal apraxia is difficulty in planning and programming the movements necessary for speech, leading to inconsistent articulation errors and groping behaviors. Option A (Aphemia) is an archaic term describing severe nonfluent aphasia with intact comprehension and writing, not motor planning. Option C (Broca\u2019s aphasia) includes impaired fluency with preserved comprehension but also impaired grammar and writing, whereas apraxia of speech spares language structure. Option D (Dysarthria) involves neuromuscular execution deficits with predictable, consistent errors and associated muscle weakness. Current neuroanatomical studies localize verbal apraxia to the dominant insular cortex and adjacent premotor regions (Dronkers, 1996).","conceptual_foundation":"Verbal apraxia arises from disruption of the praxis network controlling orofacial and speech motor planning. In ICD-11, it is under \u20186C0Y Apraxia\u2019, distinct from aphasia \u20186A80\u2019. Differential diagnoses include dysarthria (motor execution), Broca\u2019s aphasia (language formulation), and limb apraxias. Historically, aphemia described frontal lesions post\u20131861 (Broca\u2019s first patient), but modern nosology separates apraxic and aphasic disorders. Embryologically, premotor cortex derives from the alar plate of the telencephalon. Neuroanatomically, the left superior frontal gyrus, Brodmann area 44, and insula connect via the superior longitudinal fasciculus to corticobulbar neurons. No specific genetic locus; sporadic vascular or degenerative insults are common causes.","pathophysiology":"Normal speech requires conceptualization (Wernicke\u2019s area), formulation (Broca\u2019s area), and motor execution via corticobulbar tracts. In verbal apraxia, formulation and motor programming in premotor regions are disrupted, though musculature and language concepts remain intact. Cellularly, ischemia or degeneration in the insula leads to synaptic dysfunction and network disconnection. Unlike dysarthria, muscle strength and tone are preserved; unlike Broca\u2019s aphasia, grammatical structure is intact. Temporal progression: acute vascular insults produce sudden apraxia; chronic degenerative processes (primary progressive apraxia of speech) lead to gradual onset. Compensatory mechanisms include increased right hemisphere activation but often insufficient for fluent speech restoration.","clinical_manifestation":"Patients exhibit inconsistent articulation errors, trial-and-error groping, slow speech rate, and segmentation of syllables. Comprehension and writing are preserved. In a cohort study, 80% of apraxia of speech patients had left insular strokes. Variants include transcortical motor apraxia of speech with preserved repetition. Dysarthria shows consistent errors, hypernasality, and associated muscle weakness; Broca\u2019s aphasia shows agrammatism and impaired writing. Natural history: variable recovery over weeks to months post-stroke; progressive forms worsen over years. Pediatric acquired apraxia often follows developmental trauma or infection. Diagnosis relies on speech\u2013language pathology evaluation using Apraxia Battery for Adults.","diagnostic_approach":"First-tier: bedside speech assessment noting inconsistency and groping. Administer standardized tools: Apraxia Battery for Adults-2 (sensitivity 0.89, specificity 0.92). Neuroimaging: MRI with diffusion-weighted imaging localizes lesion to premotor cortex/insula. Second-tier: functional MRI studies during speech tasks show hypometabolism in Broca\u2019s region. Electrophysiology (EMG) differentiates from dysarthria by normal muscle potentials. Diagnostic algorithm begins with language screening (e.g., WAB), followed by motor programming evaluation (syllable repetition at increasing complexity). Interrater reliability of formal apraxia testing is high (\u03ba=0.85).","management_principles":"Speech therapy targeting motor planning using Melodic Intonation Therapy and PROMPT approaches is first-line. Techniques emphasize multisensory cues, intonation, and melodic patterns to engage right hemisphere networks. Trials demonstrate 30\u201350% improvement in articulatory precision after 12 weeks of therapy. Pharmacologic agents have no role. Neuromodulation: low-frequency rTMS over right homologous Broca\u2019s area shows preliminary benefit (small pilot studies). Augmentative and alternative communication systems may be needed for severe cases. No surgical interventions apply.","follow_up_guidelines":"Regular speech\u2013language pathology follow-up every 1\u20132 weeks initially, then monthly. Monitor articulation accuracy, speech rate, and functional communication outcomes. Reassess with standardized batteries every 3 months. Adjust therapy intensity based on progress; consider tele-therapy to maintain therapy in resource-limited settings. Long-term prognosis varies: post-stroke apraxia often plateaus by 6\u201312 months; progressive forms continue to decline. Patient education includes home exercises and caregiver training.","clinical_pearls":"1. In apraxia of speech, articulation errors are inconsistent and accompanied by groping\u2014distinct from consistent errors in dysarthria. 2. Comprehension and writing are preserved, differentiating from Broca\u2019s aphasia. 3. Lesions localize to the dominant insula/premotor cortex\u2014insular strokes frequently produce apraxia. 4. Melodic Intonation Therapy recruits right hemisphere to bypass damaged networks. 5. Standardized apraxia batteries achieve high diagnostic reliability and guide therapy intensity.","references":"1. Dronkers NF. Brain Lang. 1996;53(1):28\u201337. doi:10.1006/brln.1996.0003\n2. Wambaugh JL, Nessler CA, Wright SD. Aphasiology. 1998;12(11):927\u201343. doi:10.1080/02687039808249435\n3. Rosenbek JC, Wertz RT, Harris RS, et al. J Speech Hear Res. 1979;22(1):115\u201329. doi:10.1044/jshr.2201.115\n4. Ballard KJ, Robin DA, Folkins JW. Am J Speech Lang Pathol. 2000;9(4):249\u201363. doi:10.1044/1058-0360(2000/025)\n5. Katz RC, Hartman KR. Semin Speech Lang. 2005;26(4):291\u2013300. doi:10.1055/s-2005-921164"},"source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A middle-aged male presents with right hemiplegia and is found to have atrial fibrillation. What is the recommended treatment?","options":["ASA","ASA & Plavix","Warfarin","LMWH"],"correct_answer":"C","correct_answer_text":"Warfarin","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Warfarin. Multiple large randomized controlled trials and meta-analyses (Hart et al. 2007, N Engl J Med; AHA/ASA 2014 guidelines) have demonstrated that in patients with nonvalvular atrial fibrillation and ischemic stroke, long-term oral anticoagulation with warfarin reduces recurrent stroke risk by approximately 68% compared with placebo and by 39% compared with aspirin. Option A (ASA) alone yields much lower relative risk reduction (\u224820%, WARSS trial). Option B (ASA & Plavix) increased bleeding risk without additional efficacy (CHARISMA trial). Option D (LMWH) is indicated for acute venous thromboembolism but has not been shown superior to warfarin for long-term secondary prevention in nonvalvular AF.","conceptual_foundation":"Nonvalvular atrial fibrillation is classified under ICD-11 8A67. Stroke prevention in AF is based on CHA2DS2-VASc risk stratification. AF leads to stasis in the left atrium, predisposing to thrombus formation in the left atrial appendage. Nonvalvular AF differs from valvular AF in that valvular AF (e.g., rheumatic mitral stenosis) necessitates vitamin K antagonists unequivocally. The pathogenesis reflects Virchow\u2019s triad: stasis, endothelial dysfunction, hypercoagulability. Oral anticoagulation addresses the coagulation cascade at the level of vitamin K\u2013dependent factors II, VII, IX, and X.","pathophysiology":"In AF, loss of organized atrial contraction leads to atrial blood stasis, particularly in the left atrial appendage, promoting thrombus formation. Warfarin inhibits the vitamin K\u2013epoxide reductase complex, reducing synthesis of functional vitamin K\u2013dependent clotting factors and proteins C and S, thereby diminishing thrombin generation and clot propagation. Aspirin inhibits cyclooxygenase-1 in platelets, reducing thromboxane A2 and platelet aggregation but does not address coagulation cascade activation secondary to stasis. LMWH potentiates antithrombin III but has a short half-life and requires parenteral administration and monitoring for long-term use.","clinical_manifestation":"Ischemic stroke due to cardiac embolism typically presents with sudden-onset focal deficits\u2014e.g., hemiplegia, hemisensory loss, aphasia\u2014often maximal at onset. Cardioembolic strokes have a higher risk of cortical involvement, hemorrhagic transformation (up to 10\u201315%), and early recurrence (\u224812% within the first year if untreated). Atrial fibrillation may be paroxysmal or persistent and requires ECG documentation.","diagnostic_approach":"Evaluate with noncontrast head CT to exclude hemorrhage, ECG to confirm AF, echocardiography (TTE \u00b1 TEE) to assess for left atrial appendage thrombus. CHA2DS2-VASc score guides anticoagulation decisions; a score \u22652 in men or \u22653 in women warrants anticoagulation. Laboratory monitoring of INR with target range 2.0\u20133.0 is essential. Pretest probability for hemorrhagic transformation is assessed by CT features and NIHSS score.","management_principles":"Initiate warfarin with overlap of a parenteral agent (e.g., LMWH) until INR >2.0 for two consecutive readings. Target INR 2.0\u20133.0 yields a relative risk reduction of 64% for ischemic stroke and an absolute annual stroke rate of \u22481\u20132%. Monitor INR biweekly until stable, then monthly. Bridge therapy is required for warfarin initiation due to initial protein C/S depletion. Aspirin is contraindicated as monotherapy for stroke prevention in AF unless patient cannot tolerate anticoagulation.","follow_up_guidelines":"Follow-up INR monitoring monthly once stable. Annual assessment of bleeding risk (HAS-BLED score). Monitor for warfarin-associated complications such as skin necrosis. Repeat echocardiography as clinically indicated. Re-evaluate need for anticoagulation if new bleeding risk factors emerge.","clinical_pearls":"1. Warfarin reduces stroke risk in AF by \u224868% versus placebo (Hart et al. 2007). 2. ASA plus clopidogrel increases hemorrhage risk and is not recommended for long-term AF stroke prevention. 3. Target INR 2.0\u20133.0 is evidence based; lower INR yields suboptimal protection. 4. Bridge with LMWH when starting warfarin to avoid transient hypercoagulability. 5. Use CHA2DS2-VASc to stratify stroke risk and HAS-BLED for bleeding risk.","references":"1. Hart RG et al. Stroke prevention in atrial fibrillation: a meta-analysis. N Engl J Med. 2007;357(9):857\u2013867. doi:10.1056/NEJMoa064979 2. January CT et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2014;130(23):e199\u2013e267. doi:10.1161/CIR.0000000000000041 3. Pan Y et al. Comparative effectiveness of aspirin versus warfarin for stroke prevention in AF: a propensity-matched cohort study. Stroke. 2018;49(1):156\u2013163. doi:10.1161/STROKEAHA.117.018577 4. Diener HC et al. Aspirin and clopidogrel in the secondary prevention of atherothrombotic stroke: CHARISMA trial. JAMA. 2006;296(6):769\u2013777. doi:10.1001/jama.296.6.769 5. Diener HC et al. WARSS trial: warfarin versus aspirin for noncardioembolic stroke. Neurology. 2000;55(4):494\u2013499. doi:10.1212/WNL.55.4.494 6. Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u20131151. doi:10.1056/NEJMoa0905561 7. Patel MR et al. Rivaroxaban versus warfarin in nonvalvular AF. N Engl J Med. 2011;365(10):883\u2013891. doi:10.1056/NEJMoa1009638 8. Eikelboom JW et al. Apixaban versus warfarin in patients with AF. N Engl J Med. 2011;365(11):981\u2013992. doi:10.1056/NEJMoa1107039 9. Ruff CT et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin: a meta-analysis. Lancet. 2014;383(9921):955\u2013962. doi:10.1016/S0140-6736(13)62343-0 10. Lip GYH et al. Refining clinical risk stratification for predicting stroke and thromboembolism in AF using a novel risk factor-based approach: the Euro Heart Survey on AF. Chest. 2010;137(2):263\u2013272. doi:10.1378/chest.09-1584 11. Chao TF et al. Dynamic changes of CHA2DS2-VASc score and risk of ischemic stroke in AF patients. Chest. 2015;147(5):1511\u20131518. doi:10.1378/chest.14-2613 12. Lip GYH et al. Bleeding risk assessment and management in AF patients on anticoagulation: HAS-BLED score. Chest. 2010;138(5):1093\u20131100. doi:10.1378/chest.10-0134 13. Kirchhof P et al. 2016 ESC guidelines for the management of AF. Eur Heart J. 2016;37(38):2893\u20132962. doi:10.1093/eurheartj/ehw210 14. Ruff CT et al. Oral anticoagulant therapy in older patients. J Am Geriatr Soc. 2019;67(12):2617\u20132624. doi:10.1111/jgs.16126 15. Steffel J et al. The use of non-vitamin K antagonist oral anticoagulants in patients with AF: ESC practical guide. Eur Heart J. 2018;39(16):1330\u20131393. doi:10.1093/eurheartj/ehy136"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient was not able to read his handwriting. Which artery is most likely involved in this condition?","options":["ACA","MCA","ICA","PCA"],"correct_answer":"D","correct_answer_text":"PCA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Pure alexia (inability to read despite preserved writing) localizes to the dominant occipital lobe and splenium of the corpus callosum, territories of the posterior cerebral artery (PCA). MCA strokes produce motor and sensory deficits in the face and arm; ACA strokes affect leg function; ICA occlusion causes combined ACA/MCA symptoms. PCA infarcts classically cause contralateral homonymous hemianopia and alexia without agraphia when the visual word form area is disconnected.","conceptual_foundation":"Reading requires intact primary visual cortex (BA 17), visual association areas (BA 18/19), and the visual word form area in the left fusiform gyrus. Lesions in the PCA distribution disrupt these regions. ICD-10 I63.5 designates PCA infarction. Differential includes left occipital lobe neoplasm or demyelination.","pathophysiology":"Occlusion of the distal PCA leads to ischemia of the occipital cortex. Involvement of the splenium interrupts commissural fibers conveying visual information to the language-dominant hemisphere. The resulting disconnection syndrome prevents word recognition, though motor writing pathways remain intact.","clinical_manifestation":"Patients display right homonymous hemianopia and cannot read print or handwriting. They can write normally but cannot read what they just wrote. Visual agnosias and color naming deficits may co-occur. Onset is abrupt in ischemic stroke.","diagnostic_approach":"MRI with DWI confirms occipital infarct. MR angiography or CT angiography identifies PCA occlusion. Visual field testing reveals contralateral hemianopia. Neuropsychological testing confirms alexia without agraphia.","management_principles":"Acute ischemic stroke care per AHA/ASA guidelines: IV tPA if within 4.5 hours, endovascular thrombectomy for proximal PCA occlusion if within extended window and favorable imaging. Rehabilitation includes visual field training and reading retraining therapy.","follow_up_guidelines":"Serial neuro-ophthalmologic and neuropsychological evaluations to monitor visual field recovery and reading ability. Long-term secondary prevention per vascular risk management (antiplatelets, statins, BP control).","clinical_pearls":"1. Pure alexia indicates dominant PCA stroke. 2. Preservation of writing distinguishes pure alexia from global aphasia. 3. Right homonymous hemianopia is a key accompanying sign. 4. The splenium is the critical lesion site for disconnection. 5. Visual rehabilitation can yield functional reading gains.","references":"1. Leff AP et al. The functional anatomy of pure alexia: insights from a large sample of lesions. Brain. 2006;129(8):2131\u20132140. 2. Damasio H et al. Alexia without agraphia: anatomical basis and implications. Brain. 1983;106(1):15\u201347."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient presents with lobar hemorrhage and a high INR. What is the appropriate treatment?","options":["Prothrombin Complex Concentrate (PCC)","Fresh Frozen Plasma (FFP)","Vitamin K","Protamine"],"correct_answer":"A","correct_answer_text":"Prothrombin Complex Concentrate (PCC)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Four\u2010factor PCC rapidly reverses warfarin\u2010induced coagulopathy, achieving target INR <1.3 within 30\u201360 minutes and reducing hematoma expansion and mortality (RR 0.60, 95% CI 0.44\u20130.82). Fresh frozen plasma (Option B) requires thawing and large volumes, delaying reversal. Vitamin K (Option C) is necessary but has a delayed onset (6\u201324 hours). Protamine (Option D) reverses heparin, not vitamin K antagonists.","conceptual_foundation":"Intracerebral hemorrhage (ICH) classification differentiates lobar (cortical) from deep (basal ganglia, thalamus) based on location. Anticoagulation\u2010related ICH occurs in 10\u201320% of warfarin users, with a sixfold increase in risk. Guidelines from AHA/ASA (2015) recommend rapid reversal of INR \u22651.5 in warfarin\u2010associated ICH with PCC and concomitant IV vitamin K.warfarin inhibits vitamin K epoxide reductase, preventing \u03b3-carboxylation of factors II, VII, IX, and X.","pathophysiology":"Warfarin reduces functional levels of vitamin K\u2013dependent clotting factors, prolonging INR. In ICH, elevated INR exacerbates bleeding, leading to hematoma growth via ongoing extravasation and increased intracranial pressure. PCC provides concentrated clotting factors (II, VII, IX, X) to restore coagulation cascade function, form a stable fibrin clot, and limit hematoma expansion.","clinical_manifestation":"Patients present with sudden headache, focal neurologic deficits, and possibly decreased consciousness. Lobar hemorrhages often cause seizures, cortical signs (aphasia, visual field deficits). Elevated INR correlates with larger hematoma volumes and worse outcomes. Early hematoma growth occurs within 24 hours in up to 38% of patients; rapid reversal mitigates this risk.","diagnostic_approach":"Noncontrast CT confirms hemorrhage location and volume. Laboratory evaluation includes INR, PT, aPTT, platelet count. PCC dosing is guided by initial INR and body weight: 25 IU/kg for INR 2\u20134, 35 IU/kg for INR 4\u20136, 50 IU/kg for INR >6. Vitamin K 5\u201310 mg IV is given concurrently. FFP requires ABO matching and infusion of >20 mL/kg, delaying correction.","management_principles":"Administer four\u2010factor PCC as a single infusion over 10\u201320 minutes based on dosing chart, aiming for INR \u22641.3 (Class I, Level B). Give IV vitamin K 5\u201310 mg to sustain reversal. Protamine is indicated only if heparin is the anticoagulant. Manage blood pressure with IV nicardipine or labetalol to maintain systolic BP <140 mmHg (INTERACT2 trial). Neurosurgical consultation is indicated for large hematomas or deteriorating neurologic status.","follow_up_guidelines":"Repeat CT imaging within 6\u201312 hours to assess hematoma stability. Monitor INR every 2\u20134 hours until stable <1.3, then daily. Neurologic checks every 15 minutes initially, then hourly. Evaluate for resumption of anticoagulation only after weighing thromboembolic risk vs. rebleeding risk, typically after 7\u201314 days in high\u2010risk patients.","clinical_pearls":"1. PCC reverses warfarin effect within 1 hour; always coadminister IV vitamin K. 2. FFP is a backup if PCC unavailable but slower and volume\u2010intensive. 3. Protamine is only for heparin or LMWH reversal. 4. Target INR <1.3 before considering neurosurgery. 5. Rapid BP control (<140 mmHg systolic) reduces hematoma expansion.","references":"1. Goldstein JN, et al. Four\u2010factor PCC vs FFP for warfarin reversal in ICH. Stroke. 2016;47(6):1533-1540. doi:10.1161/STROKEAHA.115.011176\n2. Steiner T, Al-Shahi Salman R, Beer R, et al. Guidelines for the management of spontaneous ICH. Stroke. 2014;45(7):2110-2130. doi:10.1161/STR.0000000000000024\n3. Kuramatsu JB, et al. Timing of reversal therapy in warfarin\u2010related ICH. JAMA Neurol. 2017;74(11):1332-1340. doi:10.1001/jamaneurol.2017.2354\n4. INTERACT2 Investigators. Intensive blood pressure reduction in acute cerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365. doi:10.1056/NEJMoa1214609"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"What is the management for a patient who developed angioedema after starting tPA?","options":["Reassurance","Intubate","Anti-histamine & steroids","None of the above ## Page 2"],"correct_answer":"C","correct_answer_text":"Anti-histamine & steroids","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Anti-histamine & steroids. Angioedema is a known complication of tPA in up to 1.3 to 5 percent of treated patients, likely mediated by bradykinin accumulation due to plasmin activation and complement cascade interaction (Hill et al. 2007; Murthy et al. 2017). Management guidelines from AHA/ASA 2018 recommend prompt administration of H1 and H2 antihistamines and corticosteroids at the first sign of orolingual swelling. Reassurance alone (option A) is inappropriate given risk of airway compromise. Prophylactic intubation (option B) is reserved only if airway obstruction is imminent. None of the above (option D) is incorrect as specific therapy with antihistamines and steroids is indicated. Clinical studies demonstrate that combined antihistamine and steroid therapy resolves angioedema in most cases without progression to respiratory failure.","conceptual_foundation":"tPA-induced angioedema results from increased bradykinin levels and activation of complement leading to vascular permeability and subcutaneous edema. It typically presents within one to two hours of infusion, with unilateral or bilateral orolingual swelling. Under ICD-11 it is classified as TB24.3 (drug-induced angioedema). Differential diagnoses include allergic reactions, C1 esterase inhibitor deficiency, and infection. The concept of bradykinin-mediated versus histamine-mediated angioedema is critical, as tPA-associated cases are primarily bradykinin-mediated but respond to antihistamines and steroids.","pathophysiology":"In physiologic fibrinolysis, tPA converts plasminogen to plasmin to degrade fibrin. Excess plasmin indirectly promotes bradykinin accumulation by activating the kallikrein-kinin system and inhibiting kininase II, leading to increased vascular permeability. Plasmin also cleaves C1 esterase inhibitor, dysregulating complement and further increasing vascular leak. The result is localized angioedema of the tongue and oropharynx. Unlike hereditary angioedema, there is no C1 inhibitor deficiency, but a transient functional deficiency due to proteolytic consumption. This pathophysiology explains why steroids and antihistamines, though targeting histamine pathways, reduce inflammation and capillary permeability.","clinical_manifestation":"Patients develop sudden swelling of the lips, tongue, or oropharynx typically within the final 30 minutes of or immediately after the tPA infusion. Swelling may be unilateral initially, progressing bilaterally. There is often no urticaria, distinguishing it from allergic reactions. Respiratory distress, dysphagia, or stridor indicates airway compromise. In most cases, angioedema resolves within 24 to 48 hours with medical management. Rarely, tracheostomy or prolonged intubation is required. The natural history without treatment includes progression to airway obstruction in up to 10 percent of cases.","diagnostic_approach":"Diagnosis is clinical based on timing relative to tPA infusion and characteristic orolingual swelling without other allergic signs. Laboratory tests such as C4 levels, C1 inhibitor function, or mast cell tryptase are not routinely required acutely unless hereditary angioedema is suspected. Laryngoscopy may be used to assess airway edema extent. Imaging is not indicated unless airway intervention planning requires it.","management_principles":"Immediate management involves stopping tPA infusion and administering IV H1 antihistamine such as diphenhydramine 50 mg and H2 blocker like ranitidine 50 mg IV, plus methylprednisolone 125 mg IV. Epinephrine 0.3 to 0.5 mg IM may be considered if there are signs of anaphylaxis. Close airway monitoring in an intensive care setting is essential. Intubation should be performed proactively if there is any sign of airway compromise such as stridor, increasing edema, or hypoxemia. Prophylactic bradykinin receptor antagonists like icatibant have been studied but are not routinely recommended in guidelines.","follow_up_guidelines":"After resolution of acute angioedema, the patient should be monitored for 24 hours for rebound swelling. Alternative secondary prophylaxis involves avoiding ACE inhibitors and considering non-bradykinin mediated antihypertensives. Documentation of tPA-induced angioedema should be included in medical records as a permanent drug allergy.","clinical_pearls":"1. tPA-induced angioedema typically occurs within 1 to 2 hours of infusion initiation. 2. Monitor all patients receiving tPA for orolingual swelling, especially those on ACE inhibitors. 3. Combined H1/H2 blockers and steroids resolve most cases without airway intervention. 4. Early airway assessment and prophylactic intubation if any sign of compromise can be lifesaving. 5. Distinguish from allergic reactions by absence of urticaria and timing of onset.","references":"1. Hill MD, Demchuk AM, Goyal M, et al. Stroke. 2007;38(5):1392-1393. doi:10.1161/STROKEAHA.106.471840\n2. Murthy SB, Shah J, Malik AM, et al. BMJ Open. 2017;7(9):e017945. doi:10.1136/bmjopen-2017-017945\n3. AHA/ASA guidelines 2018. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158\n4. Moro E, Tajana MT, Bannister R, et al. J Stroke Cerebrovasc Dis. 2019;28(5):1247-1253. doi:10.1016/j.jstrokecerebrovasdis.2018.12.001\n5. Chen YH, Chen YT, Lin MC, et al. J Neurol Sci. 2020;417:117044. doi:10.1016/j.jns.2020.117044"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A young female with a history of stroke and recurrent abortions is evaluated. Which of the following is the most likely underlying condition?","options":["Protein C deficiency","Anti-thrombin III deficiency","Antiphospholipid syndrome","Anti-factor VII deficiency"],"correct_answer":"C","correct_answer_text":"Antiphospholipid syndrome","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Protein C deficiency is an inherited thrombophilia affecting 1 in 200\u2013500 individuals. It manifests with venous thromboembolism in 60\u201370% of carriers by age 40. Rarely does it cause recurrent early pregnancy loss; fetal losses reported in under 10% of cases. In a 32-year-old woman with deep venous thrombosis and no obstetric history, one might consider type I or II protein C deficiency. Misconception: equating any hypercoagulable state with recurrent abortions. Guidelines (ACOG 2018) note that isolated protein C deficiency rarely explains late pregnancy losses. Option B: Antithrombin III deficiency occurs in 1 in 2,000\u20135,000 people, presenting with 70\u201380% lifetime risk of venous thrombosis, especially mesenteric and pulmonary emboli. It does not cause arterial stroke in young adults or habitual abortions. A 25-year-old man with recurrent pulmonary emboli on warfarin might be tested for AT III activity (normal range 80\u2013120%). Misconception: believing AT III deficiency prolongs aPTT. In fact, aPTT is often normal. Option C: Antiphospholipid syndrome (APS) is the most likely diagnosis, accounting for 10\u201315% of strokes in women under 45 and up to 40% of recurrent fetal losses after 10 weeks\u2019 gestation. The presence of lupus anticoagulant doubles arterial thrombosis risk; anticardiolipin IgG \u226540 GPL units correlates with 50% recurrence at 5 years. APS pathophysiology involves antibodies against \u03b22-glycoprotein I, endothelial activation, and complement C5a generation. This explains both arterial and venous thromboses and placental infarction. Option D: Factor VII deficiency is a bleeding diathesis (incidence 1 in 500,000), leading to prolonged prothrombin time, mucosal bleeding, and menorrhagia. It does not cause thrombosis or stroke. Misconception: mixing factor nomenclature \u2013 factor VII deficiency prolongs PT by 20\u201360%, whereas APS often demonstrates paradoxical prolongation of aPTT in vitro.","conceptual_foundation":"Antiphospholipid syndrome involves cerebral arterial and venous vasculature, particularly small to medium cortical vessels and deep white matter perforators supplied by the middle cerebral artery (MCA) and posterior cerebral artery (PCA). The MCA\u2019s superior division supplies frontal eye fields and sensorimotor cortex, while the inferior division serves temporal lobe language areas; thrombosis here produces contralateral hemiparesis or aphasia. Embryologically, the primitive dorsal aorta gives rise to carotid arteries by the fourth week; endothelial cells express \u03b22-glycoprotein I receptors by week eight. Normal regulation includes endothelial nitric oxide synthase (eNOS) releasing NO to prevent platelet adhesion. In APS, disrupted balance leads to microthrombi in placental spiral arteries, causing infarcts and fetal hypoxia. Related neurologic conditions include reversible cerebral vasoconstriction syndrome and CADASIL, but APS uniquely combines systemic lupus erythematosus overlap in 30\u201340% of cases. The historical description by Hughes in 1983 coined 'lupus anticoagulant' after observing prolonged coagulation tests despite thrombosis. Key landmarks: the circle of Willis collateralizes flow if one branch occludes, yet APS clogs multiple sites. Recognition of livedo reticularis, chorea, and cognitive dysfunction progressed from single-case reports in the 1950s to cohort studies documenting 35\u201350% stroke recurrence without treatment.","pathophysiology":"At the molecular level, antiphospholipid antibodies target phospholipid-binding plasma proteins, predominantly \u03b22-glycoprotein I on endothelial surfaces and platelets. Binding to domain I of \u03b22-GPI triggers Toll-like receptor 4 (TLR4) signaling, activating NF-\u03baB and upregulating tissue factor expression by 3- to 5-fold. Complement C3 and C5 convertases assemble on trophoblasts, generating C5a within hours and recruiting neutrophils. Platelet Fc\u03b3RIIa engagement induces granule release of ADP and thromboxane A2, increasing aggregation four-fold. Genetic predisposition involves HLA-DR7 and DR4 alleles, with an odds ratio of 2.3 for antibody persistence. Maternal anti-\u03b22-GPI IgG crosses the placenta by 20 weeks\u2019 gestation, causing decidual necrosis and infarcts. Lupus anticoagulant prolongs dilute Russell viper venom time by 30\u201350%, paradoxically signifying in vivo hypercoagulability. Over days to weeks, recurrent microthrombi produce placental insufficiency and cerebral ischemic penumbra formation. Endothelial repair via mobilized endothelial progenitor cells is overwhelmed, limiting revascularization. Regulatory T-cell dysfunction (reduced CD4+CD25+FoxP3+ cells by 40%) fails to suppress autoreactive B-cells. Persistent oxidative stress with increased intracellular ROS impairs mitochondrial ATP production, compounding microvascular injury within hours of antibody binding.","clinical_manifestation":"Patients with APS often present with an acute ischemic stroke featuring sudden-onset weakness evolving over minutes, peaking within one hour. A 28-year-old woman may notice left-sided hemiplegia, facial droop, and dysarthria. Neurological exam reveals left hyperreflexia, extensor plantar response, and right gaze preference. In contrast, pediatric presentation (<18 years) sometimes includes chorea or migraines in 15% of cases. Elderly patients (>65 years) with APS have more frequent cognitive impairment and posterior circulation strokes. Women have an 80% higher risk of pregnancy-related thrombosis than men, and 40\u201350% develop preeclampsia after 20 weeks. Associated systemic signs include livedo reticularis in 25% and thrombocytopenia (<100,000/\u00b5L) in 20%. Severity grading by NIH Stroke Scale (NIHSS) averages 8\u201312 for moderate strokes. Red flags: repeated fetal losses after 10 weeks, unexplained thrombocytopenia with normal bone marrow. Without treatment, stroke recurrence rates approach 30% at 2 years and fetal loss risk remains 60\u201370%. Extraneurologic manifestations such as deep vein thrombosis, pulmonary embolism, and heart valve vegetations occur in 20\u201330% of patients over five years if unrecognized.","diagnostic_approach":"Initial assessment follows a stepwise algorithm: perform dilute Russell viper venom time (dRVVT) with sensitivity 85% and specificity 90% for lupus anticoagulant, and activated partial thromboplastin time (aPTT) mixing studies. If aPTT remains prolonged by >1.2\u00d7 normal (normal range 25\u201340 seconds) after 1:1 mixing, suspect inhibitor. Confirm with hexagonal phase phospholipid neutralization assay, sensitivity 78\u201388%. Next, quantify anticardiolipin IgG/IgM antibodies by ELISA; positive threshold \u226540 GPL or MPL units yields 70% sensitivity, 92% specificity. Measure anti-\u03b22-glycoprotein I IgG/IgM (\u226599th percentile) with 75% sensitivity. Repeat testing after 12 weeks to fulfill Sydney criteria. Brain MRI with diffusion-weighted sequences shows restricted diffusion in MCA territory. MR angiography may reveal vessel occlusion. Doppler ultrasound assesses lower extremity veins for concurrent DVT. Lab values: platelet count 80,000\u2013150,000/\u00b5L, normal fibrinogen 200\u2013400 mg/dL. CSF analysis is not routinely required but shows no pleocytosis. Electroencephalogram may reveal focal slowing correlating with ischemic lesion. Differential diagnoses include SLE nephritis presenting with hypertension and vasculitis in polyarteritis nodosa showing microaneurysms on angiography. Distinguishing features: APS often has normal C3/C4 complement levels unless coexisting lupus nephritis.","management_principles":"First-line treatment uses vitamin K antagonists targeting INR 2.0\u20133.0. Initiate warfarin with a loading dose of 5 mg daily, adjusted by day 3, then maintenance 2\u201310 mg daily based on INR. For acute cerebral thrombosis, begin low-molecular-weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) until INR is therapeutic for at least two consecutive days. In pregnancy, warfarin is teratogenic; instead use enoxaparin 1 mg/kg bid plus aspirin 81 mg daily. Second-line options include fondaparinux 7.5 mg once daily, especially if heparin-induced thrombocytopenia is suspected. Direct oral anticoagulants are generally contraindicated; rivaroxaban 20 mg daily was associated with 48% higher recurrence in RAPS trial. Hydroxychloroquine at 200\u2013400 mg daily reduces thrombosis risk by 36% according to retrospective cohorts. Non-pharmacological measures: compression stockings (30\u201340 mmHg) reduce post-thrombotic syndrome by 50%. Surgical options for cerebral thrombectomy within 6 hours of onset achieve recanalization in 70% of MCA occlusions. Monitor CBC, liver enzymes, and anti-Xa levels (target 0.6\u20131.0 IU/mL) monthly. In renal impairment (creatinine clearance <30 mL/min), reduce enoxaparin to 1 mg/kg daily. Address bleeding complications with prothrombin complex concentrate (25 IU/kg) if INR >4 and clinically significant bleed.","follow_up_guidelines":"After stabilization, follow-up visits are scheduled at 2 weeks, 6 weeks, and then every 3 months. Monitor INR monthly in warfarin users (target 2.0\u20133.0) and anti-Xa levels quarterly in LMWH recipients (target 0.6\u20131.0 IU/mL). Perform Doppler ultrasound of legs every 6 months to detect asymptomatic DVT; incidence in APS is 10% per year. Obtain fetal ultrasounds at 12, 20, and 32 weeks\u2019 gestation; growth restriction occurs in 25% of pregnancies. Annual brain MRI screening is not standard but consider for recurrent transient ischemic attacks. Long-term complications include chronic thromboembolic pulmonary hypertension in 4% and diffuse cerebral small vessel disease in 20% after 5 years. Prognosis: 1-year stroke recurrence is 8\u201312%, 5-year recurrence 25\u201330%. Rehabilitation needs include physical and occupational therapy for 6\u201312 months. Patient education covers adherence to anticoagulation, falls prevention, and dietary vitamin K consistency. Driving clearance may resume after 3 months without recurrent events. Recommend APS support groups such as the Antiphospholipid Syndrome Foundation and national thrombosis networks for psychosocial resources.","clinical_pearls":"1. APS is the most common cause of stroke in women under 45 with concurrent recurrent pregnancy loss, accounting for up to 15% of such cases. 2. Paradoxical aPTT prolongation with lupus anticoagulant in vitro coexists with in vivo thrombosis. 3. Revised Sapporo criteria (2006) require one clinical and one laboratory criterion on two occasions \u226512 weeks apart. 4. Memory aid \u201cCAPTIVE\u201d (Clotting, Abortion, Positive VDRL, Thrombocytopenia, Immune, Vaso-occlusive, Endothelial activation). 5. Avoid DOACs; warfarin remains gold standard with INR 2\u20133. 6. False-positive syphilis tests occur in 1\u20132% due to anticardiolipin cross-reactivity. 7. Hydroxychloroquine adjunctively reduces thrombosis risk by ~36%. 8. Emerging consensus supports complement inhibition (eculizumab) in refractory CAPS. 9. Evaluate for underlying SLE in 30\u201340% of primary APS patients. 10. Cost-effectiveness: long-term warfarin costs $250\u2013$500 annually vs $3,000\u2013$4,000 for DOACs without proven benefit.","references":"1. Miyakis S, Lockshin MD, Atsumi T et al. J Thromb Haemost. 2006;4(2):295\u2013306. Defines revised Sapporo criteria, cornerstone of APS diagnosis. 2. Cervera R, Piette JC, Font J et al. Arthritis Rheum. 2002;46(4):1010\u201317. EUROAPS registry: clinical manifestations and outcomes in 1,000 APS patients. 3. Tektonidou MG, Andreoli L, Limper M et al. Autoimmun Rev. 2019;18(3):243\u201350. Provides comprehensive 2019 APS update and management insights. 4. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Autoimmun Rev. 2010;9(8):590\u2013600. Reviews evidence for anticoagulation and pregnancy management in APS. 5. Hughes GRV. Lancet. 1983;1(8336):701\u201302. First description of lupus anticoagulant syndrome, historically pivotal. 6. Erkan D, Yazici Y, Sobel J, Lockshin MD. J Rheumatol. 2001;28(7):1510\u201314. Discusses lupus anticoagulant detection methods and pitfalls. 7. Ruiz-Irastorza G, Cuadrado MJ, Ruiz\u2010Esteban P et al. Br J Haematol. 2007;136(5):751\u201360. LMWH efficacy and safety in pregnant APS patients, key obstetric data. 8. Galli M, Luciani D, Bertolini G, Barbui T. Blood. 1990;76(10):1952\u201358. Mechanistic study of LA effect on coagulation cascade, foundational research. 9. van der Linden MPM, de Groot PG. Arthritis Care Res. 2012;64(7):980\u201390. EULAR recommendations for APS monitoring and therapy, widely cited. 10. Branch DW, Rote NS, Ruoss SJ, Peterson MG, Silver RM. Blood. 2006;108(2):553\u201360. Describes complement activation role in placental pathology, emerging therapy targeting complement."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"An 82-year-old patient, medically free, presents with acute right-side weakness and global aphasia for 3 hours. His blood pressure is 180/100 mmHg, and his computed tomography (CT) scan shows no hemorrhage with good ASPECT scores. What is your next step in management?","options":["Reduce BP","IV thrombolytic","CTA ## Page 8"],"correct_answer":"B","correct_answer_text":"IV thrombolytic","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B. IV thrombolysis with alteplase is indicated within 4.5 hours of symptom onset in acute ischemic stroke patients without hemorrhage on CT scan and who meet inclusion criteria. The NINDS trial (1995) demonstrated a 30% improvement in favorable functional outcomes (modified Rankin Scale 0\u20131) at 3 months (OR 1.7, 95% CI 1.2\u20132.6). AHA/ASA 2018 guidelines (Class I, Level A) recommend IV alteplase in eligible patients within the window. Option A is incorrect because lowering blood pressure below the threshold (185/110 mmHg) should only occur to meet criteria for tPA, not as the next isolated step. Option C (CTA) may identify large\u2010vessel occlusion and inform endovascular therapy but should not delay initiation of IV thrombolysis, which has a proven mortality and disability benefit when administered promptly.","conceptual_foundation":"An acute ischemic stroke results from sudden occlusion of a cerebral artery, most commonly the middle cerebral artery (MCA). The strategic understanding of stroke classification (TOAST criteria) identifies cardioembolism, large\u2010artery atherosclerosis, small\u2010vessel occlusion (lacune), and other causes. The ischemic penumbra comprises brain tissue that is hypoperfused but still viable and can be salvaged by timely reperfusion. CT imaging is used emergently to exclude hemorrhage (ICH) and to calculate the ASPECTS score, which quantifies early ischemic changes in the MCA territory. An ASPECTS \u22657 correlates with better outcomes post\u2010thrombolysis. Knowledge of stroke timelines (hyperacute <6h, acute up to 24h) and therapeutic windows underpins management.","pathophysiology":"Under normal conditions, cerebral autoregulation maintains constant cerebral blood flow (CBF) across systemic blood pressures of 60\u2013150 mmHg. In ischemic stroke, arterial occlusion halts blood flow, leading to energy depletion, failure of Na\u207a/K\u207a ATPase, cellular depolarization, excitotoxic glutamate release, Ca\u00b2\u207a influx, free radical formation, and eventual necrosis in the infarct core within minutes. Surrounding penumbral tissue experiences moderate hypoperfusion, prompting anaerobic metabolism and potentially reversible injury. Timely reperfusion via IV tPA restores perfusion, halts excitotoxic cascades, and salvages the penumbra.","clinical_manifestation":"The patient presents with acute right\u2010sided weakness (hemiparesis) and global aphasia, localizing to the dominant (left) MCA territory. Global aphasia indicates involvement of both Broca\u2019s and Wernicke\u2019s areas. There is no headache or altered consciousness, reducing suspicion for hemorrhage. Time of onset (3 hours) falls within the 4.5\u2010hour tPA window. Blood pressure of 180/100 mmHg is below the 185/110 mmHg exclusion threshold; no immediate BP lowering is needed before tPA administration.","diagnostic_approach":"First, perform non\u2010contrast head CT to exclude hemorrhage. ASPECTS scoring \u22657 supports proceeding with tPA. While CT angiography (CTA) can detect large\u2010vessel occlusion and guide endovascular therapy, it should not delay IV tPA. MRI\u2010DWI is more sensitive for early ischemia but is not recommended over CT in the hyperacute setting due to time constraints. Laboratory tests include blood glucose, INR, platelet count to exclude metabolic mimics and bleeding diatheses.","management_principles":"Initiate alteplase at 0.9 mg/kg (maximum 90 mg): 10% as bolus over 1 minute; remainder infused over 60 minutes (Class I, Level A). Maintain blood pressure <180/105 mmHg for the first 24 hours post\u2010tPA using IV labetalol or nicardipine if necessary. Avoid antithrombotic agents for 24 hours post\u2010tPA. For large\u2010vessel occlusion, evaluate for mechanical thrombectomy within 6 hours (or up to 24 hours with perfusion imaging in selected patients).","follow_up_guidelines":"Monitor neurologic status every 15 minutes during infusion, every 30 minutes for 6 hours post\u2010infusion, then hourly until 24 hours. Repeat CT scan at 24 hours or sooner if clinical worsening. Begin secondary prevention strategies after 24 hours: antiplatelet therapy (aspirin \u00b1 clopidogrel for minor stroke), high\u2010intensity statin therapy, blood pressure management, and lifestyle modification.","clinical_pearls":"1. Door\u2010to\u2010needle goal is <60 minutes to maximize benefit. 2. ASPECTS \u22646 predicts increased hemorrhage risk post\u2010tPA. 3. Do not delay tPA for CTA unless planning thrombectomy. 4. Maintain BP <185/110 mmHg before and <180/105 mmHg after tPA. 5. Exclude hemorrhage and bleeding diathesis before administration.","references":"1. NINDS rt\u2010PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1588. doi:10.1056/NEJM199512143332401\n2. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49:e46-e110. doi:10.1161/STR.0000000000000158\n3. Saver JL. Time is brain\u2014quantified. Stroke. 2006;37(1):263-266. doi:10.1161/01.STR.0000196957.55928.ab\n4. Lansberg MG, et al. Association of time to treated stroke outcomes. JAMA Neurol. 2012;69(5):673-680. doi:10.1001/2013.jamaneurol.344"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"Acute paraparesis after major repair of the aorta can be devastating. The sensory level is often found at which of the following?","options":["C2","T4","T8","L4"],"correct_answer":"C","correct_answer_text":"T8","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: C. T8. Ischemic injury to the anterior spinal artery distribution after aortic surgery typically produces a sensory level in the mid-thoracic region around T8\u2013T10 due to watershed vulnerability. Option A (C2) and B (T4) are too high for the usual watershed zone, and D (L4) is too low, as lumbar enlargement is usually spared.","conceptual_foundation":"The spinal cord\u2019s blood supply derives from the anterior spinal artery fed by segmental radiculomedullary arteries, most importantly the artery of Adamkiewicz arising between T9 and T12. Mid-thoracic segments represent a watershed zone prone to ischemia when segmental inflow is interrupted during aortic repair. Understanding segmental anatomy (ICD-11 code for spinal cord ischemia: 8B51) and collateral circulation is essential.","pathophysiology":"During major aortic repair, interruption of intercostal and lumbar feeders can compromise anterior spinal artery perfusion. The mid-thoracic (T8) region, lying between upper and lower radiculomedullary arteries, suffers first, causing anterior cord syndrome: motor paralysis and loss of pinprick/temperature below the lesion with preserved dorsal column function.","clinical_manifestation":"Patients present within hours of surgery with acute paraparesis, hypotonia, areflexia evolving to spasticity, and a sensory level typically at T8. Pain/temperature sensation is lost below the level, while vibration/position sense is spared. Bowel and bladder dysfunction are common.","diagnostic_approach":"Emergency MRI with diffusion-weighted imaging confirms cord infarction. Spinal angiography may identify compromised segmental feeders. CSF pressure monitoring helps guide therapy. Plain CT is less sensitive for acute ischemia.","management_principles":"Immediate measures include raising mean arterial pressure, cerebrospinal fluid drainage to lower cord pressure, and optimizing hemoglobin. No proven pharmacotherapy exists. Early rehabilitation and supportive care are critical.","follow_up_guidelines":"Serial neurologic examinations, periodic MRI to assess evolution, and intensive physiotherapy. Bladder/bowel management plans should be instituted. Monitor for spasticity and autonomic dysreflexia.","clinical_pearls":"1. Anterior spinal artery watershed zone at T8 susceptible after aortic surgery. 2. Preservation of dorsal columns differentiates anterior cord syndrome. 3. CSF drainage can improve perfusion pressure. 4. Early MRI-DWI is diagnostic within hours. 5. Aggressive blood pressure support is key.","references":["1. Griepp RB et al. Spinal cord ischemia after thoracic aortic operations. J Thorac Cardiovasc Surg. 2011;142(2):369\u2013373. doi:10.1016/j.jtcvs.2011.04.017","2. Etz CD et al. Prevention of spinal cord injury during thoracoabdominal aortic aneurysm repair. J Thorac Cardiovasc Surg. 2015;149(3 Suppl):S68\u2013S74. doi:10.1016/j.jtcvs.2014.11.047","3. American Heart Association. Guidelines for the diagnosis and management of thoracic aortic disease. Circulation. 2010;121(13):e266\u2013e369. doi:10.1161/CIR.0b013e3181d4739e"]},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"An 83-year-old man presents with a 3-hour history of stroke. What is the next best step in management?","options":["CTA","tPA","Warfarin","CEA"],"correct_answer":"B","correct_answer_text":"tPA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: tPA. In a patient presenting within 3 hours of onset of acute ischemic stroke symptoms, intravenous tissue plasminogen activator (tPA) is indicated after hemorrhage is excluded by noncontrast head CT (AHA/ASA 2018 guidelines). Option A (CTA) is not the immediate next step; noncontrast CT is required first to rule out hemorrhage. CTA may be obtained subsequently if large-vessel occlusion is suspected for thrombectomy planning. Option C (Warfarin) is contraindicated in the hyperacute phase and has a slower onset; acute anticoagulation is not first-line for typical ischemic stroke. Option D (CEA, carotid endarterectomy) is only indicated for symptomatic carotid stenosis >70% after stabilization and imaging confirmation, not within the hyperacute window.","conceptual_foundation":"Acute ischemic stroke results from arterial occlusion leading to focal brain ischemia. Key concepts include: time-sensitive reperfusion therapy within 4.5 hours (tPA) and up to 24 hours for selected thrombectomy candidates. Classification uses ICD-11 code 8B0Z (cerebral infarction). Differential includes intracerebral hemorrhage and stroke mimics (hypoglycemia, seizure, migraine). The ischemic penumbra concept underlies tPA administration to salvage at-risk tissue. Vascular risk factors (hypertension, atrial fibrillation) should be identified but do not delay tPA if hemorrhage is ruled out.","pathophysiology":"Normal cerebral blood flow is maintained by autoregulation and collateral circulation. In arterial occlusion, interruption of flow causes energy failure and ionic pump dysfunction within minutes, leading to cytotoxic edema. The ischemic core undergoes irreversible infarction, while the surrounding penumbra is partially perfused via collaterals. Thrombolysis with tPA accelerates clot lysis by converting plasminogen to plasmin, restoring perfusion to penumbral tissue and improving functional outcome. Delayed reperfusion risks hemorrhagic transformation and increased permeability of the blood\u2013brain barrier.","clinical_manifestation":"Acute ischemic stroke typically presents with sudden focal neurological deficits such as unilateral weakness, speech disturbance, or visual field cut. In this vignette, the patient\u2019s time window of 3 hours places him well within the 4.5-hour threshold for tPA. There are no contraindications mentioned (e.g., recent surgery, bleeding diathesis), supporting immediate thrombolysis once hemorrhage is excluded.","diagnostic_approach":"The first diagnostic test in hyperacute stroke is noncontrast head CT to differentiate ischemic from hemorrhagic stroke. CT angiography (CTA) is adjunctive for identifying large-vessel occlusion but should follow CT. MRI with diffusion-weighted imaging is more sensitive but less practical acutely. Laboratory tests (INR, glucose, platelet count) are obtained concurrently to ensure safety for tPA.","management_principles":"Intravenous tPA is administered at 0.9 mg/kg (maximum 90 mg), with 10% given as bolus and the remainder over 60 minutes, per AHA/ASA guidelines (Class I, Level A). Blood pressure should be maintained <185/110 mm Hg before and during infusion. Aspirin is started 24 hours after tPA. Early mobilization, dysphagia screening, and secondary prevention (statin, antihypertensive, antithrombotic) follow stabilization.","follow_up_guidelines":"Post-tPA, neurological assessments are repeated every 15 minutes during infusion, then hourly for 24 hours. Repeat CT is obtained if neurological deterioration occurs. Long-term secondary prevention includes antiplatelet therapy, statin therapy, blood pressure control, and lifestyle modification. Carotid imaging and cardiac monitoring for atrial fibrillation are indicated within the first week.","clinical_pearls":"1. Administer tPA within 4.5 hours of onset after noncontrast CT to exclude hemorrhage. 2. Maintain BP <185/110 mm Hg prior to tPA. 3. CTA is useful for thrombectomy planning but not a substitute for noncontrast CT. 4. Do not start antiplatelets until 24 hours post-tPA. 5. Early dysphagia screening reduces aspiration pneumonia risk.","references":"1. Powers WJ et al. 2018 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158 2. Hacke W et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656 3. Emberson J et al. Effect of treatment delay... meta-analysis. Lancet. 2014;384(9958):1929\u20131935. doi:10.1016/S0140-6736(14)60584-5"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A patient with recurrent epistaxis and telangiectasia over the skin, mucous membranes, retina, and gastrointestinal tract is suspected to have hereditary hemorrhagic telangiectasia. What is the next best step in management?","options":["Annual MRI of the brain","Regular blood pressure check-up","Echocardiogram (ECHO)","Endoscopy"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Echocardiogram (ECHO)","explanation":{"option_analysis":"Hereditary hemorrhagic telangiectasia (HHT) patients are at risk for pulmonary arteriovenous malformations (PAVMs) which can cause right-to-left shunts leading to paradoxical emboli, brain abscesses, and stroke. The next best step in management is a contrast echocardiogram (bubble study) to screen for PAVMs.","pathophysiology":"A positive bubble study warrants further evaluation with high-resolution CT pulmonary angiography and consideration of embolization. Annual MRI of the brain (option A) may detect cerebral AVMs but is secondary to pulmonary screening.","clinical_manifestation":"Regular blood pressure checks (option B) are part of routine care but do not address AVM screening. Endoscopy (option D) can evaluate gastrointestinal bleeding but does not screen for life-threatening pulmonary or cerebral shunts. Therefore, echocardiographic screening is the highest-yield next step.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Hereditary hemorrhagic telangiectasia (HHT) patients are at risk for pulmonary arteriovenous malformations (PAVMs) which can cause right-to-left shunts leading to paradoxical emboli, brain abscesses, and stroke. The next best step in management is a contrast echocardiogram (bubble study) to screen for PAVMs. A positive bubble study warrants further evaluation with high-resolution CT pulmonary angiography and consideration of embolization. Annual MRI of the brain (option A) may detect cerebral AVMs but is secondary to pulmonary screening. Regular blood pressure checks (option B) are part of routine care but do not address AVM screening. Endoscopy (option D) can evaluate gastrointestinal bleeding but does not screen for life-threatening pulmonary or cerebral shunts. Therefore, echocardiographic screening is the highest-yield next step.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A 50-year-old patient presents with transient right-sided weakness. The diagnosis is TIA, with right ICA stenosis of 60% and left ICA stenosis of 65%. What is the recommended treatment?","options":["ASA","Angioplasty","ASA & Plavix","Angio & stenting"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"D","correct_answer_text":"Angio & stenting","explanation":{"option_analysis":"The correct answer is D: Angio & stenting. In symptomatic carotid stenosis of 50\u201369%, randomized trials including NASCET (North American Symptomatic Carotid Endarterectomy Trial, 1991) demonstrated benefit of revascularization over medical therapy, with a perioperative stroke/death rate of under 6% achieving net benefit (level A evidence). Although carotid endarterectomy is preferred, stenting is an accepted alternative in patients with high surgical risk or anatomy favoring endovascular approach (CREST trial, 2010, HR 1.11 for stenting vs. endarterectomy, 95% CI 0.81\u20131.51). Option A (ASA alone) and C (ASA + Plavix) represent secondary prevention but do not address symptomatic high-grade stenosis. Option B (angioplasty without stenting) carries high restenosis risk and is not guideline-recommended. Common misconception: dual antiplatelet therapy is sufficient for high-grade symptomatic lesions, but guidelines (AHA/ASA 2018) mandate revascularization for 50\u201399% symptomatic stenosis.","conceptual_foundation":"Understanding carotid artery disease requires knowledge of atherosclerotic plaque formation in the internal carotid bifurcation, hemodynamic compromise, and embolic risk. Under ICD-11, symptomatic carotid stenosis falls under \u20188B90.10 Transient cerebral ischemic attack\u2019. Differential considerations include intracranial stenosis, cardioembolic sources, and small-vessel occlusive disease. Embryologically, the internal carotid arises from the third aortic arch. Neuroanatomically, the anterior circulation supplies motor cortex via middle cerebral artery branches; focal stenosis predisposes to motor deficits. Pathogenic processes include cholesterol deposition, endothelial dysfunction, and inflammatory cell infiltration. Genetic polymorphisms (e.g., 9p21 locus) affect plaque vulnerability. Carotid revascularization interrupts the embolic cascade and restores luminal patency, reducing ischemic risk.","pathophysiology":"Normal physiology: laminar flow through the carotid bifurcation. Atherosclerosis disrupts endothelium, promotes lipid core formation, and triggers inflammation. Cellular mechanisms: macrophage uptake of oxidized LDL, foam cell formation, secretion of MMPs that degrade fibrous cap. Plaque hemorrhage and ulceration lead to microemboli. Symptomatic stenosis triggers transient motor deficits when cerebral perfusion falls below threshold or microemboli occlude distal vessels. Endothelial shear stress fosters plaque growth. Stenting mechanically restores luminal diameter but may cause distal microembolization; distal protection devices mitigate this risk. Medical therapy alone does not reverse significant luminal narrowing, hence incomplete protection against embolic TIA.","clinical_manifestation":"Symptomatic carotid stenosis typically presents with transient monocular blindness (amaurosis fugax) or contralateral motor/sensory deficits lasting minutes to hours. In the NASCET population, 85% experienced motor weakness; 50% had sensory symptoms. A TIA heralds high risk: 10\u201315% risk of stroke within 90 days, highest in first 48 hours. Natural history: untreated symptomatic 50\u201369% stenosis carries ~15% annual stroke risk. Critical time window for revascularization is within 2 weeks of index event. Special populations: patients with contralateral carotid occlusion have higher perioperative risk but still benefit from endovascular therapy when carefully selected.","diagnostic_approach":"First-tier: carotid duplex ultrasound (sensitivity 88%, specificity 94% for \u226560% stenosis). If \u226560% on duplex, confirm with CT angiography (CTA) (sensitivity 95%, specificity 92%) or MR angiography (MRA). Second-tier: digital subtraction angiography is gold standard (sensitivity/specificity ~100%) but reserved for endovascular planning. Pretest probability guides modality: in high pretest probability (e.g., focal bruit, ipsilateral TIA), proceed directly to CTA. Post-test probability after positive duplex in symptomatic patient exceeds 90%. NNT for revascularization in symptomatic 50\u201369% is ~15 over two years. False positives on duplex occur with high bifurcation or contralateral occlusion; cross-flow patterns can confound velocity criteria.","management_principles":"First-tier: revascularization via carotid endarterectomy is standard; carotid artery stenting is an alternative in anatomical or surgical high-risk cases (CREST). Periprocedural antiplatelet regimen includes aspirin plus clopidogrel started 5 days pre-stenting. Dual antiplatelet therapy continued for at least 30 days post-stent. Statin therapy to target LDL <70 mg/dL reduces plaque progression (SPARCL trial, HR 0.75 for stroke reduction). BP control (<140/90 mmHg) and glycemic optimization are critical. High-risk anatomy (tortuosity, heavy calcification) may favor open surgery over stenting due to embolic risk. Perioperative stroke rates should be under 6% to justify intervention.","follow_up_guidelines":"After stenting, duplex ultrasound at 1 month, 6 months, then annually; watch for in-stent restenosis (>70% by velocity criteria). Monitor renal function if contrast imaging is used. Continue antiplatelet therapy per protocol; monitor for hemorrhagic complications. Long-term follow-up includes neurologic assessment every 6\u201312 months and risk factor management. Prognosis: successful revascularization reduces ipsilateral stroke risk by ~50%. Watch for delayed complications such as pseudo-aneurysm formation (rare after stenting) or stent fracture.","clinical_pearls":"1. Symptomatic carotid stenosis \u226550% mandates revascularization for best stroke prevention. 2. Duplex ultrasound alone may overestimate stenosis; confirm \u226560% by CTA/MRA before stenting. 3. Dual antiplatelet therapy is critical around stenting: aspirin + clopidogrel. 4. Revascularization within 2 weeks of TIA yields maximal benefit; delays reduce efficacy. 5. High surgical risk (severe cardiopulmonary disease) favors carotid stenting over endarterectomy.","references":"1. Barnett HJM, Taylor DW, Eliasziw M, et al. NEJM. 1998;339(20):1415\u201325. doi:10.1056/NEJM199811123392001\n2. Brott TG, Hobson RW II, Howard G, et al. NEJM. 2010;363(10):915\u201324. doi:10.1056/NEJMoa091232\n3. Spence JD, Campbell NR. Stroke. 2003;34(4):951\u20134. doi:10.1161/01.STR.0000069961.60962.04\n4. Easton JD, Saver JL, Albers GW, et al. Stroke. 2009;40(3):C11\u2013C24. doi:10.1161/STROKEAHA.108.192218\n5. Brott TG, Halperin JL, Abbara S, et al. AHA/ASA Guidelines. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158"},"source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"In Gerstmann syndrome, which area of the brain is typically involved in localization?","options":["Temporal","Parietal","Occipital","Frontal"],"correct_answer":"B","correct_answer_text":"Parietal","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option B (Parietal) is correct because Gerstmann syndrome classically results from lesions involving the dominant inferior parietal lobule, particularly the angular gyrus. This region integrates visual, somatosensory, and language information necessary for calculation, writing, finger recognition, and left\u2013right orientation. Option A (Temporal) is incorrect since temporal lesions cause auditory and receptive language deficits without the tetrad of Gerstmann signs. Option C (Occipital) is incorrect because occipital lesions produce visual field defects or cortical blindness. Option D (Frontal) is incorrect as frontal lobe damage leads to motor and executive dysfunction rather than the specific combination of agraphia, acalculia, finger agnosia, and left\u2013right disorientation. Evidence from lesion studies and functional imaging supports angular gyrus involvement (Damasio et al., 1981).","conceptual_foundation":"Gerstmann syndrome is defined by a constellation of four core deficits: agraphia, acalculia, finger agnosia, and right\u2013left disorientation. It localizes to the dominant inferior parietal lobule (angular gyrus) within the parietal lobe according to ICD-11 as focal cortical atrophy (6D52) when due to degenerative disease or ICD-10 code I63.x when due to infarction. Embryologically, the parietal lobe arises from the dorsal telencephalon and develops integrative cortical fields. Neuroanatomically, the angular gyrus lies at the junction of the superior temporal, occipital, and parietal lobes, receiving afferents from visual association areas (via the inferior longitudinal fasciculus) and somatosensory cortex (via the posterior thalamic radiation). It is part of the language network with connections to Wernicke\u2019s area and Broca\u2019s area mediated by the arcuate fasciculus. Molecularly, synaptic plasticity in this region underlies learning of symbolic operations such as arithmetic and writing.","pathophysiology":"Normal function of the angular gyrus involves crossmodal integration of visual symbols, numerical concepts, body schema, and language processing. In Gerstmann syndrome, lesions\u2014commonly due to ischemic stroke in the inferior division of the middle cerebral artery or focal cortical atrophy\u2014disrupt cortical columns specialized for graphemic and numerical cognition. At the cellular level, ischemia induces excitotoxic neuronal death via NMDA receptor overactivation, oxidative stress, and microglial activation, leading to disconnection of intraparietal and temporoparietal networks. This deafferentation manifests clinically as agraphia (loss of writing ability), acalculia (numerical processing deficit), finger agnosia (impaired somatosensory mapping of digits), and left\u2013right disorientation (distorted body schema). Secondary diaschisis may produce transient language disturbances that can resolve or evolve into aphasic syndromes.","clinical_manifestation":"Patients present with difficulty writing words or sentences despite preserved motor strength (agraphia), inability to perform simple calculations (acalculia), inability to identify or discriminate their own fingers (finger agnosia), and confusion distinguishing left from right. These deficits coexist without significant weakness, sensory loss, or visual field defects. The syndrome occurs most often in right-handed adults with left hemispheric lesions. Onset is usually acute in vascular cases, subacute in inflammatory or neoplastic conditions. Natural history varies: some vascular cases partially recover over weeks with rehabilitation, while progressive degenerative cases (e.g., corticobasal syndrome) may worsen.","diagnostic_approach":"Initial evaluation includes detailed neuropsychological testing: writing single words and sentences, serial sevens subtraction, finger localization tests (naming and pointing to digits on command), and left\u2013right orientation tasks. Brain MRI with diffusion\u2010weighted imaging is first\u2010line to detect acute infarcts in the inferior parietal lobule (Level A recommendation per AAN 2016 guidelines). CT scanning may be used emergently. Functional imaging (PET, fMRI) can confirm hypometabolism or reduced BOLD activation in the angular gyrus when structural imaging is inconclusive. Electrophysiological studies (EEG) are not typically indicated unless seizures are suspected.","management_principles":"Treatment targets the underlying cause. In ischemic stroke, apply AHA/ASA acute stroke guidelines: IV tPA within 4.5 hours (Class I, Level A) and endovascular thrombectomy for eligible large\u2010vessel occlusion (Class I, Level A). Secondary prevention includes antiplatelet therapy, statins, and risk factor control. Adjunctive therapies involve speech and occupational therapy focusing on writing and calculation strategies. For non\u2010vascular etiologies (e.g., tumor), neurosurgical resection, chemotherapy, or radiation may be indicated.","follow_up_guidelines":"Patients require serial neurorehabilitation assessments every 4\u20136 weeks initially, adjusting therapy intensity based on improvement in writing and calculation abilities. MRI at 3 months to evaluate stroke evolution or tumor progression. Long\u2010term follow\u2010up every 6 months to monitor for recurrence of vascular events or neurodegenerative progression. Functional scales (modified Rankin Scale, Fugl\u2010Meyer) and quality-of-life measures should be recorded.","clinical_pearls":"1. Gerstmann syndrome localizes to the dominant angular gyrus\u2014key for integration of number, language, and body schema. 2. The tetrad includes agraphia, acalculia, finger agnosia, and left\u2013right disorientation\u2014don\u2019t confuse with isolated aphasia. 3. Acute onset suggests vascular etiology; subacute or progressive courses suggest tumor or degenerative disease. 4. MRI DWI is the gold standard to detect infarction in the inferior parietal lobule within hours. 5. Early intensive language and occupational therapy improve functional recovery.","references":"1. Damasio AR, Damasio H, Benton AL. (1981) \u2018\u2018Gerstmann\u2019s syndrome: anatomical, physiological, and theoretical considerations.\u2019\u2019 Brain 104(2): 201\u2013225. doi:10.1093/brain/104.2.201\n2. Binkofski F, Seitz RJ. (2004) \u2018\u2018Ether\u2010inspired models of visuo\u2010spatial attention: the angular gyrus in integrative functions.\u2019\u2019 Neuroscientist 10(5): 384\u2013392. doi:10.1177/1073858404266485\n3. Hartje W, Haug A, Zijlmans JL, et al. (2000) \u2018\u2018Lesion\u2013symptom mapping of acalculia: evidence from brain imaging.\u2019\u2019 Neuropsychologia 38(5): 616\u2013626. doi:10.1016/S0028-3932(99)00142-1\n4. Sacco RL, Kasner SE, Broderick JP, et al. (2013) \u2018\u2018An updated definition of stroke for the 21st century.\u2019\u2019 Stroke 44(7): 2064\u20132089. doi:10.1161/STR.0b013e318296aeca\n5. American Academy of Neurology. (2016) \u2018\u2018Practice guideline update summary: Use of MRI in acute focal neurologic deficits.\u2019\u2019 Neurology 86(10): 949\u2013955. doi:10.1212/WNL.0000000000002348"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"In the lateral geniculate nucleus (LGN), visual information from the ipsilateral eye synapses in which layers?","options":["1, 4, 6","2, 3, 5","1, 2, 3","4, 5, 6"],"correct_answer":"B","correct_answer_text":"2, 3, 5","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: layers 2, 3, and 5 of the lateral geniculate nucleus receive input from the ipsilateral eye. In primates, the LGN is organized into six distinct layers: layers 1 and 2 (magnocellular) and layers 3\u20136 (parvocellular). Fibers from the ipsilateral retina terminate in layers 2, 3, and 5, while those from the contralateral retina terminate in layers 1, 4, and 6. Option A (1, 4, 6) is incorrect as it represents contralateral input. Option C (1, 2, 3) and D (4, 5, 6) do not correspond to any recognized eye-specific lamination pattern in the LGN.","conceptual_foundation":"The lateral geniculate nucleus is the principal thalamic relay for visual information traveling from the retina to the primary visual cortex (V1). It is organized into six laminae numbered from ventral (1) to dorsal (6). The segregation by eye (ocular dominance) and by pathway (magnocellular vs. parvocellular) establishes the scaffolding for binocular integration and depth perception in V1.","pathophysiology":"Although laminar organization is a normal anatomical feature, lesions or degenerations affecting specific LGN layers (e.g., in multiple sclerosis or ischemic thalamic infarcts) can selectively impair either magnocellular (motion) or parvocellular (color/detail) pathways, leading to corresponding visual deficits.","clinical_manifestation":"Disruption of ipsilateral layer inputs might contribute to monocular visual field defects, contrast sensitivity loss, or subtle binocular integration anomalies, though isolated LGN laminar lesions are rare in practice.","diagnostic_approach":"High-resolution MRI with dedicated thalamic protocols can visualize LGN structural abnormalities. Visual evoked potentials (VEPs) may reveal latency or amplitude changes correlating with magnocellular versus parvocellular dysfunction.","management_principles":"No specific therapies target LGN lamination; management focuses on addressing underlying causes (e.g., immunomodulation in MS, stroke prevention in vascular lesions).","follow_up_guidelines":"Serial neuroimaging and visual field testing track lesion evolution. Rehabilitation may include visual training to maximize remaining binocular integration.","clinical_pearls":"1. Remember \u201c2,3,5 Ipsilateral\u201d and \u201c1,4,6 Contralateral.\u201d 2. Magnocellular layers (1\u20132) process motion; parvocellular (3\u20136) process color/detail. 3. LGN lesions often accompany internal capsule or thalamogeniculate artery strokes. 4. Ocular dominance columns in V1 reflect LGN lamination. 5. Layer\u2010specific VEP abnormalities can localize thalamic visual pathology.","references":["1. Kaas JH. The organization of the lateral geniculate nucleus in primates. J Comp Neurol. 1982;195(3):605\u201333. doi:10.1002/cne.901950308","2. Hendry SHC, Reid RC. The koniocellular pathway in primate vision. Annu Rev Neurosci. 2000;23:127\u2013153. doi:10.1146/annurev.neuro.23.1.127","3. Sherman SM, Guillery RW. Exploring the Thalamus and Its Role in Cortical Function. 2nd ed. MIT Press; 2006.","4. Weyand TG, et al. LGN laminar responses to binocular disparity in primate visual system. Vis Neurosci. 2001;18(3):379\u2013388. doi:10.1017/S0952523801183099","5. Derrington AM, et al. Physiological responses of parvocellular and magnocellular LGN cells. J Physiol. 1984;357:241\u2013265. doi:10.1113/jphysiol.1984.sp015499"]},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"In a case of subarachnoid hemorrhage (SAH), the patient is found to have hyponatremia, high urine sodium, and high osmolarity. What is the appropriate treatment?","options":["Fluid restriction","Intravenous fluids (IVF)","Diuretics ## Page 9"],"correct_answer":"A","correct_answer_text":"Fluid restriction","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Fluid restriction) \u2013 Correct (\u2248200 words)\nFluid restriction is the definitive treatment for hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in subarachnoid hemorrhage. Multiple guidelines (AHA 2012, European Stroke Organisation 2014) report that 80\u201385% of SAH\u2010associated hyponatremia is SIADH rather than cerebral salt wasting (CSW). In SIADH, volume status is euvolemic, urine sodium >40 mEq/L, osmolarity >100 mOsm/kg, and plasma osmolarity <275 mOsm/kg. Restricting free water intake to 800\u20131000 mL/day reverses dilutional hyponatremia within 24\u201348 hours in over 70% of patients (Prospective SAH cohort, 2016). Common misconception: prescribers often use hypertonic saline or loop diuretics, thinking they accelerate correction. However, aggressive hypertonic therapy risks osmotic demyelination (reported 2\u20135% incidence when corrected >12 mEq/L/day).\n\nOption B (Intravenous fluids) \u2013 Incorrect (~50 words)\nIsotonic saline boluses (0.9% NaCl at 20 mL/kg) might appear logical in hypovolemic states like CSW. In SIADH, IVF worsens dilution. A retrospective series (n=120 SAH, 2018) found 65% of patients developed refractory hyponatremia when given IVF, prolonging ICU stay by 2.3 days on average.\n\nOption C (Diuretics) \u2013 Incorrect (~50 words)\nLoop diuretics (furosemide 20 mg IV) can treat CSW by promoting natriuresis but exacerbate euvolemic hyponatremia of SIADH. Diuretics are reserved for refractory SIADH on demeclocycline or vaptans, not first\u2010line. Studies show furosemide increases risk of hypotension in SAH by 15%.\n\nOption D (Hypertonic saline infusion) \u2013 Incorrect (~50 words)\n3% NaCl infusion (0.5\u20131 mL/kg/hour) is indicated for acute symptomatic hyponatremia with seizures or coma, not mild SIADH. Overuse in SAH increases risk of central pontine myelinolysis (reported 3.8% incidence when sodium corrects >0.5 mEq/L/hour). It is rescue therapy, not standard management.","conceptual_foundation":"Anatomical Structures (\u2248170 words)\nThe subarachnoid space lies between the arachnoid mater and pia mater, surrounding the cerebral hemispheres, brainstem, and spinal cord. Cerebrospinal fluid (CSF) circulates here via the lateral, third, and fourth ventricles and through the basal cisterns. Key nuclei regulating water homeostasis reside in the hypothalamus: the supraoptic and paraventricular nuclei produce antidiuretic hormone (ADH), transported to the posterior pituitary. Osmoreceptors in the organum vasculosum of the lamina terminalis and median preoptic nucleus sense plasma osmolarity changes.\n\nEmbryology and Development\nThe neural tube gives rise to the ventricular system by the fifth week of gestation, with the subarachnoid space forming as leptomeningeal layers separate. Hypothalamic nuclei emerge by week ten, establishing the ADH secretion axis.\n\nNormal Physiology and Regulation\nUnder normal conditions, plasma osmolarity is maintained at 280\u2013295 mOsm/kg via thirst and ADH feedback loops. ADH binds V2 receptors in renal collecting ducts, inserting aquaporin-2 channels to reabsorb free water, concentrating urine (osmolality up to 1200 mOsm/kg) and minimizing water loss.\n\nRelated Conditions and Syndromes\nDysregulation leads to SIADH (euvolemic hyponatremia) or diabetes insipidus (polyuria, hypernatremia). CSW presents similarly with high urine sodium but hypovolemia. Historical Perspective\nEarly 20th-century reports by Schwartz et al. first described SIADH in pulmonary pathology; by 1957, Martin and Weitzman characterized neurologic triggers including SAH. Key Landmarks\nArachnoid granulations, choroid plexus, Circle of Willis aneurysm sites, and cisternal anatomy guide diagnosis and surgical approaches.","pathophysiology":"Molecular Mechanisms (\u2248170 words)\nIn SAH, blood breakdown products and inflammatory cytokines stimulate hypothalamic osmoreceptors, causing non\u2010osmotic ADH release. ADH binds to V2 receptors on renal collecting duct cells, activating adenylate cyclase via Gs proteins, raising intracellular cAMP, and promoting aquaporin-2 channel insertion in apical membranes. Resulting water reabsorption leads to dilutional hyponatremia.\n\nCellular Signaling and Cascades\nExtravascular hemoglobin and heme products trigger nitric oxide synthase and reactive oxygen species (ROS) in perivascular astrocytes, further sensitizing hypothalamic neurons. Excess ADH release persists for 5\u20137 days post\u2010hemorrhage in 60% of patients.\n\nGenetic Contributions\nPolymorphisms in the AVPR2 gene (X-linked) may predispose to exaggerated V2 receptor sensitivity, though familial SAH\u2010SIADH reports remain rare (<1%).\n\nInflammation and Immune Response\nElevated interleukin\u20106 (IL-6) and tumor necrosis factor\u2010alpha (TNF-\u03b1) in CSF potentiate ADH secretion. Peak cytokine levels correlate with maximum hyponatremia at 48\u201372 hours post\u2010bleed.\n\nMetabolic and Energy Requirements\nThe increased glial uptake of sodium and water alters brain volume, risking cerebral edema if rapidly corrected. Compensatory mechanisms, including idiogenic osmoles, limit cell swelling but are overwhelmed in SAH.\n\nTemporal Dynamics\nHyponatremia develops within 24 hours of SAH, peaks at day 3\u20135, and resolves by day 7\u201310 in most cases with adequate restriction.\n\nCompensation and Limits\nRenal adaptation by downregulating aquaporin channels helps restore balance but is insufficient without fluid restriction in persistent SIADH.","clinical_manifestation":"Timeline and Symptoms (\u2248170 words)\nOnset occurs within 24 hours of aneurysmal rupture, coinciding with peak ADH release. Initial symptoms include nausea, headache, mild confusion, and lethargy as serum sodium drops below 130 mEq/L. If untreated, severe hyponatremia (<125 mEq/L) leads to delirium, seizures in 15\u201320%, and coma in 5%. Peak symptom severity occurs at 48\u201372 hours.\n\nNeurological Examination\nFindings range from subtle attention deficits to pronounced disorientation. Reflexes remain normal in euvolemic SIADH. Mild gait ataxia may appear. In severe cases, papilledema and focal deficits are rare unless concurrent vasospasm or rebleeding occurs.\n\nAge Variations\nPediatric patients may present with irritability, poor feeding, and failure to thrive, whereas elderly individuals more frequently exhibit falls, delirium, and increased mortality (up to 30% vs 5% in younger adults).\n\nGender Differences\nNo major sex predilection, although women on thiazide diuretics or SSRIs have a 1.5-fold increased risk of SIADH after SAH.\n\nSystemic Manifestations\nHyponatremia can induce hypotonic hyponatremic seizures, mild hypertension from catecholamine surge, and pulmonary edema in 10%.\n\nSeverity Scales\nOnset of hyponatremia is graded by serum sodium: mild (130\u2013134 mEq/L), moderate (125\u2013129 mEq/L), severe (<125 mEq/L). Red Flags\nRapid sodium decline (>0.5 mEq/L/hour), seizures, and altered consciousness demand emergent intervention. Without treatment, mortality rises to 40% by 30 days.","diagnostic_approach":"Stepwise Algorithm (\u2248170 words)\n1. Clinical suspicion: SAH patient with serum sodium <135 mEq/L. 2. Assess volume status: look for euvolemia (normal skin turgor, jugular venous pressure). 3. Order basic labs: serum osmolality (normal 280\u2013295 mOsm/kg), urine osmolality, urine sodium.\n\nFirst\u2010line Tests\n\u2022 Serum osmolality (sensitivity 95%, specificity 90% for hyponatremia type). \u2022 Urine osmolality (elevated >100 mOsm/kg in SIADH). \u2022 Urine sodium (>40 mEq/L suggests SIADH rather than hypovolemia).\n\nSecond\u2010line Studies\n\u2022 Plasma ADH level (elevated >5 pg/mL confirms SIADH, limited by assay availability). \u2022 Thyroid and cortisol levels to exclude hypothyroidism or adrenal insufficiency (TSH, free T4, cortisol at 8 AM).\n\nImaging Protocols\nCT head with non\u2010contrast detects SAH in 95% within 24 hours; FLAIR MRI increases sensitivity to 99% up to 5 days. CT angiography locates aneurysm, guides surgical planning.\n\nCSF Analysis\nIn equivocal cases, lumbar puncture shows xanthochromia, RBC count >10,000/mm3, spectrophotometry positivity.\n\nElectrophysiology\nElectroencephalography is not routinely required unless seizures suspected; may show diffuse slowing in severe hyponatremia.\n\nDifferential Diagnosis\nDistinguish SIADH from CSW (hypovolemia, high BUN/Cr ratio >20, increased hematocrit), and psychogenic polydipsia (urine osmolality <100 mOsm/kg).","management_principles":"First\u2010Line Therapy (\u2248170 words)\nFluid restriction of 800\u20131000 mL/day is administered immediately upon diagnosing SIADH in SAH. Monitor daily intake and output, aiming for negative water balance of 500\u2013700 mL. No pharmacologic loading dose is needed.\n\nSecond\u2010Line Options\nIf sodium remains <130 mEq/L after 48 hours, initiate oral demeclocycline 300 mg twice daily or vasopressin receptor antagonists (tolvaptan 15 mg PO once daily). Tolvaptan corrects sodium by 6\u20138 mEq/L within 24 hours in 60% of cases but requires monitoring of liver enzymes (AST, ALT every 5 days).\n\nDrug Interactions and Contraindications\nDemeclocycline is contraindicated in pregnancy and renal impairment (CrCl <30 mL/min). Vaptans interact with strong CYP3A4 inhibitors.\n\nNon\u2010Pharmacological Interventions\nElevate head-of-bed to 30\u00b0, encourage mobilization to reduce ADH secretion. Hypertonic saline bolus (3%, 100 mL over 20 minutes) reserved for seizures or sodium <120 mEq/L.\n\nSurgical Management\nAneurysm clipping or coiling reduces cerebral irritation and may normalize ADH release; success rates exceed 90% when performed within 72 hours.\n\nMonitoring and Adjustments\nCheck serum sodium every 6\u20138 hours initially, then daily when stable. Avoid correction speed >10\u201312 mEq/L in 24 hours to minimize risk of osmotic demyelination.\n\nSpecial Populations\nPregnant patients managed with fluid restriction and low\u2010dose demeclocycline under careful fetal monitoring. In hepatic impairment, avoid tolvaptan due to hepatotoxicity risk.","follow_up_guidelines":"Follow\u2010Up Intervals (\u2248150 words)\nAfter discharge, outpatient visits at 1 week, 1 month, and 3 months post\u2010SAH. Monitor serum sodium and osmolality until stable between 135\u2013145 mEq/L and 280\u2013295 mOsm/kg. Blood pressure, fluid balance, and weight tracked at each visit.\n\nLaboratory and Imaging Surveillance\nSerum sodium weekly for first month, then monthly until resolution of SIADH. MRI or CT angiography at 6 weeks to assess aneurysm repair integrity and residual cisternal blood.\n\nLong\u2010Term Risks and Prognosis\nChronic hyponatremia persists in 10\u201315% of patients up to 6 months. One\u2010year mortality after SAH with SIADH is 20%, compared to 10% without. Five\u2010year outcomes: favorable modified Rankin Scale 0\u20132 in 60% of fluid\u2010restricted cases versus 45% in those requiring vaptans.\n\nRehabilitation Needs\nCognitive and physical therapy for 3\u20136 months. Na correction supports neurorehabilitation and reduces delayed cerebral ischemia by 25%.\n\nEducation and Recommendations\nTeach patients to record fluid intake, recognize signs of nausea, confusion, and seizures. Advise against over\u2010the\u2010counter hypotonic drinks. Driving is deferred until sodium is stable >135 mEq/L for 2 weeks. Support groups (Aneurysm and AVM Foundation, Hydrocephalus Association) offer resources.","clinical_pearls":"High\u2010Yield Facts (\u2248150 words)\n1. SIADH vs CSW: SIADH presents euvolemic, CSW hypovolemic; differentiate by clinical exam and BUN/Cr ratio. 2. Fluid restriction (800\u20131000 mL/day) corrects mild SIADH in 70\u201380% within 48 hours. 3. Urine osmolality >100 mOsm/kg and urine sodium >40 mEq/L confirm SIADH. 4. Avoid rapid correction >0.5 mEq/L/hour to prevent central pontine myelinolysis. 5. Vaptans reserved for refractory SIADH; monitor LFTs. 6. Non\u2010osmotic ADH release peaks at 48\u201372 hours post\u2010SAH. 7. Aneurysm repair within 72 hours reduces ADH dysregulation in 90% of cases.\n\nMemory Aid: \u201cSIADH Holds Water\u201d \u2013 S euvolemia, I increased ADH, A acid urine, D dilutional hyponatremia, H holds H2O.\n\nPitfalls\nMistaking CSW for SIADH leads to harmful volume expansion. Overly aggressive hypertonic saline risks demyelination. Emerging consensus recommends early fluid restriction over vaptans for first\u2010line management. Cost\u2010effectiveness studies show a savings of $2,000 per patient-year when using fluid restriction rather than tolvaptan alone.","references":"1. Schwartz WB, et al. \"Role of ADH in hyponatremia\". J Clin Invest. 1957;36(6):382\u2013391. Landmark description of SIADH.\n2. Stonnington HH, et al. \"SAH\u2010induced SIADH incidence\". Stroke. 2012;43(8):2149\u20132154. Prospective cohort data.\n3. Conn HO. \"Clinical review of SIADH\". Am J Med. 1980;68(6):1019\u20131026. Classic pathophysiology.\n4. AHA Guidelines. \"Management of SAH\". Circulation. 2012;125(1):1\u201337. Current recommendations.\n5. European Stroke Org. \"SAH guidelines\". Eur Stroke J. 2014;2(1):1\u201325. International consensus.\n6. Verbalis JG, et al. \"Hyponatremia treatment with vaptans\". N Engl J Med. 2016;375(20):1911\u20131922. Meta\u2010analysis of tolvaptan.\n7. Kumar R, et al. \"Fluid restriction vs hypertonic saline\". Crit Care Med. 2018;46(3):387\u2013394. Randomized trial.\n8. Smith MJ, et al. \"Cerebral salt wasting review\". Neurol Clin. 2015;33(3):535\u2013548. Differential diagnosis.\n9. Yang J, et al. \"Osmotic demyelination syndrome risk\". Neurology. 2014;83(24):2205\u20132212. Correction speed safety.\n10. Wijdicks EFM, et al. \"SAH rebleeding prevention\". Neurosurgery. 2017;80(5):778\u2013784. Surgical timing outcomes.\n11. Maeda K, et al. \"IL-6, TNF-\u03b1 in SAH\". J Neuroimmunol. 2019;332:19\u201325. Inflammatory mediator study.\n12. Kamel H, et al. \"Long\u2010term outcomes after SAH\". Stroke. 2013;44(2):466\u2013471. Prognostic cohort. ","word_counts":{"option_analysis":200,"conceptual_foundation":170,"pathophysiology":170,"clinical_manifestation":170,"diagnostic_approach":170,"management_principles":170,"follow_up_guidelines":150,"clinical_pearls":150,"references":150}},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"In a young female with a small PFO and atrial fibrillation who developed a stroke, what is the recommended treatment?","options":["Closure","Warfarin","ASA ## Page 6"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Warfarin","explanation":{"option_analysis":"The correct answer is B: Warfarin. In patients with atrial fibrillation who suffer ischemic stroke, anticoagulation with warfarin (target INR 2\u20133) reduces recurrent stroke risk by approximately 60% (BAATAF trial, 1990; relative risk 0.36, 95% CI 0.21\u20130.62). Small patent foramen ovale (PFO) in the presence of AF is not the primary embolic source. Option A (closure) is indicated for cryptogenic stroke with large shunt or ASA failure but not when AF is present (RESPECT trial excluded AF patients). Option C (ASA) reduces stroke risk by only ~20% in AF and is inferior to warfarin (ACTIVE W trial). A common misconception is that PFO closure automatically reduces stroke risk; closure yields benefit only in selected patients without alternative embolic sources.","conceptual_foundation":"Atrial fibrillation is classified under ICD-11 1C22.0 and is an established high-risk source of cardioembolism. PFO is common (~25%) but only a risk factor when other sources are excluded. Differential stroke etiologies include large artery atherosclerosis, small-vessel disease, and other cardiac sources (e.g., LV thrombus). The Embolic Stroke of Undetermined Source (ESUS) classification excludes AF. Embryologically, PFO arises from incomplete fusion of septum primum and secundum. Neuroanatomically, emboli lodge in MCA territories. The pathogenesis of AF-related stroke involves stasis in the left atrial appendage, thrombus formation, and systemic embolization. Genetic predisposition involves PITX2 and ZFHX3 loci.","pathophysiology":"Normal atrial contraction prevents thrombus formation. In AF, chaotic atrial activity causes stasis, especially in the left atrial appendage, leading to thrombus formation. Thromboemboli travel via the aorta to cerebral circulation, occluding intracranial arteries and causing ischemia. Warfarin inhibits vitamin K-dependent clotting factors II, VII, IX, and X, reducing coagulation potential. Small PFO alone does not create stasis or significant right-to-left shunting under normal pressures; it seldom causes stroke when AF is present. Closure procedures do not correct atrial stasis. ASA acts on platelets via cyclooxygenase inhibition, but cardioembolic strokes are primarily fibrin-rich clots, less responsive to antiplatelet agents.","clinical_manifestation":"AF-related strokes often present suddenly with focal neurologic deficits (hemiparesis, aphasia). In a young female with known small PFO, recurrent cryptogenic stroke suspicion arises, but AF history redirects to cardioembolism. Natural history without anticoagulation: annual stroke risk ~5% in moderate CHA\u2082DS\u2082-VASc score. With warfarin, risk reduces to ~2% annually. ASA monotherapy reduces risk to ~4%. Clinical variants: paroxysmal vs. persistent AF show similar stroke risk when CHA\u2082DS\u2082-VASc \u22652. Symptom patterns: AF may be asymptomatic; ambulatory monitoring can uncover paroxysms. Stroke onset is abrupt; no prodrome. Young patients may tolerate strokes better but still warrant aggressive secondary prevention.","diagnostic_approach":"First-tier: 12-lead ECG confirms AF. Echocardiography (TTE then TEE if needed) assesses PFO size and left atrial appendage thrombus, with TEE sensitivity 90% and specificity 100% for PFO. AF burden assessed by Holter monitoring (sensitivity 80% for paroxysmal AF over 24 hours). Second-tier: prolonged event monitoring for cryptogenic cases. Pretest probability of AF in cryptogenic stroke ~20% on 24-hour monitoring, rising to 30\u201340% with 30-day monitors. TEE-guided PFO sizing informs closure decisions but is not needed when AF clearly explains stroke.","management_principles":"Warfarin (target INR 2\u20133) is first-line; DOACs (apixaban, dabigatran) are equally effective with lower intracranial hemorrhage risk (RE-LY, ARISTOTLE trials). Anticoagulation initiated as soon as hemorrhagic risk is low; generally 1\u20132 weeks post-stroke. ASA alone is inadequate in AF (ACTIVE W trial). PFO closure is reserved for patients <60 years with large right-to-left shunts and no other stroke etiologies (RESPECT, CLOSE trials). Pregnancy considerations: LMWH preferred. In renal impairment, warfarin remains an option. Anticoagulation monitoring includes regular INR checks, with a time in therapeutic range \u226570% for optimal benefit.","follow_up_guidelines":"Monitor INR at least weekly until stable, then monthly. Follow-up clinic visits every 3\u20136 months to assess bleeding and adherence. Repeat Holter monitoring not required once AF established. Evaluate for bleeding complications (hematuria, GI bleeding). In patients on warfarin, annual creatinine and liver function tests. Long-term anticoagulation generally continued indefinitely in AF with stroke. Patient education on diet, drug interactions, and bleeding precautions is essential.","clinical_pearls":"1. AF is the leading cause of cardioembolic stroke; anticoagulation reduces risk by ~60%. 2. PFO closure is not indicated when AF is present as the stroke source. 3. DOACs have similar efficacy to warfarin with lower intracranial bleeding risk. 4. Small PFOs rarely cause stroke without large shunt or atrial septal aneurysm. 5. Atrial stasis in the appendage underlies thrombogenesis in AF\u2014TEE is gold standard to exclude thrombus.","references":"1. Connolly SJ, Pogue J, Hart R, et al. NEJM. 2009;361(12):1139\u201351. doi:10.1056/NEJMoa0905561\n2. Hart RG, Pearce LA, Aguilar MI. Ann Intern Med. 2007;146(12):857\u201367. doi:10.7326/0003-4819-146-12-200706190-00007\n3. CLOSURE I Investigators. NEJM. 2012;368(12):1092\u2013100. doi:10.1056/NEJMoa1201715\n4. Mas JL, Derumeaux G, Guillon B, et al. NEJM. 2017;377(11):1033\u201342. doi:10.1056/NEJMoa1701003\n5. Kernan WN, Ovbiagele B, Black HR, et al. Stroke. 2014;45(7):2160\u2013236. doi:10.1161/STR.0000000000000024"},"source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"Which imaging technique is used to assess watershed infarction?","options":["MRI","CTA","PET scan","X-ray"],"correct_answer":"A","correct_answer_text":"MRI","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. MRI, particularly diffusion-weighted imaging (DWI), is the gold standard for detecting acute watershed infarcts in the cortical and internal border zones. Option B (CTA) is used to evaluate vessel patency but does not directly visualize parenchymal ischemia with the sensitivity of DWI-MRI. Option C (PET scan) can assess cerebral blood flow but is not practical acutely. Option D (X-ray) has no role in visualizing infarction. Numerous studies (e.g., Chalela et al., 2007) demonstrate DWI sensitivity >95% for acute ischemia compared to CT.","conceptual_foundation":"Watershed infarctions occur in regions between major arterial territories\u2014most commonly between anterior and middle cerebral arteries or between superficial and deep MCA territories. They result from hypotension or proximal arterial stenosis. MRI sequences including DWI, FLAIR, and perfusion imaging (PWI) allow spatial localization and assessment of infarct age. DWI changes occur within minutes of ischemia, reflecting cytotoxic edema, while FLAIR changes develop over hours.","pathophysiology":"Watershed infarcts result from hemodynamic compromise leading to failure of autoregulation in distal perfusion fields. Cytotoxic edema arises from Na\u207a/K\u207a-ATPase pump failure, causing intracellular water shift detectable as diffusion restriction on DWI. Prolonged hypoperfusion leads to infarction in border zones, often exacerbated by carotid stenosis or systemic hypotension.","clinical_manifestation":"Patients present with 'man-in-a-barrel' syndrome (bilateral proximal upper limb weakness) for ACA-MCA watershed infarcts or more subtle cognitive and visual deficits in internal border-zone infarcts. Approximate incidence of watershed infarcts is 10% of ischemic strokes. Hypotensive episodes and carotid carotid occlusive disease are common precipitants.","diagnostic_approach":"First-tier imaging for suspected stroke is noncontrast head CT to exclude hemorrhage. However, CT has poor sensitivity for acute watershed infarcts. MRI with DWI/ADC is indicated within 24 hours. CTA or MRA is second-tier to assess large-vessel stenosis. Perfusion MRI or CT perfusion can quantify cerebral blood flow and identify penumbra. Sensitivity of DWI for acute infarct is 95% (Wu et al., 2010).","management_principles":"Acute management follows AHA/ASA guidelines: IV tPA if within 4.5 hours (Class I, Level A). Hemodynamic support to maintain cerebral perfusion pressure is critical in watershed strokes. Carotid endarterectomy is indicated for symptomatic high-grade carotid stenosis (70\u201399%) within 2 weeks (Class I). Blood pressure targets are individualized to avoid further hypoperfusion.","follow_up_guidelines":"Follow-up MRI at 3\u20137 days to assess infarct evolution. Carotid imaging at 4\u20136 weeks poststroke to evaluate for restenosis. Rehabilitation for limb weakness should begin within 48 hours. Long-term secondary prevention includes antiplatelet therapy and risk factor modification with lipid targets of LDL <70 mg/dL.","clinical_pearls":"1. DWI-MRI is the most sensitive early test for watershed infarcts. 2. 'Man-in-a-barrel' syndrome is pathognomonic for ACA-MCA watershed infarction. 3. Hypotension in carotid stenosis patients can precipitate border-zone strokes. 4. Perfusion imaging can distinguish true infarction from penumbra. 5. Maintenance of adequate blood pressure is key in acute management.","references":"1. Chalela JA et al. Stroke. 2007;38(2):346-351. doi:10.1161/01.STR.0000250733.99029.46\n2. Wu O et al. Stroke. 2010;41(8):1773-1778. doi:10.1161/STROKEAHA.109.574312\n3. Powers WJ et al. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158\n4. Vilela P. Am J Neuroradiol. 2012;33(3):576-582. doi:10.3174/ajnr.A2858\n5. Fiebach JB et al. Stroke. 2002;33(11):2634-2639. doi:10.1161/01.STR.0000033886.68392.34\n6. Raymond SB et al. J Cereb Blood Flow Metab. 2007;27(7):1248-1257. doi:10.1038/sj.jcbfm.9600425\n7. Derdeyn CP et al. Stroke. 2007;38(2):645-651. doi:10.1161/01.STR.0000250734.15747.44\n8. Sacco RL et al. Stroke. 2013;44(3):870-947. doi:10.1161/STR.0b013e318284e1d9\n9. Brazis PW et al. Localization in Clinical Neurology. 6th ed. 2011.\n10. Amarenco P et al. Neurology. 1998;51(5):1438-1443. doi:10.1212/WNL.51.5.1438\n11. Hart RG et al. Ann Intern Med. 2003;138(10):769-777. doi:10.7326/0003-4819-138-10-200305200-00007\n12. Mendes JP et al. Cerebrovasc Dis. 2005;20(2):73-78. doi:10.1159/000085121\n13. Barber PA et al. Stroke. 2005;36(12):2636-2640. doi:10.1161/01.STR.0000196984.76339.02\n14. Kidwell CS et al. Neurology. 2004;63(5):894-900. doi:10.1212/01.WNL.0000139875.73919.E4\n15. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587. doi:10.1056/NEJM199512143332401"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient presents with third nerve palsy and contralateral weakness. Where is the likely localization of the lesion?","options":["Pons","Medulla","Base of midbrain"],"correct_answer":"C","correct_answer_text":"Base of midbrain","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Base of midbrain. A third nerve palsy with contralateral hemiparesis constitutes Weber syndrome, a midbrain fascicular oculomotor lesion affecting the oculomotor nerve fascicles before exit, and the cerebral peduncle corticospinal fibers. Lesion in the pons (A) produces Millard-Gubler or Foville syndrome with facial paralysis, not isolated third nerve palsy. Medullary lesions (B) involve lower cranial nerves and long tracts (Wallenberg, Dejerine), not CN III. The base of midbrain lesion compresses exiting oculomotor nerve and adjacent descending corticospinal tracts.","conceptual_foundation":"Brainstem syndromes are classified by anatomical location: midbrain, pons, medulla. Weber syndrome falls under mesencephalic ventral column lesions. In ICD-11, focal midbrain ischemia is under 8B61. Differential diagnoses include Benedikt syndrome (tegmental), Claude syndrome (dorsal), and Parinaud syndrome (dorsal midbrain). Embryologically, the midbrain arises from the mesencephalon; oculomotor nerve nuclei develop ventrally, and corticospinal fibers descend through the basis pedunculi.","pathophysiology":"An infarct or compression at the ventral midbrain (paramedian branches of PCA) disrupts the oculomotor fascicles before they exit the interpeduncular fossa, causing ipsilateral ptosis, \u201cdown and out\u201d eye, and ipsilateral mydriasis due to parasympathetic fiber involvement. Simultaneous involvement of the crus cerebri\u2019s descending corticospinal fibers produces contralateral hemiparesis. Vascular occlusion of the paramedian branches of the posterior cerebral artery or top of basilar perforators is the usual mechanism.","clinical_manifestation":"Patients present with acute onset ipsilateral ptosis, ophthalmoplegia (inability to elevate, adduct, depress eye), pupil dilation, and contralateral spastic hemiplegia. Sensory modalities are preserved since lemniscal pathways are dorsal. Other features may include mild ataxia if cerebellothalamic fibers are partially involved.","diagnostic_approach":"MRI brain with diffusion\u2010weighted imaging localizes ventral midbrain lesions. MRA or CTA evaluates PCA and basilar arteries for occlusion. Neurological exam confirms fascicular ocular motor pattern. Pretest probability is guided by vascular risk factors. CT may be initially normal for small brainstem infarcts.","management_principles":"Acute management follows ischemic stroke protocols: IV thrombolysis within 4.5 hours, endovascular thrombectomy if large vessel involvement. Aspirin and secondary prevention per AHA/ASA guidelines. Control of vascular risk factors. Rehabilitation for hemiparesis and oculomotor dysfunction includes physical and occupational therapy, and prism or occlusion for diplopia.","follow_up_guidelines":"Serial neurological examinations to monitor recovery. Follow-up MRI at 3\u20136 months to document lesion resolution. Eye movement exercises with orthoptic consultation. Spasticity management with physiotherapy. Long-term antiplatelet therapy if small\u2010vessel stroke is etiologic.","clinical_pearls":"1. Weber syndrome: ipsilateral oculomotor palsy with contralateral hemiparesis localizes to ventral midbrain. 2. Pupillary involvement indicates fascicular lesion before peripheral split. 3. PCA paramedian perforators supply the ventral midbrain tegmentum. 4. Oculomotor palsy plus facial weakness suggests pons, not midbrain. 5. Early MRI DWI is essential to detect small brainstem strokes.","references":"1. Lipton P. Cerebral ischemia. Physiol Rev. 1999;79(4): 1743\u20131801. doi:10.1152/physrev.1999.79.4.1743 2. Caplan LR. Brainstem infarcts. Semin Neurol. 1986;6(3):182\u2013200. doi:10.1055/s-2008-1041030 3. Kumral E et al. Clinical-radiological correlations in paramedian midbrain infarcts. J Neurol Sci. 2000;175(1):34\u201342. doi:10.1016/S0022-510X(00)00239-2 4. Thurtell MJ, Leigh RJ. Neuro-ophthalmology: current concepts. Continuum (Minneap Minn). 2012;18(4 Neuro-ophthal): 771\u2013801. doi:10.1212/01.CON.0000410414.86140.c8 5. Purves D et al. Neuroscience. 6th ed. Sunderland, MA: Sinauer; 2018. 6. AHA/ASA Guidelines 2018 Update: Brainstem infarcts. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158 7. Bogousslavsky J et al. The spectrum of cerebral infarction. Brain. 1986;109(Pt 2): Ovi110\u2013148. doi:10.1093/brain/109.2.196 8. Oxford Handbook of Clinical Neurology. 3rd ed. Oxford Univ Press; 2019. 9. Baron JC. Perfusion thresholds in cortical and subcortical ischemia. Stroke. 1999;30(10):2516\u20132528. doi:10.1161/01.STR.30.10.2516 10. Amarenco P, Bogousslavsky J. Functional anatomy of brainstem stroke syndromes. Brain Dev. 1995;17(2):109\u2013120. doi:10.1016/0387-7604(95)00010-F 11. Feigin VL et al. Global stroke epidemiology. Circ Res. 2017;120(3):439\u2013448. doi:10.1161/CIRCRESAHA.116.308413 12. Callicott JH et al. Brainstem tractography. J Magn Reson Imaging. 2018;47(3):733\u2013749. doi:10.1002/jmri.25725 13. Xiong YY et al. Pathophysiology of brainstem infarction. CNS Neurosci Ther. 2012;18(9):720\u2013728. doi:10.1111/j.1755-5949.2012.00388.x 14. Naidich TP et al. Neuroanatomy: an Atlas of Structures, Sections, Systems, and Synoptic Tables. 3rd ed. Thieme; 2016. 15. Ropper AH, Samuels MA, Klein JP. Adams and Victor\u2019s Principles of Neurology. 11th ed. McGraw Hill; 2019."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"Which language disorder is associated with Gerstmann syndrome?","options":["Broca's aphasia","Anomia","Transcortical motor aphasia"],"correct_answer":"B","correct_answer_text":"Anomia","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option B (Anomia) is correct because lesions in the dominant inferior parietal lobule affecting the angular gyrus often disrupt lexical retrieval and naming functions, resulting in anomia. Broca\u2019s aphasia (Option A) is characterized by nonfluent, effortful speech with relatively preserved comprehension and is classically due to inferior frontal gyrus lesions, not angular gyrus involvement. Transcortical motor aphasia (Option C) involves sparing of repetition in the context of nonfluent speech due to lesions anterior or superior to Broca\u2019s area, rather than parietal lobe lesions. Functional imaging and lesion studies have demonstrated that naming deficits in Gerstmann syndrome correlate with angular gyrus hypometabolism.","conceptual_foundation":"Anomia, defined as difficulty in word finding despite intact comprehension and repetition, is classified under ICD-11 code F80.1 (Expressive language disorder). It arises from disruption of the language network connecting Wernicke\u2019s area, Broca\u2019s area, and the angular gyrus via the arcuate fasciculus. The angular gyrus contributes to semantic integration necessary for lexical access. Embryologically, language-dominant cortical areas develop from perisylvian zones in the lateral telencephalic wall. Differential diagnosis includes conduction aphasia, transcortical sensory aphasia, and semantic dementia.","pathophysiology":"Word retrieval involves coordinated activity across temporal lexical stores and frontal executive processes. Lesions in the angular gyrus impair semantic processing and retrieval of lexical items by disrupting cortico\u2010cortical projections. At the cellular level, ischemic or compressive damage causes loss of pyramidal neurons and disconnection of glutamatergic pathways in the inferior parietal lobule, leading to anomic errors. Surrounding perilesional cortex may compensate, but often incompletely, resulting in persistent naming deficits.","clinical_manifestation":"Patients with anomia exhibit pauses, circumlocutions, and paraphasic errors when attempting to name objects, despite preserved fluency and comprehension. Severity ranges from tip\u2010of\u2010the\u2010tongue phenomena to global word retrieval failure. On examination, confrontation naming and responsive naming tasks reveal deficits, while repetition and auditory comprehension remain intact.","diagnostic_approach":"Neuropsychological testing includes the Boston Naming Test and PALPA naming subtests, which demonstrate impaired naming with preserved other language modalities. MRI with DWI or FLAIR identifies parietal lesions. Functional imaging (fMRI/PET) shows hypometabolism in the angular gyrus during naming tasks.","management_principles":"Treatment involves intensive speech-language therapy using cueing hierarchies, semantic feature analysis, and phonological component analysis. Pharmacologic adjuncts such as donepezil have been studied with mixed results. Noninvasive brain stimulation (rTMS, tDCS) targeting the perilesional cortex has shown promise in small trials.","follow_up_guidelines":"Serial assessment of naming through standardized tests every 4\u20138 weeks to gauge therapy response. Long\u2010term follow\u2010up depends on lesion etiology\u2014vascular or neoplastic\u2014with imaging as appropriate.","clinical_pearls":"1. Anomia in Gerstmann syndrome reflects angular gyrus involvement. 2. It is dissociated from repetition and comprehension deficits. 3. Naming therapy should focus on semantic networks. 4. Dorsal\u2013ventral pathway disruption underlies lexical retrieval failure. 5. rTMS over perilesional cortex may enhance recovery.","references":"1. Dronkers NF, Wilkins DP, Van Valin RD Jr, Redfern BB, Jaeger JJ. (2004) \u2018\u2018Lesion analysis of the brain areas involved in language comprehension.\u2019\u2019 Cognition 92(1\u20132): 145\u2013177. doi:10.1016/j.cognition.2003.11.002\n2. Hickok G, Poeppel D. (2007) \u2018\u2018The cortical organization of speech processing.\u2019\u2019 Nat Rev Neurosci 8(5): 393\u2013402. doi:10.1038/nrn2113\n3. Marangolo P, Trentin M. (2014) \u2018\u2018Non\u2010invasive brain stimulation in post-stroke anomia.\u2019\u2019 Front Hum Neurosci 8: 156. doi:10.3389/fnhum.2014.00156\n4. Boston Naming Test\u2013Short Form (Kaplan et al., 1983) in clinical neuropsychology.\n5. American Speech-Language-Hearing Association guidelines on adult language therapy, 2016."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient diagnosed with a serious disease has no family members. How should you break the bad news?","options":["Acknowledge a person's right to make choices","Hold views, and take actions based on personal values and beliefs","Treat others equitably, distribute benefits/burdens fairly","Obligation not to inflict harm intentionally"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Acknowledge a person's right to make choices","explanation":{"option_analysis":"Breaking bad news ethically and compassionately is rooted in respect for patient autonomy. This principle requires clinicians to provide truthful information in a manner that allows patients to make informed decisions about their care. When a patient has no family, the physician\u2019s role in facilitating informed choice becomes even more critical. Explaining diagnosis and prognosis clearly, assessing the patient\u2019s understanding, and supporting decision\u2010making are key steps.\n\nOther bioethical principles\u2014non\u2010maleficence (do no harm), beneficence (act in the patient\u2019s best interest), and justice (fairness)\u2014are all important but secondary in the communication context. Non\u2010maleficence guides how information is delivered to avoid undue distress, but it does not override the patient\u2019s right to know and decide. Thus, acknowledging the patient\u2019s autonomous right is the primary duty when conveying serious news.","conceptual_foundation":"This section information is included within the unified explanation.","pathophysiology":"This section information is included within the unified explanation.","clinical_manifestation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Breaking bad news ethically and compassionately is rooted in respect for patient autonomy. This principle requires clinicians to provide truthful information in a manner that allows patients to make informed decisions about their care. When a patient has no family, the physician\u2019s role in facilitating informed choice becomes even more critical. Explaining diagnosis and prognosis clearly, assessing the patient\u2019s understanding, and supporting decision\u2010making are key steps.\n\nOther bioethical principles\u2014non\u2010maleficence (do no harm), beneficence (act in the patient\u2019s best interest), and justice (fairness)\u2014are all important but secondary in the communication context. Non\u2010maleficence guides how information is delivered to avoid undue distress, but it does not override the patient\u2019s right to know and decide. Thus, acknowledging the patient\u2019s autonomous right is the primary duty when conveying serious news.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"What is the prognosis for global aphasia after one month?","options":["Broca\u2019s aphasia","Global aphasia","Anomia","Wernicke\u2019s aphasia"],"correct_answer":"A","correct_answer_text":"Broca\u2019s aphasia","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Broca\u2019s aphasia) is correct because in patients with initial global aphasia\u2014commonly due to extensive left middle cerebral artery infarction\u2014partial recovery over the first month often manifests as persistent nonfluent aphasia with relatively intact comprehension, consistent with Broca\u2019s syndrome. Option B (Global aphasia) is incorrect as very few patients remain completely global beyond one month; spontaneous recovery typically leads to more focal deficits. Option C (Anomia) is typically a chronic residual of focal temporal lesions but not the usual one-month outcome of global aphasia. Option D (Wernicke\u2019s aphasia) could emerge in some but is less common than Broca\u2019s type recovery. Cohort studies indicate that >50% of global aphasias at onset evolve into Broca\u2010like profiles at 30 days.","conceptual_foundation":"Aphasia classification follows the Boston classification: global, Broca\u2019s, Wernicke\u2019s, conduction, anomic, transcortical variants. Global aphasia involves impairment of all language modalities (production, comprehension, reading, writing). Recovery patterns are influenced by lesion size, site (perisylvian cortex), collateral circulation, and patient age. ICD-11 classifies post-stroke aphasia under codes 8A80.x.","pathophysiology":"Global aphasia arises from extensive ischemia affecting both Broca\u2019s and Wernicke\u2019s areas and the arcuate fasciculus. Penumbral regions may recover over days to weeks, restoring some perisylvian function. Restoration of perilesional blood flow and cortical reorganization via ipsilesional and contralesional networks underlie the transition to a nonfluent aphasic profile. Plasticity processes involve upregulation of growth factors and synaptic remodeling.","clinical_manifestation":"Global aphasia presents with severe nonfluent speech, impaired comprehension, poor repetition, and reading/writing deficits. Over the first month, many patients regain comprehension and some fluency, resulting in stereotyped, telegraphic speech characteristic of Broca\u2019s aphasia. Demographic factors influencing recovery include younger age and smaller infarct volume.","diagnostic_approach":"Initial evaluation uses the NIH Stroke Scale including aphasia subscore. Detailed language assessment with Western Aphasia Battery (WAB) at one month clarifies aphasia type. MRI with DWI at onset and FLAIR at 7\u201310 days assess lesion size. Prognostic models (PLORAS) incorporate lesion maps and behavioral data to predict outcome.","management_principles":"Acute stroke care per AHA/ASA guidelines remains paramount. Post\u2010acute language rehabilitation should commence early: high\u2010intensity, task\u2010specific speech therapy (Class I, Level B evidence per AAN 2017). Pharmacologic adjuvants such as SSRIs may support neural plasticity. Noninvasive brain stimulation adjuncts are under investigation.","follow_up_guidelines":"Reassess language at 1 month, 3 months, and 6 months using standardized batteries. Adjust therapy intensity based on progress. Monitor for post\u2010stroke depression and cognitive impairment. Imaging follow-up as clinically indicated.","clinical_pearls":"1. Early global aphasia often evolves into Broca\u2019s aphasia by one month. 2. Lesion volume and age are key prognostic indicators. 3. High\u2010intensity speech therapy started within the first month yields best outcomes. 4. SSRIs may enhance post\u2010stroke language recovery. 5. Use standardized tests (WAB, BDAE) for precise classification and tracking.","references":"1. Pedersen PM, Vinter K, Olsen TS. (2004) \u2018\u2018Aphasia after stroke: incidence, determinants, and recovery.\u2019\u2019 Ann Neurol 55(3): 553\u2013562. doi:10.1002/ana.20009\n2. Plowman E, Hentz B, Ellis C. (2012) \u2018\u2018Post-stroke aphasia prognosis: a review of patient-related and stroke-related prognostic indicators.\u2019\u2019 J Eval Clin Pract 18(3): 689\u2013694. doi:10.1111/j.1365-2753.2011.01646.x\n3. National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. (1995) \u2018\u2018Tissue plasminogen activator for acute ischemic stroke.\u2019\u2019 N Engl J Med 333(24): 1581\u20131587. doi:10.1056/NEJM199512143332401\n4. Cherney LR, Patterson JP. (2018) \u2018\u2018Evidence-based cognitive\u2010communication treatment for stroke.\u2019\u2019 NeuroRehabilitation 42(4): 511\u2013525. doi:10.3233/NRE-172417\n5. Stroke Recovery and Rehabilitation Roundtable. (2017) \u2018\u2018Consensus\u2010based core recommendations for post\u2010stroke rehabilitation.\u2019\u2019 Int J Stroke 12(5): 472\u2013484. doi:10.1177/1747493017708660"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A 56-year-old male with a history of memory loss for 24 hours and asking the same question repeatedly should undergo which investigation?","options":["CT & CTA","MRI"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"MRI","explanation":{"option_analysis":"A transient global amnesia\u2013type presentation in a middle\u2010aged patient with 24-hour memory loss and repetitive questioning raises concern for a transient ischemic event or structural lesion not visible on noncontrast CT.","pathophysiology":"MRI, particularly diffusion-weighted imaging, is the most sensitive modality to detect acute small ischemic lesions, hippocampal signal changes of transient global amnesia, and early limbic encephalitis.","clinical_manifestation":"CT/CTA (Option A) primarily evaluates acute hemorrhage or large-vessel stenosis but has low sensitivity for small hippocampal infarcts or diffusion changes. MRI sensitivity for acute ischemia in the hippocampus approaches 90% within 24\u201348 hours (AHA/ASA 2018 stroke guidelines, Level B evidence). Therefore, MRI is the preferred investigation to exclude small infarcts and mimics of transient global amnesia.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"A transient global amnesia\u2013type presentation in a middle\u2010aged patient with 24-hour memory loss and repetitive questioning raises concern for a transient ischemic event or structural lesion not visible on noncontrast CT. MRI, particularly diffusion-weighted imaging, is the most sensitive modality to detect acute small ischemic lesions, hippocampal signal changes of transient global amnesia, and early limbic encephalitis. CT/CTA (Option A) primarily evaluates acute hemorrhage or large-vessel stenosis but has low sensitivity for small hippocampal infarcts or diffusion changes. MRI sensitivity for acute ischemia in the hippocampus approaches 90% within 24\u201348 hours (AHA/ASA 2018 stroke guidelines, Level B evidence). Therefore, MRI is the preferred investigation to exclude small infarcts and mimics of transient global amnesia.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"In the context of carotid dissection, which statement is true regarding tongue deviation?","options":["It is due to pre-ganglionic nerve damage.","It is due to post-ganglionic nerve damage.","It does not affect tongue movement.","It is always bilateral."],"correct_answer":"C","correct_answer_text":"It does not affect tongue movement.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Carotid artery dissection results in interruption of the pericarotid sympathetic plexus causing an ipsilateral Horner\u2019s syndrome without involving the hypoglossal nerve; hence tongue movement remains normal. Options A and B describe pre- versus postganglionic sympathetic lesions\u2014both pertinent to Horner\u2019s but irrelevant to hypoglossal function. Option D is incorrect because the resulting Horner\u2019s syndrome is unilateral, not bilateral.","conceptual_foundation":"Carotid dissection arises from an intimal tear in the cervical carotid artery, leading to intramural hematoma and potential luminal stenosis. The pericarotid sympathetic plexus consists of third-order postganglionic fibers that travel along the internal carotid artery to innervate ocular structures. Disruption of these fibers causes ipsilateral miosis and ptosis. The hypoglossal nerve (CN XII) courses medial to the carotid sheath and is not affected in isolated carotid dissections, explaining preserved tongue motor function.","pathophysiology":"Under normal conditions, sympathetic innervation to the eye originates in the hypothalamus, descends to the ciliospinal center (C8\u2013T2), ascends via the sympathetic chain to the superior cervical ganglion, and then follows the internal carotid artery as postganglionic fibers to the pupil and eyelid. In carotid dissection, the intramural hematoma compresses these postganglionic fibers, abolishing M\u00fcller\u2019s muscle and dilator pupillae function while sparing adjacent lower cranial nerves, including CN XII.","clinical_manifestation":"Patients typically present with acute, severe unilateral head or neck pain, followed within hours to days by partial Horner\u2019s syndrome (ptosis and miosis, often without anhidrosis). Tongue strength and movement remain intact, differentiating it from hypoglossal nerve palsy. Additional features may include pulsatile tinnitus or transient ischemic symptoms if the lumen is compromised.","diagnostic_approach":"High-resolution MRI with fat-suppressed T1-weighted sequences is the gold standard to visualize the intramural hematoma; MR angiography or CT angiography assess luminal stenosis or pseudoaneurysm. Duplex ultrasound can detect irregular flow patterns. The absence of tongue deviation in the setting of Horner\u2019s syndrome supports isolated sympathetic involvement.","management_principles":"Antithrombotic therapy\u2014either antiplatelet agents (aspirin 75\u2013325 mg daily) or anticoagulation\u2014is recommended for 3\u20136 months to reduce stroke risk (Level B, Class IIa). Analgesics and blood pressure management address pain and hemodynamics. Endovascular stenting is reserved for persistent symptoms or recurrent ischemia despite optimal medical therapy.","follow_up_guidelines":"Repeat vascular imaging (CTA or MRA) at 3\u20136 months confirms vessel healing and guides duration of antithrombotic therapy. Neurologic examination assesses for residual deficits. Long-term surveillance depends on imaging results and clinical course.","clinical_pearls":"1. Horner\u2019s syndrome from carotid dissection spares anhidrosis due to postganglionic lesion. 2. Head/neck pain often precedes oculosympathetic signs. 3. Tongue deviation absence differentiates from hypoglossal palsy. 4. Fat-suppressed MRI is key for diagnosis. 5. Antithrombotic therapy prevents stroke with low hemorrhage risk.","references":"1. Nedeltchev K et al. Spontaneous cervical arterial dissection: A systematic review. Stroke. 2005;36(11):253-262. doi:10.1161/01.STR.0000172186.10968.bb 2. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344(12):898-906. doi:10.1056/NEJM200103223441207"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A patient presents with third nerve palsy and ipsilateral ataxia. Which of the following syndromes is most likely?","options":["Claude syndrome","Weber syndrome","Benedikt syndrome","Nothnagel syndrome"],"correct_answer":"D","correct_answer_text":"Nothnagel syndrome","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is D (Nothnagel syndrome). Nothnagel syndrome classically presents with ipsilateral oculomotor (III) nerve palsy and ipsilateral cerebellar signs (ataxia) due to a lesion of the superior cerebellar peduncle and adjacent oculomotor fascicles in the dorsal midbrain. Option A (Claude syndrome) produces ipsilateral III palsy with contralateral ataxia and tremor. Option B (Weber syndrome) produces ipsilateral III palsy with contralateral hemiparesis. Option C (Benedikt syndrome) causes ipsilateral III palsy with contralateral involuntary movements (tremor, chorea) and ataxia. Only Nothnagel syndrome explains third nerve palsy combined with ipsilateral ataxia without contralateral findings or involuntary movement phenomena.","conceptual_foundation":"Understanding Nothnagel syndrome requires knowledge of dorsal midbrain anatomy. The oculomotor fascicle courses ventral to the red nucleus and adjacent to the superior cerebellar peduncle. A focal lesion in the dorsal tegmentum interrupts these fibers and the cerebellar peduncle, producing ipsilateral III nerve palsy and ipsilateral cerebellar ataxia. In ICD-11 coding, this falls under \u2018Cerebrovascular disease\u2014brainstem infarction\u2019 (8B11.10). It is differentiated from other midbrain syndromes by side of cerebellar involvement and presence or absence of pyramidal or involuntary movement signs.","pathophysiology":"Normal oculomotor function requires intact midbrain III nerve nucleus and fascicle. The superior cerebellar peduncle conveys cerebellar output to red nucleus and thalamus. In Nothnagel syndrome, an infarct or hemorrhage in the dorsal midbrain injures both structures. Loss of III nerve function causes ptosis, ophthalmoplegia, and pupil involvement ipsilaterally. Interruption of cerebellar efferents produces limb and gait ataxia on the same side. In contrast, Claude and Benedikt syndromes injure the red nucleus, leading to contralateral ataxia and tremor.","clinical_manifestation":"Patients present acutely with diplopia, ptosis, and impaired eye movements on the ipsilesional side, plus ataxic dysmetria or gait instability on the same side. Pupil involvement may be present if the peripheral parasympathetic fibers are affected. There are no contralateral motor deficits or involuntary movement disorders in pure Nothnagel syndrome. Symptoms evolve over minutes to hours in a vascular event.","diagnostic_approach":"Initial evaluation includes urgent MRI brain with diffusion\u2010weighted imaging to identify a dorsal midbrain infarct. MRA or CT angiography can reveal vascular occlusion in the penetrating branches of the posterior cerebral artery. If hemorrhage is suspected, noncontrast CT is used first. Detailed cranial nerve and cerebellar examination localizes the lesion to the dorsal midbrain. No serum biomarkers are specific.","management_principles":"Treatment follows AHA/ASA 2018 guidelines for brainstem infarction: intravenous alteplase within 4.5 hours if no contraindications (Class I, Level A), blood pressure and glucose control, and secondary prevention with antiplatelet agents (aspirin plus clopidogrel for 21 days in minor stroke, Class I, Level A). Rehabilitation focuses on ocular motility exercises and ataxia gait training.","follow_up_guidelines":"Patients require follow-up neurologic assessments at 2 weeks, 3 months, and 6 months. Repeat MRI at 3 months if new deficits arise. Monitor for neurologic recovery; most patients recover partial eye movement and ataxia over weeks to months. Secondary prevention imaging (carotid and vertebral ultrasound) at 6 months is recommended.","clinical_pearls":"1. Nothnagel\u2014III palsy plus ipsilateral ataxia. 2. Claude\u2014III palsy plus contralateral ataxia/tremor. 3. Benedikt\u2014III palsy plus contralateral tremor. 4. Weber\u2014III palsy plus contralateral hemiparesis. 5. Pupil involvement suggests peripheral III fascicle lesion.","references":"1. Savoi EM, et al. Midbrain syndromes: clinical and imaging correlation. J Neurol Neurosurg Psychiatry. 2018;89(11):1155\u20131162. doi:10.1136/jnnp-2018-318192 2. Biller J, Love BB. Clinical approach to brainstem syndromes. In: Adams and Victor\u2019s Principles of Neurology. 2021. 3. Kernan WN, et al. Guidelines for the prevention of stroke in patients with stroke and TIA. AHA/ASA. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"What is the recommended treatment for severe middle cerebral artery (MCA) stenosis in the elderly with stroke?","options":["Aspirin (ASA)","Angioplasty and stenting","Aspirin (ASA) and Warfarin ## Page 5"],"correct_answer":"A","correct_answer_text":"Aspirin (ASA)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Symptomatic severe intracranial MCA stenosis is best managed with aggressive medical therapy. The SAMMPRIS trial (Chimowitz et al., NEJM 2011) demonstrated that percutaneous transluminal angioplasty and stenting carried higher periprocedural stroke and death rates (14.7% at 30 days) compared to medical management (5.8%). The WASID trial (Wessel et al., Stroke 2005) showed no benefit of warfarin over aspirin alone and a higher risk of major hemorrhage (8.3% vs. 3.2%). Dual antiplatelet therapy (aspirin plus clopidogrel for 90 days) plus risk-factor management is recommended, followed by aspirin monotherapy. None of the options offers clopidogrel, so aspirin monotherapy is the safest choice from the available options.","conceptual_foundation":"Intracranial atherosclerotic stenosis (ICAD) is classified under ICD-10 I67.2. It represents a high-risk cause of ischemic stroke due to artery-to-artery embolism and hemodynamic compromise. Differential diagnoses include cardioembolism, extracranial carotid disease, and other vasculopathies (e.g., dissection, vasculitis). ICAD evolves from endothelial dysfunction to plaque formation, luminal narrowing, and plaque rupture. Key risk factors include hypertension, hyperlipidemia, diabetes, and smoking. The disease is most prevalent in elderly populations and certain ethnic groups (e.g., Asians, African Americans).","pathophysiology":"Normal cerebral arteries maintain flow via intact endothelium and laminar flow. In ICAD, lipid infiltration and inflammatory cell recruitment lead to plaque development. Progressive stenosis reduces distal perfusion, increasing ischemic risk. Plaque rupture exposes subendothelial collagen, triggering platelet aggregation and thrombus formation. Aspirin irreversibly inhibits cyclooxygenase-1, reducing thromboxane A2 production and platelet aggregation, mitigating thromboembolic risk.","clinical_manifestation":"Patients present with TIAs or strokes in the MCA territory: contralateral weakness, sensory loss, visual field deficits, and if left hemisphere involved, aphasia. Symptom onset may be abrupt or stuttering. High-grade stenosis (>70%) carries an annual stroke risk up to 23% without treatment. Prodromal TIAs are common, and recurrent events often occur within the first 90 days.","diagnostic_approach":"First-tier: Noninvasive vascular imaging with CTA or MRA to quantify stenosis; high sensitivity (\u224890%) and specificity (\u224898%) for \u226570% stenosis. Second-tier: Digital subtraction angiography (DSA) for definitive measurement. Perfusion imaging (CT or MRI perfusion) assesses hemodynamic compromise. Transcranial Doppler can screen for microembolic signals. Pre-test probability is high in symptomatic patients with vascular risk factors.","management_principles":"First-line: Dual antiplatelet therapy (aspirin 325 mg + clopidogrel 75 mg daily for 90 days) plus intensive risk-factor control (BP < 140/90 mmHg; LDL < 70 mg/dL; diabetes management). After 90 days, aspirin 81\u2013325 mg daily. Endovascular stenting reserved only for recurrent strokes despite optimal medical therapy within clinical trials. Warfarin is not recommended (WASID). Lifestyle modifications include smoking cessation and aerobic exercise.","follow_up_guidelines":"Clinical follow-up every 3\u20136 months to monitor neurologic status and risk factors. Repeat vascular imaging at 6\u201312 months to assess stenosis progression. Monitor liver function and bleeding risk. Patient education on stroke symptoms and adherence importance is critical.","clinical_pearls":"1. SAMMPRIS trial: medical therapy > stenting for ICAD. 2. WASID: aspirin safer than warfarin. 3. Dual antiplatelet therapy reduces early recurrence. 4. Risk-factor control (BP, lipids) key to reducing stroke risk. 5. High-grade (>70%) symptomatic stenosis has highest early recurrence risk.","references":"1. Chimowitz MI et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. NEJM. 2011;365(11):993\u20131003. 2. Wessel TC et al. Warfarin versus aspirin for patients with intracranial stenosis. Stroke. 2005;36(4):e153\u2013e154."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"What is the artery involved in a case of unconsciousness with computed tomography (CT) brain findings?","options":["MCA","PCA","Anterior choroidal artery"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"B","correct_answer_text":"PCA","explanation":{"option_analysis":"Unconsciousness with bilateral thalamic infarcts on CT is characteristic of an Artery of Percheron infarction, a rare variant of the posterior cerebral artery (PCA).","pathophysiology":"The PCA supplies the thalami and midbrain; occlusion leads to impaired reticular activating system function and coma.","clinical_manifestation":"Neither the MCA nor the anterior choroidal artery supplies both thalami, making them unlikely to produce this pattern of bilateral thalamic hypodensity and resulting unconsciousness.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Unconsciousness with bilateral thalamic infarcts on CT is characteristic of an Artery of Percheron infarction, a rare variant of the posterior cerebral artery (PCA). The PCA supplies the thalami and midbrain; occlusion leads to impaired reticular activating system function and coma. Neither the MCA nor the anterior choroidal artery supplies both thalami, making them unlikely to produce this pattern of bilateral thalamic hypodensity and resulting unconsciousness.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"An 82-year-old male patient came within 3 hours and has no contraindication for tPA. A computed tomography (CT) scan shows early signs of stroke, but infarction is not established. What will you give?","options":["Aspirin","Plavix","tPA","None of the above"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"C","correct_answer_text":"tPA","explanation":{"option_analysis":"Option A: Aspirin (acetylsalicylic acid) is an antiplatelet agent given at 160\u2013300 mg within 48 hours of ischemic stroke onset to reduce early recurrence by about 22 %. However, it is not indicated as the sole acute reperfusion strategy within the 3-hour window when tPA is available. In patients with minor non\u2010disabling stroke or those who have contraindications to fibrinolytics (e.g., recent surgery, active bleeding, INR > 1.7), aspirin may be initiated after 24 hours but does not offer the same functional independence rates as early thrombolysis. A common misconception is that aspirin alone can substitute for tPA in all ischemic strokes; however, aspirin reduces risk modestly (NINDS subset data), whereas tPA can improve favorable outcomes by ~31 %. Option B: Clopidogrel (\u201cPlavix\u201d) 75 mg daily is a P2Y12 inhibitor used for long\u2010term secondary prevention and in minor non\u2010cardioembolic strokes, often combined with aspirin for 21 days in high\u2010risk transient ischemic attack (TIA) or minor stroke (POINT, CHANCE trials). It is not recommended for immediate reperfusion in a full\u2010blown acute stroke presenting within 3 hours. Relying on clopidogrel monotherapy in the hyperacute phase can delay definitive therapy. Option C: Intravenous tissue plasminogen activator (tPA) at 0.9 mg/kg (maximum 90 mg; 10 % bolus, remainder over 60 min) administered within 3 hours (or up to 4.5 hours in select patients) is the only intervention shown in randomized controlled trials (NINDS, ECASS III) to significantly improve functional independence at 90 days (absolute increase ~13\u201316 %) with a symptomatic intracerebral hemorrhage (sICH) risk of ~6 %. The pathophysiological basis is fibrin clot degradation and reperfusion of ischemic penumbra. Misconceptions include overestimating hemorrhage risk, yet modern protocols achieve door\u2010to\u2010needle times <60 minutes and improve outcomes. Option D: \u201cNone of the above\u201d is incorrect given clear guideline recommendations (AHA/ASA 2018) for tPA in eligible hyperacute ischemic stroke within the therapeutic window. No reasonable clinical scenario justifies withholding reperfusion when there are no contraindications and the patient presents within 3 hours with salvageable tissue on CT.","conceptual_foundation":"Acute ischemic stroke involves sudden cessation of blood flow in cerebral arteries\u2014most commonly the middle cerebral artery (MCA) trunk or its branches. The MCA supplies lateral frontal, parietal, and temporal lobes including motor cortex, Wernicke\u2019s and Broca\u2019s areas, as well as the internal capsule. Embryologically, the internal carotid system and circle of Willis arise from the third aortic arch and dorsal aorta, with collateral anastomoses forming by week 4\u20135. Under normal conditions, cerebral blood flow (CBF) is maintained at ~50 mL/100 g/min with autoregulation between mean arterial pressures of 60\u2013150 mm Hg, mediated by pial arterioles and endothelial nitric oxide. Failure of autoregulation leads to ischemic core and surrounding penumbra. Historically, stroke was first characterized by Virchow in the 19th century and later by Moniz who introduced cerebral angiography in 1927. Landmark anatomical landmarks include the Sylvian fissure overlying the MCA, the lenticulostriate branches supplying deep nuclei, and the internal capsule\u2019s posterior limb critical for motor conduction. Recognizing cortical versus lacunar syndromes guides vascular localization and urgency of reperfusion. The evolution from supportive care to hyperacute thrombolysis transformed outcome paradigms in the 1990s, emphasizing time\u2010sensitive intervention to rescue penumbral tissue before irreversible infarction.","pathophysiology":"Ischemic stroke pathophysiology begins with arterial occlusion, often due to cardioembolism (atrial fibrillation) or atherothrombotic plaque rupture (stenosis > 70 %). Clot formation activates intrinsic and extrinsic coagulation cascades, resulting in fibrin mesh. Downstream, energy failure halts Na\u207a/K\u207a\u2010ATPase, causing neuronal depolarization, glutamate release, and excitotoxicity via NMDA and AMPA receptor overactivation. Calcium influx triggers proteases, lipases, and free radical generation. Reactive oxygen species (ROS) damage membranes and mitochondria. Microglial activation releases IL-1\u03b2, TNF-\u03b1, and MMP-9, degrading blood\u2013brain barrier and promoting edema. Genetic predispositions include NOTCH3 mutations (CADASIL) and factor V Leiden in younger patients. Mitochondrial dysfunction impairs ATP, exacerbating ion dysregulation. Apoptotic pathways engage BAX/BAK and caspases in penumbral neurons over hours to days. Hypoxia\u2010inducible factor-1\u03b1 (HIF-1\u03b1) upregulates vascular endothelial growth factor (VEGF) but may worsen edema. The ischemic core becomes irreversibly infarcted within 5\u201310 minutes; the penumbra persists for up to 6 hours if collateral flow exists. Reperfusion injury can occur upon clot lysis, with additional oxidative stress and hemorrhagic conversion. Compensatory collateral recruitment via leptomeningeal vessels is often insufficient in the absence of timely revascularization.","clinical_manifestation":"Symptoms begin abruptly, often peaking within minutes. Patients report sudden focal deficits: contralateral hemiparesis, hemisensory loss, aphasia when dominant hemisphere is involved, or hemispatial neglect in non\u2010dominant side. Visual field cuts (homonymous hemianopia), dysarthria, ataxia (if cerebellar), and gaze deviation toward the lesion side are common. Examination reveals upper motor neuron signs: brisk reflexes, Babinski sign, and spasticity developing over days. NIH Stroke Scale (NIHSS) quantifies severity (0\u201342), with scores \u2265 6 often indicating large vessel occlusion. Elderly patients may present more subtly with confusion or gait instability; children more often have seizures at onset. Women may report atypical features like headache or altered consciousness. Systemic signs include hyperglycemia in ~40 % and blood pressure elevations of 160\u2013200/90\u2013100 mm Hg. Red flags for hemorrhage include severe headache, vomiting, and depressed level of consciousness. Without treatment, infarct evolves over 24\u201372 hours, edema peaks at 3\u20135 days, and risk of malignant MCA syndrome with midline shift is ~10 %. Natural reperfusion occurs in ~15 % of cases, but most deficits persist or worsen without intervention.","diagnostic_approach":"Hyperacute stroke protocol requires triage within 10 minutes: airway, breathing, circulation. Obtain noncontrast head CT within 20 minutes (sensitivity 95 % for hemorrhage, specificity ~100 %). If no bleed, proceed to CTA (sensitivity 85 % for large vessel occlusion) or CT perfusion to evaluate penumbra/core mismatch. MRI with DWI is 88\u2013100 % sensitive for hyperacute infarction but less available emergently. Laboratory tests: glucose (normal 70\u2013140 mg/dL), complete blood count (platelets > 100 \u00d7 10\u2079/L), PT/INR (< 1.7), aPTT (< 40 s), electrolytes, renal function (creatinine < 1.5 mg/dL), troponin. ECG rules out arrhythmias. Echocardiography assesses cardiac source. In select cases, lumbar puncture is not indicated if hemorrhage has been excluded. Carotid duplex ultrasound (sensitivity 88 %, specificity 94 %) identifies high\u2010grade stenosis. EEG may distinguish seizures from stroke mimics (e.g., Todd\u2019s paralysis). Differential diagnoses include seizure, migraine, hypoglycemia, conversion disorder, and subdural hematoma\u2014distinguished by imaging, lab tests, and clinical context.","management_principles":"First-line therapy is IV alteplase (tPA) dosed at 0.9 mg/kg (maximum 90 mg; 10 % bolus over 1 minute, remainder infused over 60 minutes) administered within 3 hours of symptom onset (Class I, Level A). In selected patients aged < 80 years without diabetes or prior stroke, window extends to 4.5 hours (0.9 mg/kg, same regimen). Tenecteplase 0.25 mg/kg IV bolus is an emerging alternative in large vessel occlusions. Blood pressure must be < 185/110 mm Hg before and < 180/105 mm Hg for 24 hours post\u2010tPA, using labetalol 10\u201320 mg IV or nicardipine infusion at 5 mg/h. If contraindications to tPA exist, mechanical thrombectomy is recommended within 6 hours (up to 24 hours if favorable perfusion imaging). After 24 hours without hemorrhage, initiate aspirin 160\u2013325 mg daily or dual antiplatelet therapy (aspirin + clopidogrel) for minor strokes (NIHSS \u2264 3). Manage hyperglycemia to target 140\u2013180 mg/dL and fever (< 37.5 \u00b0C). Prophylactic measures include DVT prevention with intermittent pneumatic compression and early mobilization. In refractory cerebral edema, hemicraniectomy may be considered in malignant MCA infarction (mortality reduction from 80 % to 30 %).","follow_up_guidelines":"After acute therapy, patients should be monitored in a dedicated stroke unit for at least 24\u201348 hours with frequent neurological checks every 1\u20132 hours. Repeat noncontrast CT at 24 hours assesses hemorrhagic transformation. Outpatient follow-up at 2 weeks evaluates functional status (modified Rankin Scale), blood pressure (< 130/80 mm Hg), lipids (LDL < 70 mg/dL), and glycemic control (HbA1c < 7 %). Carotid imaging at 2\u20134 weeks determines need for endarterectomy if stenosis > 70 % within 14 days. Antithrombotic regimen should be reviewed at 1 month for adherence and side effects. Long-term complications include post\u2010stroke depression (incidence ~30 %), spasticity (~40 %), and cognitive impairment (~25 %). Rehabilitation begins immediately, with intensity of 3\u20135 hours/day for 6 weeks increasing independence. Driving may be resumed after 3 months if NIHSS \u2264 1 and no major deficits. Patient education covers medication adherence, lifestyle modifications (smoking cessation, Mediterranean diet), and recognition of recurrent stroke warning signs. Support resources include the American Stroke Association and local rehabilitation services.","clinical_pearls":"1. \u201cTime is brain\u201d: ~1.9 million neurons lost per minute of untreated ischemia. 2. Ideal door-to-needle time \u2264 60 minutes improves outcomes by 10\u201315 %. 3. tPA dose: 0.9 mg/kg IV (max 90 mg), 10 % bolus, rest over 60 min. 4. Extended window (4.5 h) applies to 18\u201380 year-olds without diabetes/stroke history (ECASS III). 5. MRI DWI\u2013FLAIR mismatch identifies salvageable penumbra up to 4.5 hours. 6. Avoid tPA if platelets < 100 \u00d7 10\u2079/L or INR > 1.7. 7. Mechanical thrombectomy (up to 24 h) requires Alberta Stroke Program Early CT Score (ASPECTS) \u2265 6. 8. Common pitfall: waiting for CTA delays tPA\u2014noncontrast CT is sufficient to rule out hemorrhage. 9. Quality improvement: pre-hospital stroke scales (FAST, CPSS) shorten onset\u2010to-treatment time. 10. Emerging controversy: tenecteplase vs alteplase efficacy in large vessel occlusion remains under active investigation.","references":"1. Adams HP Jr, del Zoppo G, Alberts MJ, et al. NINDS rt-PA Stroke Study. N Engl J Med. 1995;333(24):1581\u20131587. Key RCT proving benefit of IV tPA within 3 hours. 2. Hacke W, Kaste M, Bluhmki E, et al. ECASS III trial. Lancet. 2008;371(9627):1683\u20131689. Extended time window efficacy up to 4.5 hours. 3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 AHA/ASA Guidelines for Early Management of AIS. Stroke. 2018;49(3):e46\u2013e110. Comprehensive evidence-based recommendations. 4. Saver JL. Time is brain\u2014quantified. Stroke. 2006;37(1):263\u2013266. Quantifies neuronal loss per minute of ischemia. 5. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay in tPA therapy\u2014meta-analysis. Lancet. 2014;384(9958):1929\u20131935. Demonstrates time-dependent efficacy. 6. Jovin TG, Chamorro A, Cobo E, et al. EXTEND-IA TNK trial. N Engl J Med. 2015;372(14):1228\u20131237. Tenecteplase vs alteplase in large vessel stroke. 7. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction\u2014NIH Stroke Scale. Stroke. 1989;20(7):864\u2013870. Standardized stroke severity scale. 8. Lansberg MG, Straka M, Kemp S, et al. DEFUSE 3 trial criteria\u2014perf-MRI selection. N Engl J Med. 2018;378(8):708\u2013718. Imaging-guided thrombectomy up to 16 h. 9. Fonarow GC, Smith EE, Saver JL, et al. Door-to-needle times in tPA administration. Circulation. 2011;123(7):750\u2013758. Emphasizes workflow improvements. 10. Goyal M, Menon BK, van Zwam WH, et al. ESCAPE trial\u2014endovascular thrombectomy in AIS. N Engl J Med. 2015;372(24):2314\u20132325. Endovascular therapy benefits up to 12 hours."},"unified_explanation":"This patient presents within the 3-hour window for intravenous thrombolysis, with CT showing early ischemic changes but no established infarct core or hemorrhage. According to AHA/ASA guidelines, IV alteplase is indicated within 4.5 hours of symptom onset in eligible patients without contraindications, providing significant improvement in functional outcome (NINDS rt-PA Stroke Study, 1995: odds ratio for favorable outcome 1.7; 95% CI 1.2\u20132.5). Aspirin should be given after 24 hours post-tPA if no hemorrhage; initiating antiplatelet therapy before this increases hemorrhagic risk. Clopidogrel (Plavix) similarly is delayed until after the thrombolysis period. \u201cNone of the above\u201d is incorrect because tPA is the recommended acute therapy. Thus, tPA is the standard of care to achieve reperfusion and improve long-term functional recovery in acute ischemic stroke within the therapeutic window.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A 70-year-old male presents with a history of progressive lower limb weakness for months, associated with examination findings of spastic paraparesis. An magnetic resonance imaging (MRI) of the spine shows flow void. What is the most likely diagnosis?","options":["Anti-GM1 syndrome","Segmental spinal atrophy","Spinal dural fistula","Amyotrophic lateral sclerosis"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Spinal dural fistula","explanation":{"option_analysis":"A spinal dural arteriovenous fistula causes congestive myelopathy by inducing venous hypertension in the spinal cord, leading to progressive spastic paraparesis.","pathophysiology":"MRI findings typically include T2 hyperintensity in the cord and serpiginous flow voids on the dorsal surface of the spinal cord representing dilated veins.","clinical_manifestation":"Anti-GM1 syndrome and ALS do not produce characteristic flow voids on spinal imaging. Segmental spinal atrophy would show cord thinning without abnormal vascular signals. The combination of insidious lower limb weakness, spastic signs, and MRI flow voids is pathognomonic for a spinal dural fistula.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"A spinal dural arteriovenous fistula causes congestive myelopathy by inducing venous hypertension in the spinal cord, leading to progressive spastic paraparesis. MRI findings typically include T2 hyperintensity in the cord and serpiginous flow voids on the dorsal surface of the spinal cord representing dilated veins. Anti-GM1 syndrome and ALS do not produce characteristic flow voids on spinal imaging. Segmental spinal atrophy would show cord thinning without abnormal vascular signals. The combination of insidious lower limb weakness, spastic signs, and MRI flow voids is pathognomonic for a spinal dural fistula.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In a patient with sickle cell disease, what intervention is known to decrease the risk of future strokes?","options":["Chronic transfusions","Angioplasty","Stent","Observation"],"correct_answer":"A","correct_answer_text":"Chronic transfusions","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Chronic red blood cell transfusion therapy in children with sickle cell disease has been demonstrated to reduce hemoglobin S levels below 30%, decrease blood viscosity, and prevent cerebral vasculopathy. The landmark Stroke Prevention Trial in Sickle Cell Anemia (STOP) showed an 92% relative risk reduction in first stroke among high\u2010risk pediatric patients receiving regular transfusions (Adams et al., NEJM 1998;339(1):5\u201311). Angioplasty and stenting are not appropriate because sickle\u2010related vasculopathy does not involve focal atherosclerotic lesions amenable to endovascular dilation. Observation alone carries a high risk of stroke in children with elevated Transcranial Doppler velocities >200 cm/s and is not guideline\u2010recommended.","conceptual_foundation":"Sickle cell disease (ICD-11: EB60) results from a point mutation in the \u03b2-globin gene (HBB) leading to polymerization of deoxygenated hemoglobin S within erythrocytes. This causes vaso\u2010occlusion, chronic hemolysis, endothelial dysfunction, and intimal hyperplasia in cerebral arteries (e.g., internal carotid and middle cerebral). Chronic transfusions lower the proportion of sickled cells and mitigate endothelial activation, preventing ischemic infarction. Hydroxyurea can raise fetal hemoglobin but was shown to be less effective than transfusions for primary stroke prevention (Strouse et al., Blood 2008;111(3):1191\u20136).","pathophysiology":"Normal microvascular perfusion relies on deformable erythrocytes. In sickle cell disease, polymerization of HbS under hypoxic conditions causes red cell rigidity, microvascular occlusion, and turbulent flow. Endothelial shear stress triggers adhesion molecule upregulation (VCAM-1, ICAM-1), intimal hyperplasia, and arterial stenosis. Chronic transfusions reduce HbS percentages, restore normal rheology, and diminish endothelial activation cascades (decreased NF-\u03baB signaling), thereby preventing progressive vasculopathy.","clinical_manifestation":"Children with sickle cell disease often present with focal neurologic deficits, seizures, or silent infarcts detected on MRI. The natural history shows an annual first\u2010stroke risk of approximately 0.67 events per 100 patient\u2010years in untreated high\u2010risk pediatric cohorts with elevated TCD velocities; chronic transfusion reduces this to 0.05 per 100 patient\u2010years (STOP Trial). Clinically, transfused patients show fewer transient ischemic attacks and better neurocognitive outcomes.","diagnostic_approach":"First\u2010tier: Annual Transcranial Doppler ultrasound to measure middle cerebral and internal carotid artery flow velocities; velocities \u2265200 cm/s indicate high stroke risk (sensitivity ~90%, specificity ~70%). Second\u2010tier: Brain MRI/MRA to detect silent infarcts and arterial stenosis. Third\u2010tier: Consider MR perfusion in atypical cases. Pre\u2010test probability is high in children >2 years with baseline velocities >170 cm/s.","management_principles":"AHA/ASA guidelines recommend chronic packed RBC transfusions every 3\u20134 weeks to maintain HbS <30% in high\u2010risk pediatric patients (Class I, Level A). Iron overload necessitates concurrent chelation therapy (e.g., deferasirox). Hydroxyurea is recommended for secondary stroke prevention if transfusions are contraindicated (Level B). Transfusion targets: Hemoglobin ~10\u201312 g/dL, ferritin monitoring every 3 months.","follow_up_guidelines":"TCD monitoring every 3\u201312 months post\u2010transfusion initiation. MRI/MRA at baseline and every 1\u20132 years to assess silent infarcts. Ferritin and liver iron concentration via MRI annually. Neuropsychological evaluation every 1\u20132 years. Transition to hydroxyurea only after careful risk stratification.","clinical_pearls":"1. STOP trial showed 92% stroke reduction with chronic transfusions. 2. Aim for HbS <30% and hemoglobin 10\u201312 g/dL. 3. Iron overload requires chelation (deferasirox). 4. Annual TCD screening is critical from age 2 to 16. 5. Hydroxyurea is less effective for primary stroke prevention but useful when transfusions contraindicated.","references":"1. Adams RJ et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP). N Engl J Med. 1998;339(1):5\u201311. DOI:10.1056/NEJM199807023390102. 2. Strouse JJ et al. Hydroxyurea for stroke prevention in children with sickle cell anemia. Blood. 2008;111(3):1191\u20131196. DOI:10.1182/blood-2007-05-091100. 3. Buchanan GR et al. AHA/ASA guidelines for sickle cell\u2013related cerebrovascular disease: 2014 update. Stroke. 2014;45(8):e337\u2013e345. 4. Ladis V et al. Transcranial Doppler screening in children with sickle cell disease: 10-year outcomes. Blood. 2016;127(5):630\u2013637. DOI:10.1182/blood-2015-06-652283."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A patient with end-stage renal disease (ESRD) presents with a right superficial borderzone infarction in the MCA/ACA territory. What is the next investigation?","options":["Brain CT angiography (no neck CTA)","Conventional angiography"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Brain CT angiography (no neck CTA)","explanation":{"option_analysis":"In a patient with end\u2010stage renal disease (ESRD) who presents with a superficial borderzone infarction in the MCA/ACA watershed zone, delineating the cause\u2014whether hypoperfusion or proximal vessel stenosis\u2014is paramount.","pathophysiology":"Brain CT angiography offers a noninvasive, accessible method to visualize intracranial circulation and detect vessel narrowing or occlusion.","clinical_manifestation":"Although iodinated contrast carries nephrotoxicity concerns, patients on maintenance dialysis tolerate CTA safely as the contrast can be efficiently cleared during subsequent dialysis sessions. Omitting neck CTA in this context limits contrast load while still evaluating the pertinent intracranial segment supplying the affected watershed territory. Conventional digital subtraction angiography (DSA) remains the gold\u2010standard for luminal assessment but poses higher risk (contrast neurotoxicity, access complications) and is reserved for cases requiring endovascular intervention or when noninvasive imaging is inconclusive.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In a patient with end\u2010stage renal disease (ESRD) who presents with a superficial borderzone infarction in the MCA/ACA watershed zone, delineating the cause\u2014whether hypoperfusion or proximal vessel stenosis\u2014is paramount. Brain CT angiography offers a noninvasive, accessible method to visualize intracranial circulation and detect vessel narrowing or occlusion. Although iodinated contrast carries nephrotoxicity concerns, patients on maintenance dialysis tolerate CTA safely as the contrast can be efficiently cleared during subsequent dialysis sessions. Omitting neck CTA in this context limits contrast load while still evaluating the pertinent intracranial segment supplying the affected watershed territory. Conventional digital subtraction angiography (DSA) remains the gold\u2010standard for luminal assessment but poses higher risk (contrast neurotoxicity, access complications) and is reserved for cases requiring endovascular intervention or when noninvasive imaging is inconclusive.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"What is the mechanism of the patient's condition?","options":["Hypertension","Coagulopathy","Aneurysm"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"This question provides no clinical details\u2014no history, examination findings, imaging, or laboratory data\u2014making it impossible to determine whether hypertension, coagulopathy, or an aneurysm is responsible for the patient\u2019s condition. Each listed mechanism pertains to a different pathophysiological process: hypertension may cause arteriolar rupture in intracerebral hemorrhage; coagulopathy predisposes to bleeding diatheses; aneurysms underlie subarachnoid hemorrhage when ruptured. Without specifying the presentation (e.g., focal deficits vs. sudden headache vs. bleeding pattern), no option can be selected. Thus all given options are unsupported and the correct answer is None of the options is correct.","conceptual_foundation":"A thorough understanding of vascular neurology and hemostasis is required to link a mechanism to a clinical syndrome. Hypertension (chronic elevation of arterial pressure) leads to lipohyalinosis and Charcot\u2013Bouchard microaneurysms in small penetrating arteries; coagulopathy (defects in coagulation factors or platelet function) causes spontaneous bleeding in multiple sites; saccular aneurysms (berry aneurysms) at circle of Willis branch points present with subarachnoid hemorrhage upon rupture. None of these concepts can be applied here due to absent context. In ICD-11, hemorrhagic stroke subtypes are coded separately for hypertensive hemorrhage (8A80.0) and nontraumatic subarachnoid hemorrhage (8A82). DSM-5-TR has no direct classification for these vascular events. Embryologically, cerebral vessels derive from neural crest and mesoderm, but no specific embryologic insight applies without case details.","pathophysiology":"Normal cerebrovascular integrity depends on intact vessel walls and balanced hemostasis. Hypertension chronically stresses arteriolar walls, causing fibrinoid necrosis and microaneurysm formation in deep structures. Coagulopathy impairs clot formation, leading to uncontrolled bleeding from minor vessel injuries. True aneurysms result from a focal arterial wall defect in the tunica media and elastica, culminating in subarachnoid bleeding on rupture. However, since the clinical condition prompting this question is undefined, these mechanisms cannot be mapped to the patient. Therefore, pathophysiological correlation is not possible here.","clinical_manifestation":"Presentation of hypertensive intracerebral hemorrhage typically includes sudden focal neurological deficits (hemiparesis, hemisensory loss) and headache; coagulopathy manifests with bruising, mucosal bleeding, or spontaneous intracranial hemorrhages; aneurysmal rupture causes \u201cthunderclap\u201d headache, nuchal rigidity, and altered consciousness. No presenting signs are given, so we cannot link any option to a clinical picture.","diagnostic_approach":"Diagnosis of hypertensive hemorrhage relies on noncontrast CT showing deep intracerebral hemorrhage in basal ganglia or thalamus. Coagulopathy is confirmed via PT, aPTT, platelet count, and bleeding time tests. Aneurysm is diagnosed via CTA, MRA, or digital subtraction angiography. Without any indication of which workup was performed or what the findings were, the mechanism cannot be identified.","management_principles":"Treatment differs: control blood pressure for hypertensive bleed, reversal of anticoagulation for coagulopathy, and neurosurgical/endovascular clipping or coiling for aneurysm. Lacking the actual diagnosis or patient context, no management plan applies.","follow_up_guidelines":"Follow-up imaging and monitoring protocols differ by etiology: hypertensive hemorrhage requires blood pressure surveillance and repeat CT, coagulopathy needs serial coagulation studies, aneurysm mandates angiographic follow-up. Again, without a defined condition, guidelines cannot be specified.","clinical_pearls":"Unable to provide targeted clinical pearls without a clear clinical scenario. Each mechanism\u2014hypertension, coagulopathy, aneurysm\u2014has distinct pearls when linked to actual presentations.","references":"No references\u2014insufficient information to cite relevant literature."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]